Health — Cancer — August 13th, 2026

ASTRO updates guideline on radiation therapy for pancreatic cancer
An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer.
August 13th, 2026 — Source

Bacterial extracellular vesicles show potential for cancer diagnosis and treatment
Bacteria shed membrane-enclosed tiny particles filled with proteins, lipids, DNA, RNA and metabolites. These particles, commonly known as bacterial extracellular vesicles (BEVs), are now being explored as possible tools for cancer diagnosis and treatment.
August 13th, 2026 — Source

For early prostate cancer, 'active surveillance' is now the number 1 choice
Three decades after UC San Francisco pioneered "active surveillance" for patients with low-risk prostate cancer, a new study has found that the vast majority of veterans with the diagnosis pursued this option instead of treatment.
August 13th, 2026 — Source

Half of prostate cancer focal therapy use found to fall outside current guideline-supported groups
As focal therapy gains popularity as a less invasive treatment option for some men with prostate cancer, a national study led by researchers at the University of Pittsburgh found that some men may be receiving treatment that is either unnecessary or not aggressive enough for their cancer.
August 13th, 2026 — Source

Researchers develop mathematical measures to better personalize therapy for prostate cancer
Researchers at Moffitt Cancer Center have developed three mathematical biomarkers that may help physicians personalize adaptive therapy for prostate cancer by predicting treatment outcomes early in treatment. The biomarkers are specialized mathematical measures calculated from routine prostate-specific antigen (PSA) blood tests.
August 13th, 2026 — Source

What is the optimal prostate-specific antigen cutoff to determine the success of prostate cancer treatment?
After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that the treatment is working. A recent real-world study indicates that reaching a PSA level below 0.2 ng/mL is an indicator of improved patient survival. The study is published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
August 13th, 2026 — Source

Health — Cancer — August 12th, 2026

Analysis reveals geographic and ethnic inequities in cancer radiotherapy access across New Zealand
The first nationwide study comparing urban and rural rates of receiving radiotherapy treatment for three major cancers highlighted significant geographic and equity differences. Led by the University of Otago -- Ōtākou Whakaihu Waka, the study compared radiotherapy rates among rural Māori and non-Māori New Zealanders with those of their urban counterparts for breast, prostate and lung cancers.
August 12th, 2026 — Source

How to decide which breast cancer surgery is right for you: A surgical oncologist explains
Women diagnosed with breast cancer are almost immediately confronted with treatment decisions. If a surgical oncologist gives a choice between a lumpectomy and a mastectomy to remove a tumor, that's often because either option will lead to a similar long-term health outcome.
August 12th, 2026 — Source

Health — Cancer — August 9th, 2026

Dense breasts or breast cancer in the family? What screening changes mean for you
The way women are screened for breast cancer in Australia is changing. According to a newly released review, this means moving away from screening based largely on someone's age. Instead, screening would be tailored according to individual risk.
August 9th, 2026 — Source

Protein 'switch' determines whether liposarcoma cells will become aggressive
New research from an expert in cancer biology explains what triggers liposarcoma cells to become more or less aggressive and identifies potential targets that could keep aggressive tumors in check. A study led by Blake Wilde, Ph.D., of Roswell Park Comprehensive Cancer Center highlights how this discovery may pave the way for new treatment options for this cancer.
August 9th, 2026 — Source

Health — Cancer — August 8th, 2026

A protein older than blood circulation could transform cancer immunotherapy
An ancient immune molecule may help turn stubborn, treatment-resistant tumors into targets for cancer immunotherapy.
August 8th, 2026 — Source

Study points to new target for treating aggressive brain cancer
Glioblastoma remains one of the deadliest cancers, with limited treatment advances and tumors that often resist radiation and chemotherapy. New research from The Ohio State University Comprehensive Cancer Center--Arthur G. James Cancer Hospital and Richard J. Solove Research Institute points to SET as a potential target for making glioblastoma cells more vulnerable to treatment.
August 8th, 2026 — Source

Two-stage process helps metastatic cancer cells hide, then multiply in the lungs
Most cancer deaths are caused not by the initial tumor but by the spread of cancer cells to distant organs in the process called metastasis. Since it occurs at the cellular level, the earliest stages of metastasis are difficult to observe in patients. A new study, published in Science, has made headway in understanding this process by mapping how some cancer cells survive in a new organ, even when most are eliminated by the immune system.
August 8th, 2026 — Source

Health — Cancer — August 7th, 2026

Cells in breast tumor microenvironment may reveal who benefits most from hormone treatment
Tamoxifen is a drug used to treat hormone-sensitive breast cancer by blocking the effects of the hormone estrogen. In the new study, researchers investigated whether the tumor microenvironment, meaning the immune cells, connective tissue cells and other cells found within and around a tumor, can influence how well the treatment works.
August 7th, 2026 — Source

Close digital support helps women with breast cancer
Approximately 68,000 women in Germany are living with breast cancer that has metastasized—meaning that the tumor has spread to other organs. At this stage, the cancer is no longer curable. With the help of modern therapies, however, the disease can be temporarily controlled and life expectancy extended by several years. Some women are even able to continue working. Today's therapeutic options, however, also present challenges.
August 7th, 2026 — Source

D-serine accelerates gastric tumor growth by suppressing killer T cells
One of the crucial steps in cancer proliferation is evading killer immune cells. Cancer cells use a variety of signaling molecules to evade the immune system. Immune checkpoint inhibitor (ICI) therapy interferes with some of these evasion tactics, improving the immune system's ability to suppress tumors. However, the success of ICI therapy depends on the specific signals being secreted by the tumor.
August 7th, 2026 — Source

FLT3 inhibitors trigger ferroptosis, exposing new weakness in acute myeloid leukemia
A study published in Nature Cell Biology reports a new vulnerability in acute myeloid leukemia (AML) that might lead to novel therapies to treat the cancer while minimizing harm to normal cells. Researchers at Baylor College of Medicine and collaborating institutions studied a new mechanism by which drugs that neutralize FLT3 mutations work.
August 7th, 2026 — Source

High glucose thickens cancer cells' sugar shield, helping them evade immune attack
Like spies evading detection by mastering disguises, many cancer cells are adorned with a copious coat of sugar-derived molecules that throws the proverbial hounds of the immune system off the scent.
August 7th, 2026 — Source

Newly identified C/EBPγ protein links cancer cell plasticity and DNA repair
EMT is a reversible cellular program in which epithelial cancer cells acquire mesenchymal characteristics, enhancing their mobility, invasiveness and adaptability. This process is closely associated with tumor progression, metastasis and resistance to therapy. Although several major EMT-inducing transcription factors have been identified, less is known about factors that connect EMT with other malignant properties that help cancer cells survive treatment.
August 7th, 2026 — Source

Protective drug dexrazoxane reduces heart damage in pediatric cancer survivors years after treatment ends
A new study reveals that the cardioprotective drug dexrazoxane significantly reduces heart damage caused by chemotherapy in pediatric cancer patients 15 years or more after treatment ends.
August 7th, 2026 — Source

Radiopharmaceutical may benefit patients with metastatic prostate cancer sooner
Radiopharmaceutical may benefit patients with metastatic prostate cancer sooner
August 7th, 2026 — Source

Researchers find a new genetic vulnerability in acute myeloid leukemia
The team worked with a combination of mouse models and cell line experiments, as well as patient-derived AML samples grown in animal models. They discovered that FLT3 inhibitors also kill AML cells by triggering ferroptosis. "This mechanism involves lipid peroxidation -- oxygen damages lipids in cells in ways that cause cell death," said Nakada, a member of Baylor's Dan L Duncan Comprehensive Cancer Center and a CPRIT Scholar. "This is the first time FLT3 has been connected to ferroptosis."
August 7th, 2026 — Source

Study identifies care steps that start head and neck cancer patients on lifesaving treatment sooner
For patients with advanced head and neck cancer, surgery is often the first step in treatment. Many also need radiation therapy to destroy remaining cancer cells and reduce the risk that their cancer will return. Starting radiation within six weeks of surgery gives patients the best chance of beating their cancer. But for more than half of patients nationwide, that does not happen.
August 7th, 2026 — Source

Vitamin C may fight cancer — but not the way scientists once thought
Linus Pauling was widely mocked for claiming that vitamin C could fight cancer, especially after trials using vitamin C pills showed no benefit. Researchers now know that intravenous vitamin C reaches vastly higher concentrations and can behave more like an experimental cancer drug than an ordinary supplement. Early studies suggest it may damage vulnerable cancer cells, reduce treatment side effects, and possibly improve outcomes for some patients.
August 7th, 2026 — Source

Health — Cancer — August 5th, 2026

Obscure X chromosome protein emerges as key driver in several cancers
A little-known protein encoded on the X chromosome is attracting growing attention for its potential role in cancer development and treatment. A new review highlights the expanding importance of CXorf67, an epigenetic regulator that influences gene activity, DNA repair processes, and tumor behavior across several malignancies, including aggressive brain tumors, osteosarcoma, lung cancer, endometrial stromal sarcoma, and Merkel cell carcinoma.
August 5th, 2026 — Source

Q&A: Harnessing statistics to improve personalized medicine
Scientific advancements—including understanding health conditions and developing new treatments—hinge on data and its implications. Statistician Alex Luedtke is developing new methods to make data analysis as efficient and effective as possible with the goal of improving personalized treatment recommendations in mental health and other fields.
August 5th, 2026 — Source

Review highlights the importance of miR-23b in shaping cancer development and progression
A new review highlights the growing importance of miR-23b, a small but powerful regulator of gene expression, in shaping the development and progression of a wide range of cancers. This molecule, part of the broader family of microRNAs, is increasingly recognized for its complex and sometimes contrasting influence on tumor behavior, offering fresh perspectives on how cancer can be better understood and managed.
August 5th, 2026 — Source

Scientists unmask immune cells that supercharge the fight against cancer
A little‑known group of hard-to-find immune cells could help transform cancer treatment, scientists at the University of Manchester's Cancer Research UK Manchester Institute, have found.
August 5th, 2026 — Source

Targeted dendritic cell vaccines emerge as a major step forward in cancer immunotherapy
A major step forward in cancer immunotherapy is emerging through the growing development of dendritic cell vaccines, a highly targeted approach designed to harness the body's own immune system to fight tumors. These advanced therapies center on dendritic cells, which act as the body's most powerful antigen-presenting cells, orchestrating immune responses by activating T cells and natural killer cells to recognize and destroy cancer.
August 5th, 2026 — Source

Tumor-like tissue environments could hold clues to curing HIV
The findings help explain why HIV has been so difficult to cure. Scientists found that viral reservoirs exist within tissue microenvironments that resemble immunosuppressive tumor microenvironments, suggesting that future HIV cure strategies may benefit from approaches traditionally used in cancer therapy.
August 5th, 2026 — Source

Health — Cancer — August 3rd, 2026

A simple supplement could help the immune system fight cancer and viruses
Low arginine levels may allow cancer cells and viruses to slip past the immune system by reducing production of a crucial cellular warning protein. In mice, arginine-rich diets led to fewer colon tumors and milder viral infections, suggesting a simple supplement could have powerful therapeutic potential.
August 3rd, 2026 — Source

Health — Cancer — July 31st, 2026

AI blood assay detects liver cancer across diverse international populations
Researchers at the Johns Hopkins Kimmel Cancer Center validated an artificial intelligence (AI)-powered blood test that accurately detected liver cancer in people from two geographically and biologically distinct populations and uncovered the underlying biological signals that make the test effective.
July 31th, 2026 — Source

Natural tooth count indicates long-term survival following pancreatic cancer surgery
Oral health is known to be linked to overall health, and research has shown relationships with a variety of diseases. Impaired oral health has been linked to prognosis in colorectal cancer and esophageal cancer. Previous studies have also shown an association between oral health and postoperative complications in pancreatic ductal adenocarcinoma (PDAC), one of the more lethal forms of cancer.
July 31th, 2026 — Source

Tumor-responsive capsules control engineered bacteria for cancer immunotherapy
Programmable polymer shells keep engineered bacteria metabolically active during delivery, then restore growth and local drug production inside tumors while reducing toxicity in mice.
July 31th, 2026 — Source

Health — Cancer — July 29th, 2026

Despite Medicare coverage, many cancer patients still do not receive testing that guides treatment options
While there has been a recent increase among Medicare recipients in genomic testing that helps match cancer patients to the most effective treatment for their tumor, many Medicare beneficiaries with cancer are still not receiving next-generation sequencing (NGS), according to a new analysis by Georgetown University researchers.
July 29th, 2026 — Source

Donor cord blood composition may influence CAR NK cell therapy outcomes
The composition of donor cord blood may play a critical role in the success of chimeric antigen receptor (CAR) natural killer (NK) cell therapies. A small population of immature NK cells present in donor cord blood can undermine the activity of CAR NK cell therapy by redirecting potent immune cells away from tumors and causing them to attack one another, according to researchers from The University of Texas MD Anderson Cancer Center.
July 29th, 2026 — Source or Source

FDA grants fast track designation to Insilico's AI-designed mesothelioma drug candidate
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico's proprietary AI, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA), for the treatment of adult patients with unresectable malignant pleural mesothelioma whose disease has progressed on or after prior treatment with anti-PD-1 antibody therapy, with or without anti-CTLA-4 antibody therapy, and platinum-based chemotherapy.
July 29th, 2026 — Source

New AI-based method could improve detection and classification of brain tumors from MRI scans
Researchers have developed a new artificial intelligence-based method that could significantly improve the detection and classification of brain tumors from MRI scans, achieving higher accuracy than conventional diagnostic systems.
July 29th, 2026 — Source

Researchers discover pathway that makes glioblastoma cells vulnerable to treatment
A team of scientists from Virginia Commonwealth University, VCU Massey Comprehensive Cancer Center and the University of Texas MD Anderson Cancer Center uncovered a protein, TRNAU1AP, that plays an essential role in helping glioblastoma cells survive and multiply, along with a potential pathway to make these cancer cells more vulnerable to treatment.
July 29th, 2026 — Source

Health — Cancer — July 27th, 2026

Scientists decipher how T cells sense enemies—such as cancer—at point of contact
Every encounter between a T cell and a potential target—especially when that target is a developing tumor—begins with a rapid series of molecular decisions. Within seconds, the immune cell must determine whether to launch an attack or stand down. T cells are so potent, so potentially devastating, that misreading the situation can cause serious tissue injury.
July 27th, 2026 — Source

Study finds shift away from cigarettes could reshape future cancer burden
As cigarette smoking reaches historic lows in the U.S., new research from MUSC Hollings Cancer Center suggests a fundamental shift in tobacco use is driving that trend. Younger adults are increasingly switching to noncombustible nicotine products, particularly electronic cigarettes, also known as e-cigarettes.
July 27th, 2026 — Source

Synthetic tumor data helps AI improve long-read cancer mutation detection
A research team at The University of Hong Kong (HKU), has developed ClairS—a deep-learning algorithm that significantly improves the detection of cancer mutations using long-read sequencing. Tested on breast cancer, lung cancer and melanoma cell line datasets, ClairS has demonstrated high accuracy across various cancer types and sequencing conditions.
July 27th, 2026 — Source

Understanding financial conflicts of interest in cancer care and research
Cary Gross, MD, professor of medicine (general internal medicine) at Yale School of Medicine, has studied financial conflicts of interest in American medicine for more than 20 years. In a recent systematic review published in JNCI: Journal of the National Cancer Institute, Gross and his colleagues examined the prevalence of financial conflicts of interest in cancer research and care in the United States, where cancer care spending exceeds $200 billion per year.
July 27th, 2026 — Source

Why the same DNA damage causes cancer in some people but not others
A controlled mouse study has provided direct evidence that inherited genetics can steer how cancer begins and evolves after DNA damage. The discovery could eventually help doctors better predict cancer risk and tailor screening and treatments to each patient.
July 27th, 2026 — Source

Health — Cancer — July 24th, 2026

Giving antibodies 'eyes' may help target hidden KRAS mutations in cancer cells
Antibodies are like "guided missiles" that find and attack cancer cells, but cancer-causing mutations inside cells have remained a "blind spot" for treatment because antibodies cannot reach them. KAIST researchers have now succeeded in precisely targeting intracellular cancer mutations using a newly designed antibody created through computational methods.
July 24th, 2026 — Source

Gold-catalyzed chemical reaction advances next-generation anticancer prodrugs
Anticancer prodrugs have attracted significant attention from the medical and scientific communities in recent years because of their potential to improve treatment precision while reducing side effects. These drugs are engineered to remain inactive until they are activated at specific sites or under particular physiological conditions within the body, at which point they release their therapeutic effect.
July 24th, 2026 — Source

Inherited gene variants may shape CAR-T therapy benefits and toxic side effects
Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma. But in some patients, the treatment can cause serious side effects. New research led by investigators at the Mass General Brigham Cancer Institute, the Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute has shown that patients' inherited genetic makeup can influence whether they benefit from CAR-T cell therapy or experience toxicity from the treatment.
July 24th, 2026 — Source or Source

Iowa State study identifies potential new target for leukemia treatment
In leukemia's most aggressive forms, the blood cell factories in our bone marrow falter. Instead of dividing and multiplying at their usual prolific pace, generating hundreds of billions of new cells daily, some precursor cells stall out at an immature stage.
July 24th, 2026 — Source

Metal-ion coating improves extracellular vesicles for cancer detection and targeted delivery
Researchers, including those from the University of Tokyo, found a way to optimize how cells bind to small packages they release called extracellular vesicles. By coating the vesicles with metal ions, they made cells and their corresponding vesicles stick together more strongly than they would naturally. This reduced the time needed for cells to capture their own vesicles, even in mixtures containing billions of other vesicles.
July 24th, 2026 — Source

New mechanoresistant cancer cells show how they survive high stress environments
When a cancer cell leaves the original tumor to spread to a new, faraway location, it first has to survive what most cells cannot: periodic high-force moments in the vessels and heart of up to 5,000 dynes per centimeter squared as it circulates throughout the body.
July 24th, 2026 — Source or Source

New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer
Bladder cancer is the sixth most common cancer in the United States. The American Cancer Society estimates that nearly 85,000 Americans will be diagnosed with the disease this year. About 1 in 4 bladder cancers are muscle-invasive, an aggressive form of the disease that carries a high risk of recurrence and spreading to other parts of the body.
July 24th, 2026 — Source

Redesigned lung cancer drug matches tumor control with fewer off-target interactions
Researchers at Moffitt Cancer Center have developed a new chemical approach that could help make targeted cancer medicines safer and more precise. The discovery gives scientists a new way to design drugs that bind more selectively to cancer-driving proteins while reducing unwanted interactions that can lead to side effects.
July 24th, 2026 — Source

Tiny BAP1 mutations can disrupt internal signals that suppress tumor growth
Scientists at the Institute of Biochemical Sciences at National Taiwan University have uncovered how tiny genetic changes can disable one of the body's most important tumor-suppressing proteins. Their study, published in Nature Communications, reveals how cancer-associated mutations interfere with the function of BRCA1-associated protein 1 (BAP1), a protein that helps maintain normal cell growth and is frequently mutated in cancers such as mesothelioma, uveal melanoma and kidney cancer.
July 24th, 2026 — Source

Two interconnected signaling pathways drive papillary thyroid carcinoma progression
The research perspective was authored by first and corresponding author Gunvanti Rathod and Pragnesh Parmar, both from AIIMS Bibinagar, India. The authors examine how two interconnected signaling pathways drive the development and progression of papillary thyroid carcinoma (PTC), the most common type of thyroid cancer, while highlighting how molecular diagnostics and targeted therapies are shaping more personalized treatment strategies.
July 24th, 2026 — Source

Health — Cancer — July 23rd, 2026

A patient-focused health care system is key to tackling missingness
Embedding a patient-focused approach across all health care settings could help better address the problem of missingness in health care, according to researchers.
July 23rd, 2026 — Source

Ancient molecule made inside tumors drives immune response, study finds
An ancient molecule that existed long before the circulatory system evolved has been found to support cancer immunotherapy. Researchers at Nagoya University in Japan found that complement C3 protein acts inside tumors to prevent the accumulation of immunosuppressive cells, but only when produced inside the tumor. C3 circulating in the blood did not affect treatment outcomes.
July 23rd, 2026 — Source

Brain cancer map uncovers thousands of hidden targets for personalized immunotherapies
Researchers from the Clinical Neuroscience Consortium (CNC), a collaborative platform jointly established by the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) and Queen Mary Hospital, in collaboration with the Hong Kong Genome Institute (HKGI), have developed the most comprehensive map to date of isoform diversity in glioblastoma, the most common and aggressive form of brain cancer in adults.
July 23rd, 2026 — Source

Chemotherapy leaves early genomic fingerprints in childhood tumors
Nearly half of childhood tumors treated with common types of chemotherapy showed detectable DNA changes linked to treatment within 18 months, according to a new international study led by The Hospital for Sick Children (SickKids). Researchers say these changes could eventually help clinicians spot treatment resistance earlier, before cancer returns or spreads, opening the door to a more precise use of chemotherapy.
July 23rd, 2026 — Source or Source

Colorectal cancer isn't the only gastrointestinal cancer rising in young adults
You may have heard that colorectal cancer is increasingly affecting young adults. However, it is not the only gastrointestinal (GI) cancer that doctors are diagnosing in patients below the age of 50, explains Christina Wu, M.D., an oncologist at Mayo Clinic Comprehensive Cancer Center in Arizona.
July 23rd, 2026 — Source

How systemic immune regulation is 'hijacked' during tumor progression
The immune system plays a critical role in protecting the body from cancer by recognizing and eliminating abnormal cells before they can develop into tumors. This process relies on T cells that can recognize tumor-derived antigens presented by dendritic cells (DCs). However, tumor cells frequently evade immune surveillance and establish immune tolerance through various mechanisms, most of which are thought to occur within the tumor microenvironment.
July 23rd, 2026 — Source

Mass-producible immune cells fight solid human tumors in mice
Off-the-shelf and mass-producible immune cells fight solid human tumors engrafted into mice. The Kobe University development is a significant contribution towards faster and cheaper cancer immunotherapy.
July 23rd, 2026 — Source or Source

MEK inhibition could limit T cell exhaustion and give a boost to immunotherapy
A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack tumors. But this strategy has been undermined by the tendency of T cells to tire out before finishing the job. When the cells reach the fatigued stage - called T cell exhaustion - these immune cells lose the ability to sustain the attack and keep cancer growth under control.
July 23rd, 2026 — Source

New immune mechanism helps explain why ovarian cancer stops responding to chemotherapy
Scientists at The Wistar Institute have identified a new mechanism behind the chemotherapy resistance that makes ovarian cancer so lethal. In a new study published in The Journal for ImmunoTherapy of Cancer, the researchers show that chemotherapy triggers an inflammatory cascade that recruits immune cells into the tumor microenvironment, which ultimately function to protect the cancer from subsequent chemotherapy.
July 23rd, 2026 — Source

New mechanism behind chemotherapy resistance in ovarian cancer discovered
Scientists at The Wistar Institute have identified a new mechanism behind the chemotherapy resistance that makes ovarian cancer so lethal. In a new study, funded by top cancer research foundations and published in The Journal for ImmunoTherapy of Cancer, the researchers showed that chemotherapy triggers an inflammatory cascade that recruits immune cells into the tumor microenvironment, which ultimately function to protect the cancer from subsequent chemotherapy. Notably, this finding could improve outcomes for patients because the molecular pathway the researchers discovered has the potential to be blocked using drugs already in clinical use for other diseases.
July 23rd, 2026 — Source

Proactive telehealth program helps cancer patients quit smoking
For patients diagnosed with cancer, continuing to smoke during treatment may shorten survival. Persistent smoking can increase treatment toxicity, reduce the effectiveness of cancer therapy, and raise the risk of disease recurrence and second primary cancers. Yet despite longstanding clinical practice guidelines recommending tobacco treatment as part of cancer care, most cancer patients are only briefly advised to quit ("you need to quit") and are rarely provided with any cessation assistance.
July 23rd, 2026 — Source

RNA-based testing can improve detection of key lung cancer biomarkers
The mutations leading to MET exon 14 skipping occur in 3% to 4% of non-small cell lung cancer (NSCLC) patients. They are exceptionally heterogeneous and occur across a broad splice-site region, creating significant analytical challenges for both DNA- and RNA-based next-generation sequencing (NGS) assays.
July 23rd, 2026 — Source

Study reveals how networks of switches in DNA, which regulate gene expression, drive cancer growth
Enhancers are pieces of DNA that act like switches, regulating when genes are turned on and off and how strongly they are activated. Scientists know these switches play a critical role in cancer and other diseases, but they have yet to fully understand how enhancers work together to control gene expression.
July 23rd, 2026 — Source

Study reveals regional disparities in Brazilian childhood leukemia mortality
An international study involving LMU found regional differences in childhood lymphoid leukemia mortality across Brazil.
July 23rd, 2026 — Source

Test offers new way to personalize treatment, reduce unnecessary chemotherapy for patients with breast cancer
A new cancer diagnostic test marketed by Veracyte and developed by a group of researchers, including UNC geneticist Charles Perou, Ph.D., has been found to accurately predict whether patients with breast cancer need chemotherapy or whether hormone therapy alone can safely and effectively lead to remission.
July 23rd, 2026 — Source

Health — Cancer — July 22nd, 2026

A single blood sample may improve the prediction of colorectal cancer recurrence or metastasis
A single preoperative blood sample may help improve the prediction of recurrence or metastasis in patients with colorectal cancer. A joint research team from KAIST, Gangnam Severance Hospital and Asan Medical Center has shown that, as colorectal cancer advances, the network of relationships among circulating amino acids (a kind of metabolic map) undergoes systematic remodeling.
July 22nd, 2026 — Source

Brain-penetrating nanoparticles, ultrasound and microbubbles show promise in treating glioblastoma
University of Virginia Comprehensive Cancer Center scientists have developed a promising new experimental approach to targeting glioblastoma, the most common and deadliest brain cancer. The approach could overcome many of the limitations of treatments using existing drugs.
July 22nd, 2026 — Source

Colorectal cancer warning signs younger adults should never ignore
Colorectal cancer is now the leading cause of cancer death among people under 50, and cases in younger adults continue to rise. Warning signs can include persistent bowel changes, recurring rectal bleeding, dark or narrow stools, unexplained weight loss, and fatigue. These symptoms often have harmless causes, but they should not be dismissed, especially when they are new or ongoing. Early detection can greatly improve treatment outcomes.
July 22nd, 2026 — Source

Combined nanoparticle and internal laser method could make cancer therapy less invasive
In a promising development for cancer treatment, a collaborative research team has overcome two issues that have prevented photothermal therapy, a much less invasive treatment option than surgery and/or radiation, from becoming more common.
July 22nd, 2026 — Source

Curcumin shows the best balance against cancer, study shows
Curcumin, berberine, and other plant-derived compounds have long attracted scientific interest because of their anti-inflammatory and anticancer properties. A new study by researchers from Wroclaw Medical University and the University of Wroclaw, however, shows that not all natural compounds act in the same way, and strong anticancer activity does not always go hand in hand with a good safety profile.
July 22nd, 2026 — Source

How p53 mutations drive immunotherapy resistance—and a path to overcome it
Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant. A new study from researchers at the Hackensack Meridian Center for Discovery and Innovation (CDI) identifies a previously unrecognized mechanism by which mutations in the p53 gene can limit the effectiveness of immunotherapy—while also revealing a potential strategy to overcome this resistance.
July 22nd, 2026 — Source

Natural compounds against sarcoma: Which one shows the greatest potential?
Curcumin, berberine and other plant-derived compounds have long attracted scientific interest because of their anti-inflammatory and anticancer properties. A new study by researchers from Wroclaw Medical University and the University of Wroclaw, however, shows that not all natural compounds act in the same way, and strong anticancer activity does not always go hand in hand with a favorable safety profile.
July 22nd, 2026 — Source

Measles cases set 35-year US record with months to go in 2026
The United States has recorded more measles cases this year than in any year since 1991, with more than five months still left on the calendar.
July 22nd, 2026 — Source

New photothermal therapy overcomes major cancer treatment barriers
Photothermal therapy uses near-infrared laser light to selectively heat and destroy cancer cells. However, when the immune system senses the nanoparticles carrying therapeutic agents it often begins clearing them before they can reach the tumors. A second problem with photo thermal therapy lies in the technology itself. Conventional external laser irradiation loses energy as it passes through overlying skin and tissue, making it difficult to heat deep-seated tumors effectively.
July 22nd, 2026 — Source

New study links specific microRNAs to cancer-associated cachexia
Cachexia-a syndrome characterized by progressive muscle wasting-affects both humans and dogs with chronic diseases such as cancer. A recent study in Molecular Oncology found that lower circulating levels of certain microRNAs-small non-coding RNAs that regulate gene expression-often indicate the presence of cachexia in senior dogs.
July 22nd, 2026 — Source

New therapeutic target expands options for multiple myeloma
In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, and produced a median duration of response of 11.2 months before the cancer progressed.
July 22nd, 2026 — Source

Same carcinogen, different tumors: Mouse study reveals the role of genetic background
Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has demonstrated in mice that an organism's genetic makeup significantly influences the course of cancer development.
July 22nd, 2026 — Source

Star Trek Legend William Shatner and His Daughter Melanie Reveal They Battled Stage 4 Cancer at the Same Time
"I'm healthier now than I've been in years."
July 22nd, 2026 — Source

Study reveals how p53 mutations cause tumors to resist cancer immunotherapy
Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant. A new study from researchers at the Hackensack Meridian Center for Discovery and Innovation (CDI) identifies a previously unrecognized mechanism by which mutations in the p53 gene can limit the effectiveness of immunotherapy-while also revealing a potential strategy to overcome this resistance.
July 22nd, 2026 — Source

Transmissible cancer cells discovered in fish act more like parasites than traditional tumors
A team of Vermont researchers has discovered that mysterious black skin lesions afflicting catfish in Lake Memphremagog and other New England and Canadian lakes are caused by a transmissible cancer—the first identified in a freshwater fish species. The cancer cells behave more like parasites than conventional tumors, moving from fish to fish.
July 22nd, 2026 — Source

Two cellular components unlock maturation in human leukemia cells, study finds
In leukemia's most aggressive forms, the blood cell factories in our bone marrow falter. Instead of dividing and multiplying at their usual prolific pace, generating hundreds of billions of new cells daily, some precursor cells stall out at an immature stage.
July 22nd, 2026 — Source

UVA researchers develop a new experimental approach to target glioblastoma
University of Virginia Comprehensive Cancer Center scientists have developed a promising new experimental approach to targeting glioblastoma, the most common and deadliest brain cancer. The approach could overcome many of the limitations of treatments using existing drugs.
July 22nd, 2026 — Source

Health — Cancer — July 16th, 2026

Clinical trial proves effectiveness of FLASH treatment for pain reduction in cancer patients
FLASH radiation therapy delivers treatment in a fraction of a second rather than minutes, making it up to 1,000 times faster than typical radiation therapy.
July 16th, 2026 — Source or Watch Video

Dynamic 3D scaffold could advance fibrosis and cancer research
Because living systems are dynamic, biomaterials should be dynamic in their mechanical properties, including stiffness. The bioelectronic conducting material PEDOT:PSS is often used in electronics and biomedical applications. The material can change stiffness in response to applied voltage, but this capability had not been rigorously studied—until now.
July 16th, 2026 — Source

Experimental KRAS vaccine safely generates durable immune response against pancreatic cancer
Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.
July 16th, 2026 — Source

Immune cells use previously unknown pathway to eliminate acute myeloid leukemia
Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based treatments and could guide the development of future cancer immunotherapies.
July 16th, 2026 — Source

New biological feedback loop helps the immune system attack colorectal cancers
A subset of cancers, known as microsatellite instability (MSI) and deficient DNA mismatch repair (dMMR) cancers, are more visible to the immune system than others. Because their DNA repair systems are defective, these tumors are more likely to be recognized and attacked by immune cells and tend to respond better to immunotherapy. But scientists do not fully understand why.
July 16th, 2026 — Source

Researchers identify immune cell that builds cancer-fighting hubs inside tumors
Researchers at the Icahn School of Medicine at Mount Sinai have identified the immune cell that acts as the architect and coordinator of powerful immune hubs that form inside tumors and plays a key role in antitumor immunity. This discovery could lead to new strategies for making cancer immunotherapies more effective.
July 16th, 2026 — Source

Stopping myeloma maintenance after two years shows no survival loss in trial
With a median follow-up of 7 years, overall survival rates in the ENDURANCE study (E1A11, NCT01863550) were almost identical between patients who continued lenalidomide until disease progression and those who stopped after 2 years. Overall survival was 69.0% in the continuous-treatment group and 68.6% in the limited-duration group.
July 16th, 2026 — Source

Study reveals why some colorectal cancers respond better to immunotherapy
A subset of cancers, known as microsatellite instability (MSI) and deficient DNA mismatch repair (dMMR) cancers, are more visible to the immune system than others. Because their DNA repair systems are defective, these tumors are more likely to be recognized and attacked by immune cells and tend to respond better to immunotherapy. But scientists do not fully understand why.
July 16th, 2026 — Source

Weill Cornell Medicine receives DoD grant to target triple-negative breast cancer
Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers. The highly competitive DoD Breast Cancer Research Program Breakthrough Award supports innovative projects with strong potential to transform breast cancer treatment.
July 16th, 2026 — Source

Health — Cancer — July 10th, 2026

Fasting primes gut microbiome to improve intestinal recovery after radiation treatment
A new preclinical study from the University of Texas MD Anderson Cancer Center has identified a gut bacterium that, when combined with short-term fasting, helps prepare the small intestine to regenerate more effectively after radiation damage.
July 10th, 2026 — Source

First-in-human immunotherapy more than doubles progression-free survival in glioblastoma patients
Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat because of limited treatment options and a poor prognosis. Patient outcomes have remained largely unchanged in the past two decades, underscoring the need for innovative research and new treatments that can improve both survival and quality of life for patients and their families.
July 10th, 2026 — Source

Global hotspots where breast cancer and atrial fibrillation overlap
A global analysis of women aged 55 and older reveals where breast cancer and atrial fibrillation most closely overlap, highlighting smoking and alcohol use as shared modifiable risk factors that could inform more targeted prevention strategies.
July 10th, 2026 — Source

Health — Cancer — July 9th, 2026

Experimental compound BA-101 overcomes chemotherapy resistance in glioblastoma
Scientists have identified a promising new strategy to tackle one of the biggest obstacles in treating glioblastoma, one of the most aggressive form of brain cancer: resistance to chemotherapy. The study shows that an experimental compound called BA-101 can restore the effectiveness of the standard drug temozolomide (TMZ) by blocking a biological process known as nitrosative stress, which helps tumors survive and resist treatment. In preclinical models, the combination therapy slowed tumor growth, reduced the cancer's ability to spread, and increased cancer cell death, opening the door to a potential new approach for treating drug-resistant glioblastoma.
July 9th, 2026 — Source

The untapped potential of bowel cancer samples to boost understanding of other diseases
About half a million samples are collected from over-50s in Scotland each year in a highly successful NHS program that significantly boosts early cancer detection. But only a tiny amount of the sent-in poo—mixed with fluid—is needed to test for traces of blood, and the rest is discarded.
July 9th, 2026 — Source

Health — Cancer — July 8th, 2026

A long‑standing mystery in the deadliest breast cancer just yielded 81 new treatment targets
Researchers have solved a long-standing mystery of how abnormal chromosomes drive cancer, identifying 81 new genes involved in aggressive breast cancer. The discovery expands understanding of the cellular processes behind the disease and opens new avenues for treatment.
July 8th, 2026 — Source

Australian cancer trials are getting worse at reporting sex differences, putting patients at risk
Women with cancer may not have the same chance of cure or quality of life as men—yet fewer than 2% of Australian cancer clinical trials report results separately for men and women. Women are also more likely to experience severe side effects from cancer treatment, including immunotherapy and chemotherapy, but without these data, clinicians have no way of knowing whether a treatment's safety or effectiveness profile applies equally to their patients.
July 8th, 2026 — Source

Creatine doesn't just build muscle. It may also help fight cancer
A UCLA study suggests the popular supplement creatine may help supercharge the immune system's fight against cancer.
July 8th, 2026 — Source

Do breast cancer and irregular heartbeat have common risk factors and rates?
The number of breast cancer and atrial fibrillation, also called AFib or irregular heartbeat, cases represents a growing global health burden, according to study authors. Why these conditions have similar rates in specific parts of the world is not well understood.
July 8th, 2026 — Source

New study identifies shared risk factors for breast cancer and atrial fibrillation
Alcohol use and smoking were linked to breast cancer and atrial fibrillation/flutter in women ages 55 years and older in multiple regions of the world, according to new, independent research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.
July 8th, 2026 — Source

Obesity promotes lung cancer by suppressing immune response, study shows
A research team led by experts at Roswell Park Comprehensive Cancer Center has documented new evidence that excess abdominal fat increases the risk of developing non-small cell lung cancer. Published in the Journal of Thoracic Oncology, the findings show that the immune system's attack on developing tumors is undermined in obese patients, contradicting earlier studies suggesting that patients with a high body mass index (BMI) are at lower risk for the disease.
July 8th, 2026 — Source

Sexual and gender minority populations are less likely to receive cancer screening
Sexual and gender minority populations remain less likely to receive recommended breast and cervical cancer screening, highlighting ongoing healthcare disparities and the need for more inclusive, equitable preventive care.
July 8th, 2026 — Source

Turning up the heat on cancer: Manganese ferrite nanoparticles outperform rivals
Scientists have long known that heat can be used to help fight cancer. But heating tumors and cancer cells is trickier than it sounds. Apply too much heat and patients could get hurt; apply too little or target the wrong location and the therapy will not be effective.
July 8th, 2026 — Source

Health — Cancer — July 4th, 2026

Common brain cancer mutation changes DNA shape to drive progression, exposing therapeutic target
A new study from researchers at The University of Texas MD Anderson Cancer Center has uncovered how one of the most common genetic alterations in glioma rewires the cancer cell genome to fuel tumor progression, suggesting a potential new therapeutic strategy for patients with ATRX-mutant gliomas.
July 4th, 2026 — Source

Health — Cancer — July 2nd, 2026

Biomarker-matched drug combos shrink treatment-resistant melanoma in preclinical models
A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug combinations based on specific tumor biology to improve outcomes for treatment-resistant advanced melanoma.
July 2nd, 2026 — Source or Source

Cancer also knows how to wait: Study uncovers the hidden step between mutation and tumor biomass appearance
The development of cancer is not a process triggered immediately by the emergence of an oncogenic mutation. There is growing evidence for the existence of an intermediate phase—hitherto poorly defined—in which mutated cells remain in a latent state, "accumulating the potential needed to grow, like a biological time bomb," explains Antonio Gentilella, a professor at the Faculty of Pharmacy and Food Sciences at the University of Barcelona and head of the Cancer Metabolism Research Group at the Bellvitge Biomedical Research Institute (IDIBELL), part of the Bellvitge Campus.
July 2nd, 2026 — Source

Going from the lab into the fire to study cancer risk in wildland firefighters
Cancer researchers at the Sylvester Firefighter Cancer Initiative (SFCI), part of the University of Miami Miller School of Medicine, took a rare step to better understand the cancer risks wildland firefighters face: They became wildland firefighters themselves. The firsthand experience is shaping a new study of smoke, heat, heavy gear and environmental exposures as Wildland Firefighter Week of Remembrance, June 30--July 6, brings national attention to the dangers of the job.
July 2nd, 2026 — Source

Long sitting bouts linked to increased cancer risk
Each additional hour of prolonged, uninterrupted sedentary behavior in a person's day is associated with a 9% higher risk of cancer death, according to a study published in PLOS Medicine by Frederick Ho of the University of Glasgow, UK, and colleagues.
July 2nd, 2026 — Source

Researchers call for increased screening for parasitic disease linked to HIV and cervical cancer risk
New research from Liverpool School of Tropical Medicine (LSTM) has highlighted the need to test millions of women and girls for female genital schistosomiasis (FGS), a neglected disease that can increase the risk of chronic illness, HIV and cervical cancer.
July 2nd, 2026 — Source

Tumors hijack macrophages after they clear dead cells, real-time tracking reveals
Researchers at Tel Aviv University's Gray Faculty of Medical and Health Sciences have uncovered how a natural and essential immune system process can be hijacked to promote cancer progression. In a new study, the research team developed an advanced technology that enabled it to track macrophages, immune system cells, in real time and reveal how they alter their behavior within a cancerous tumor after consuming dead cancer cells. The findings may pave the way for the development of new treatments targeting the specific macrophages identified in the study, restoring the immune system's ability to fight the tumor instead of helping it.
July 2nd, 2026 — Source

Two prostate cancer mutations reveal opposite responses to ferroptosis therapy
A new study by researchers at The University of Texas MD Anderson Cancer Center has identified genetic factors that determine whether prostate cancers are susceptible to a type of cell death known as ferroptosis. These findings, published in Nature Communications, could help guide treatment strategies for patients whose tumors do not respond to current treatment options.
July 2nd, 2026 — Source

Using ultrasound to attack oral cancer cells
Oral cancer is a major health challenge in India, where tobacco and areca nut use contribute substantially to the disease burden. Despite advances in surgery, chemotherapy and radiotherapy, treatment remains difficult because current approaches can damage healthy tissues along with cancer cells, often affecting patients' quality of life.
July 2nd, 2026 — Source

Health — Cancer — June 28th, 2026

Scientists uncover how ovarian cancer resists chemotherapy—and how to reverse it
Michigan State University researchers have identified how ovarian cancer cells become resistant to chemotherapy and discovered a protein that, when blocked, can restore the drug's effectiveness.
June 28th, 2026 — Source

Health — Cancer — June 27th, 2026

The fittest founder in the room got cancer. Here's how he used AI to fight back.
Conno Christou doesn't leave things to chance. He tracks his sleep with a Whoop band, cross-references it with an Oura ring, and gets nearly 100 biomarkers checked every year. He had been doing the annual bloodwork for four consecutive years, following the protocols of longevity researchers like Peter Attia and Rhonda Patrick. He was optimizing his supplements, his circadian rhythm, his protein intake.
June 27th, 2026 — Source

Health — Cancer — June 26th, 2026

AI and multiomics reveal how gut bacteria trigger colon cancer
Over the past two decades, high‑throughput sequencing has dramatically expanded our understanding of the gut microbiome's composition. However, most studies have simply listed which bacteria are present in colorectal cancer (CRC) patients, without explaining how they actually function. The field now faces major analytical hurdles: microbiome data are compositional (a change in one microbe forces apparent changes in all others), extremely sparse (most bacteria are absent from most samples), and high‑dimensional (thousands of features for a small number of patients).
June 26th, 2026 — Source

Engineered CAR T cells successfully target bladder cancer in mice
Approximately 600,000 new cases of bladder cancer are diagnosed worldwide each year, including about 80,000 cases in the US alone. Treatment generally involves surgical removal of the tumor followed by chemotherapy or immunotherapy. But these approaches are associated with high recurrence and progression rates, often necessitating complete removal of the bladder, a life-altering procedure that can lead to significant complications.
June 26th, 2026 — Source

Intravesical CAR T therapy opens door to bladder-sparing cancer treatment
Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells. The study, published in the Journal of Experimental Medicine (JEM), demonstrates that direct delivery of these CAR T cells via a catheter can control bladder tumors in mice, raising hopes that a similar approach may be effective in humans.
June 26th, 2026 — Source

What happens when celebrities talk about their prostate cancer?
When high-profile figures publicly discuss their prostate cancer, the public health impact can be immediate. The media coverage raises awareness. More men may seek information or medical advice.
June 26th, 2026 — Source

Young New Zealanders are waiting too long for bowel cancer diagnosis, study finds
Researchers from the University of Otago Faculty of Medicine—Christchurch Ōtautahi, working with Bowel Cancer New Zealand, surveyed 353 people diagnosed with colorectal cancer before age 50, uncovering significant gaps in diagnosis, treatment and support, as well as a lack of information tailored to their needs.
June 26th, 2026 — Source

Health — Cancer — June 23rd, 2026

Analysis reveals a rise in colorectal cancer among young adults in Germany, but still below US levels
Colorectal cancer is generally considered a disease of older adults. However, a new analysis of German cancer registries shows that the number of new colorectal cancer cases among younger adults has risen slightly over the past two decades. Those most affected are people between the ages of 20 and 39.
June 23rd, 2026 — Source

Artificial intelligence helps breast cancer patients avoid unnecessary chemotherapy
Research led by RCSI University of Medicine and Health Sciences and University College Dublin (UCD) has identified immune markers that could help doctors more accurately determine which breast cancer patients are unlikely to benefit from chemotherapy, potentially sparing some patients from unnecessary treatment. Chemotherapy is regularly used in the treatment of early-stage, ER+HER2- breast cancer, which accounts for around 70% of all breast cancer diagnoses annually.
June 23rd, 2026 — Source

Astral Systems raises £23M to make cancer isotopes by fusion
Bristol fusion startup Astral Systems has raised £23mn to scale the medical isotopes that cancer scans depend on. The Astral Systems £23M round backs a rare fusion company that already runs reactors and earns revenue.
June 23rd, 2026 — Source

Changes in AI mammogram image-based risk scores over time help predict future breast cancer
Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer derived from screening mammograms evolve over time and differ between women who develop cancer and those who do not, opening the door to a new era of dynamic breast cancer risk assessment. The new research was published in Radiology.
June 23rd, 2026 — Source

Low testosterone linked to cancer risk in men
New research shows men with very low testosterone levels are at higher risk of both fatal and nonfatal cancer later in life. But while the research found men with low testosterone were 18% more likely to die of cancer years down the track, the results did not hold for prostate cancer. Rather, prostate cancer appeared more closely linked with low levels of two other sex hormones: sex hormone-binding globulin (SHBG) and luteinising hormone.
June 23rd, 2026 — Source

New blood test detects more high-risk prostate cancer cases
A new blood test may make it easier to detect the most dangerous forms of prostate cancer early. In a study from Karolinska Institutet, the Stockholm3 blood test detected more clinically significant cancer cases than the PSA test, without subjecting more men to unnecessary testing
June 23rd, 2026 — Source

New framework renders AI more trustworthy for cancer subtyping
Medical artificial intelligence (AI) faces a fundamental challenge: uncertainty quantification. Artificial neural networks are largely unaware of the limits of their training data and can become overconfident when confronted with unfamiliar inputs. Suppose you train a neural network to distinguish among African mammals. If you then present it with an image of a South American jaguar—an animal it has never encountered—the model cannot say "unknown." Instead, it may confidently declare the jaguar to be a leopard.
June 23rd, 2026 — Source

Review of metformin's benefits for cardiovascular and brain health finds surprising reduction in prostate cancer
A drug commonly used to treat type 2 diabetes has the added bonus of reducing the risk of prostate cancer, new research has found. For the study, published in Rejuvenation Research, researchers conducted a literature review of research from the past 10 years, covering 2.25 million patients with type 2 diabetes taking metformin. They found metformin use in people with type 2 diabetes was associated with a reduced risk of death, cardiovascular disease and dementia.
June 23rd, 2026 — Source

Stockholm3 blood test may offer more accurate prostate cancer detection
A new blood test may make it easier to detect the most dangerous forms of prostate cancer early on. In a study from Karolinska Institutet, the Stockholm3 blood test detected more clinically significant cancer cases than the PSA test, without subjecting more men to unnecessary testing. The study is published in the Annals of Internal Medicine.
June 23rd, 2026 — Source

Health — Cancer — June 22nd, 2026

A common vitamin could help fight one of the deadliest brain cancers
A surprising vitamin B3 strategy is showing early promise in helping the immune system battle one of the world's deadliest brain cancers.
June 22nd, 2026 — Source

Algae microbots take aim at bladder cancer
Tiny algae-based robots guided by magnets could improve bladder cancer treatment by boosting delivery of chemotherapy drugs into tumors, researchers say.
June 22nd, 2026 — Source or Source

Certain demographic, birth, and parental characteristics may increase risk of early-onset colorectal cancer
A recent study has found that factors such as a person's birth weight, sex, ethnicity and father's age may affect their risk of being diagnosed with colorectal cancer at a young age.
June 22nd, 2026 — Source

Chatbot-provided information about alcohol consumption and breast cancer risk is inconsistent, new study finds
Artificial intelligence (AI) is loosely defined as a narrow form of data-driven intelligence exhibited by machines. Generative AI (GenAI) creates new content based on learned patterns and supports online chatbots such as ChatGPT, Gemini and Copilot. Given the low awareness of the relationship between alcohol consumption and breast cancer risk in the U.S., as well as the increasing use of chatbots to find health information, a new study examined GenAI chatbot responses about alcohol consumption and breast cancer risk.
June 22nd, 2026 — Source

Colon cancer cells may change identity to metastasize
Loss of GATA6—a transcription factor that controls which genes are turned on or off—can reprogram colorectal cancer cells into more primitive, adaptable states that can then spread to the liver and establish new tumors, according to Weill Cornell Medicine and Massachusetts Institute of Technology (MIT) researchers. Understanding how cancer cells acquire the ability to metastasize could reveal new ways to stop this deadly process.
June 22nd, 2026 — Source

Copper-induced cell death stimulates antitumor immune cell responses
A preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Cell, details a connection between the immune system and cuproptosis, a type of copper-induced cell death. The findings suggest a new approach to help overcome resistance to immunotherapy.
June 22nd, 2026 — Source

How neutrophils help triple-negative breast cancer cells spread
"The studies we have conducted in the past decade on the microenvironment of triple-negative breast cancer have shown that not every TNBC tumor is the same," said corresponding author Dr. Xiang Zhang, professor and William T. Butler, M.D., Endowed Chair for Distinguished Faculty in molecular and cellular biology and director of the Lester and Sue Smith Breast Center at Baylor. "Each tumor has a particular cellular composition of tumor cells and immune cells, such as macrophages and neutrophils. Depending on this composition, a tumor may follow a different path to grow, spread and resist therapies."
June 22nd, 2026 — Source

Modular nanorobot targets cancer cells and can be reused for other tasks
Researchers developed a versatile nanorobot with propulsion and payload modules. The two reusable modules autonomously self-assemble and could be used in medicine or industry.
June 22nd, 2026 — Source

New guidance to help adolescents and young adults living with and beyond cancer
Adolescents and young adults (AYA) living with and beyond cancer have unique needs and perspectives that clinicians should be aware of when providing health care.
June 22nd, 2026 — Source

Quantum-inspired AI could tailor patients' cancer treatment to their entire molecular background
For a child diagnosed with neuroblastoma—the most common infant cancer, occurring when early nerve cells grow out of control—the path to treatment isn't simple. Some types of neuroblastoma resolve on their own, while others require aggressive intervention. Researchers have tried matching treatments to patients based on one-gene mutations with limited success. This is because patients' outcomes depend on their entire molecular background, containing millions or even billions of features, such as DNA and RNA from tissues and blood.
June 22nd, 2026 — Source

Study identifies risk factors for early-onset colorectal cancer
A recent study found that factors such as a person's birthweight, sex, ethnicity, and father's age may affect the risk of being diagnosed with colorectal cancer at a young age. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
June 22nd, 2026 — Source

Tiny algae-based robots could improve bladder cancer treatment
Tiny algae-based robots guided by magnets could improve bladder cancer treatment by boosting delivery of chemotherapy drugs into tumors, researchers say.
June 22nd, 2026 — Source

Health — Cancer — June 20th, 2026

Mass spectrometry platform could shrink cancer drug discovery cycle to four hours
Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to accelerate one of the slowest and most challenging stages of cancer drug discovery: identifying promising compounds that could eventually become new therapies.
June 20th, 2026 — Source

Only a third of eligible breast cancer patients receive a gene expression test
A gene expression test can help prevent unnecessary chemotherapy in breast cancer patients, yet its use in the Netherlands remains limited. This is shown by new research from the Netherlands Comprehensive Cancer Centre (IKNL), led by Sabine Siesling, principal investigator at IKNL and professor at the University of Twente. Even after reimbursement was introduced, only about one in three eligible patients receives a test.
June 20th, 2026 — Source

This DNA repair gene went rogue and exposed a cancer weakness
A DNA-repair gene gone into overdrive may reveal a hidden weakness in many cancers—and point patients toward more effective treatments.
June 20th, 2026 — Source

Health — Cancer — June 19th, 2026

A renewable cell source for cancer immunotherapy could make off-the-shelf treatments possible
In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages. These immune cells help drive the body's response against pathogens, and they hold strong promise as the basis for immunotherapies against cancer and other diseases.
June 19th, 2026 — Source

Examining the cardioprotective effects of heart failure treatments in patients with cancer
The analysis involved systematically searching biomedical literature databases for studies in patients treated with anticancer drugs that evaluated the effects of therapies recommended in the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2023 update. Randomized controlled trials and retrospective and prospective nonrandomized studies were included.
June 19th, 2026 — Source or Source

New tool maps how T cells move within tumors
Researchers at UT Southwestern Medical Center led a study to develop a computational method that reveals how immune cells navigate the complex environment inside tumors, offering insights that could inform future cancer therapies. T cells are key players in the body's defense against cancer, but many tumors create barriers that limit their ability to enter and function effectively.
June 19th, 2026 — Source

One gene deletion tears off colon cancer's invisibility cloak, boosting immunotherapy
"Only about 15% of colon cancers respond to immunotherapy. We performed a genetic analysis of them against those that don't."
June 19th, 2026 — Source

Quick optical biopsy could be early detection method for endometrial cancer
Endometrial cancer is the most common gynecologic cancer, with more than 69,000 cases diagnosed in the U.S. in 2025 and increasing by up to 3% annually. Diagnosis requires an often painful, invasive biopsy that carries a risk of false negatives.
June 19th, 2026 — Source

Targeting enzyme could block cancer spread to brain with fewer side effects
The new drug candidates are designed to intercept rogue cancer cells before they depart from primary tumors and ultimately travel to the brain.
June 19th, 2026 — Source

Health — Cancer — June 16th, 2026

Purdue develops next-generation platform to accelerate cancer drug discovery
Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to dramatically accelerate one of the slowest and most challenging stages of cancer drug discovery: identifying promising compounds that could eventually become new therapies.
June 16th, 2026 — Source

Health — Cancer — June 15th, 2026

Experimental treatment directly kills prostate tumor cells while reawakening antitumor immunity
Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing antitumor immunity, according to a preclinical study led by investigators at Weill Cornell Medicine and the Cornell Duffield College of Engineering.
June 15th, 2026 — Source

FDA approves combination therapy for higher-risk clear cell kidney cancer after surgery
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.
June 15th, 2026 — Source

How H. pylori uses extracellular vesicles to drive stomach cancer
Scientists at the Hudson Institute of Medical Research have discovered how Helicobacter pylori, the bacterium responsible for most stomach cancers and peptic ulcers, delivers a key disease-causing protein into human cells. This breakthrough provides new insight into how H. pylori modulates chronic inflammation and promotes cancer, potentially opening new diagnostic and therapeutic pathways.
June 15th, 2026 — Source

Light-controlled molecular switch wakes lung cancer cells for treatment
Researchers from ETH Zurich have developed a molecular switch that is controlled by light. It wakes lung cancer cells up from a protective dormant state so that they are more accessible for treatment.
June 15th, 2026 — Source

Review focuses on sustaining smoking cessation support in lung cancer screening programs
Researchers from Flinders University say that building lung cancer screening programs that include strong, consistent and long-term quit-smoking support could play a crucial role in preventing smoking-related deaths.
June 15th, 2026 — Source

Targeted reminders increase serious illness conversations in cancer care
The randomized controlled trial out of Dana-Farber Cancer Institute tested two simple nudges designed to encourage important conversations between patients with cancer and their oncologists about goals and preferences for care. One nudge consisted of a reminder email to clinicians prior to patients' appointments and another was a letter and questionnaire mailed to patients. When these nudges were combined, these conversations occurred significantly more often.
June 15th, 2026 — Source

Well-timed nudges help care providers to honor the wishes of patients with cancer according to study
New research in the June 2026 issue of Journal of the National Comprehensive Cancer Network finds that small, targeted prompts delivered to both patients and providers at the right moment can significantly increase the number of serious illness conversations that take place.
June 15th, 2026 — Source

Why some cancers return: Robotic mini tumor tests point to new ways to target persister cells
Cancer drugs can shrink fast-growing tumors. But sometimes a few tumor cells survive. These "persister" cells seed new tumors, forcing cancer patients into arduous cycles of testing and treatment.
June 15th, 2026 — Source

Health — Cancer — June 10th, 2026

AI diagnoses brain tumors in minutes instead of weeks
Experts in Heidelberg, Germany, have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes and could accelerate the diagnosis of brain tumors worldwide.
June 10th, 2026 — Source

CRISPR enzyme precisely detects and shreds DNA in cancer mutations once considered 'undruggable'
In 2020, Jennifer Doudna won the Nobel Prize in chemistry for her work on the CRISPR-Cas9 gene-editing technology that allows scientists to precisely modify DNA by cutting it at specific locations. Six years later, a new study in Nature by a team led by Doudna has uncovered a powerful new approach to selectively kill cancer cells using a CRISPR enzyme called Cas12a2.
June 10th, 2026 — Source

Developing DNA-based nanostructures for targeted cancer therapy
Researchers use a Vitamin E-derived molecule to enhance the ability of DNA-based nanostructures for drug delivery, imaging, and therapeutics.
June 10th, 2026 — Source

DNA tetrahedrons unlock sharper cancer targeting with vitamin E tweak
Conventional cancer treatments, such as chemotherapy, often lack specificity and can damage both cancerous and healthy cells, leading to severe side effects. With this in mind, researchers at Indian Institute of Technology Gandhinagar (IITGN) have developed DNA nanostructures called tetrahedrons and modified them by attaching a vitamin E-derived molecule called alpha-tocopherol succinate (αT), which can disrupt vital functions inside cancer cells while acting protectively in healthy cells. By incorporating αT into the DNA tetrahedrons, the researchers significantly enhanced cellular uptake and improved anticancer efficacy, resulting in more selective and effective elimination of cancer cells.
June 10th, 2026 — Source

First report on the clinical efficacy of chemoimmunotherapy for ultra-rare urachal cancer
Physician-scientists at Kanazawa University have demonstrated, for the first time, the clinical efficacy of chemoimmunotherapy in patients with ultra-rare urachal cancer. Furthermore, their reverse translational research elucidated the mechanism by which the addition of immunotherapy enhances the efficacy of chemotherapy.
June 10th, 2026 — Source

Immune biomarkers may predict response to bladder cancer treatment
In the study, scientists investigating Bacillus Calmette-Guerin (BCG)—the standard immunotherapy treatment for high-risk bladder cancer—uncovered immune system biomarkers that distinguish patients who respond to treatment from those who do not.
June 10th, 2026 — Source

Laverock Therapeutics reports key oncology research milestones
Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage oncology programs for solid tumor indications. The data support lead program selection and progression towards the clinic.
June 10th, 2026 — Source

'Molecular eraser' destroys cancerous mRNA before protein forms, reshaping cancer cells
Many of the deadliest forms of cancer are caused by a pathological mutation in the RAS protein. Yet, to date, no effective treatment for this cancer protein has been found. A new research approach aims to prevent the protein from forming in the first place by destroying its blueprint—the mRNA. Based on this strategy, the research group led by Peng Wu at the Max Planck Institute of Molecular Physiology has now developed a new type of "molecular eraser" targeting the mRNA of the cancer protein NRAS.
June 10th, 2026 — Source

New AI system classifies brain tumors with unprecedented accuracy
Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide.
June 10th, 2026 — Source

Oral therapy enables at-home treatment for acute myeloid leukemia
For years, treatment of older patients with acute myeloid leukemia—an aggressive cancer of the blood and bone marrow—has required injections administered in a clinic for five to seven consecutive days each month, in addition to an oral pill. For these older patients, that clinic cadence can be quite intensive.
June 10th, 2026 — Source

Ultrasensitive blood test predicts head and neck cancer relapse months earlier
A new study by investigators from Mass General Brigham Cancer Institute has found that an ultrasensitive blood test called HPV-DeepSeek could help identify which people with HPV-associated head and neck cancer still had cancer cells in their bodies after surgery and may benefit the most from additional treatments.
June 10th, 2026 — Source

Uncertainty-aware AI and lensfree holography enable reliable automated HER2 assessment for breast cancer diagnostics
The integration of AI into digital pathology has the potential to transform cancer diagnostics by enabling scalable, quantitative analysis of tissue specimens. However, widespread deployment of AI-assisted pathology remains challenged by the need for costly imaging infrastructure and the lack of reliable mechanisms to assess prediction confidence.
June 10th, 2026 — Source

Health — Cancer — June 8th, 2026

AI can reveal brain tumor risks without costly genetic testing
Mayo Clinic researchers and collaborators have shown that artificial intelligence (AI) can analyze routine pathology slides to help classify meningiomas, the most common primary brain tumor in adults, and predict a patient's risk of tumor recurrence.
June 8th, 2026 — Source

Brain-targeted estrogen reduces breast cancer treatment side effects
Most breast cancers are worsened by estrogens. To combat the recurrence of these cancers, clinicians treat patients with inhibitors for estrogen production, like letrozole. But many patients do not adhere to this treatment due to negative side effects. Preclinical work in rodents suggests that a drug called 10&beta,17&beta-dihydroxyestra-1,4-dien-3-one (DHED), which delivers estrogen only to the brain, may be an effective, safe way to reduce these side effects. New in JNeurosci, researchers led by Agnès Lacreuse, from the University of Massachusetts Amherst, explored how DHED works in a more advanced animal model than rodents: aged marmosets.
June 8th, 2026 — Source

Early-onset breast cancer in Black women links most often to BRCA1 and BRCA2 variants
In the study of 686 young Black women diagnosed in Florida and Tennessee with invasive breast cancer at age 50 or younger in 2005--2018, genetic testing showed that 15.3% of the women carried a gene variant with a suspected link to breast and/or ovarian cancer, with most occurring in the BRCA1 and BRCA2 genes and fewer in PALB2, ATM, and other genes.
June 8th, 2026 — Source

Left-handed DNA tubes double cancer drug killing by boosting cell uptake
The Wang lab found that "left-handed" chiral configurations of aptamers—arranged on a DNA origami tube targeting the cancer cell surface protein (CD117)—were internalized by cancer cells much more efficiently than "right-handed" patterns. Formation of the DNA tube and its ability to arrange external elements into left- or right-handed form was characterized by gel electrophoresis, transmission electron microscopy, and super-resolution fluorescence imaging.
June 8th, 2026 — Source

Melanoma cases and deaths highest among Florida's older adults
Florida's year-round sunshine and intense ultraviolet (UV) exposure help drive one of the nation's heaviest skin cancer burdens, with older adults shouldering much of the impact. A new study from Florida Atlantic University's Charles E. Schmidt College of Medicine shows that melanoma—the deadliest form of skin cancer—continues to disproportionately affect Florida's senior population, revealing persistent gaps in both diagnosis and mortality across sex, race and ethnic groups.
June 8th, 2026 — Source or Source

Online tool transforms patient experience in national cancer trials
In a step forward for patient-centered cancer research, a new pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal (PEP). Alliance created PEP to foster direct connection between cancer researchers and the individuals who volunteer for clinical studies. The goal was to make it easier for patients and clinicians to share information, deliver trial updates, and self-report on social risk factors. The results of this national project are published in JNCI Cancer Spectrum.
June 8th, 2026 — Source

Resistance training appears to restore physical strength, immune health in frail or at-risk cancer survivors
Cancer survivors significantly improved their strength and immune health after completing a 10-week resistance training program as part of a pilot study led by Shernan Holtan, MD, Chief of Blood and Marrow Transplantation at Roswell Park Comprehensive Cancer Center. Published in the journal Cancers, the study results suggest that this type of exercise has the potential to overcome some of the effects of chemotherapy and radiation treatments, which can cause rapid aging of both the immune and musculoskeletal systems.
June 8th, 2026 — Source

Reducing side effects from breast cancer treatment
Most breast cancers are worsened by estrogens. To combat the recurrence of these cancers, clinicians treat patients with inhibitors for estrogen production, like letrozole. But many patients do not adhere to this treatment due to negative side effects.
June 8th, 2026 — Source

Rice University receives CPRIT funding to advance cancer research
New funding from the Cancer Prevention and Research Institute of Texas (CPRIT) will help Rice University advance cancer research on several fronts, from strengthening a core genetic engineering facility that serves researchers across Texas to supporting new studies in cancer immunotherapy and ovarian cancer.
June 8th, 2026 — Source

Study identifies new therapeutic candidate for KRAS-driven pancreatic cancer
A new research paper was published in Volume 17 of Oncotarget on June 3, 2026, titled "The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation."
June 8th, 2026 — Source

Trial to test AI for prostate MRI cancer diagnosis
A new UCL-led international trial will assess whether AI can perform as well as expert radiologists at detecting prostate cancer on MRI scans.
June 8th, 2026 — Source

Ultrasound turns anticancer molecule into deep-lung bacteria killer
An anticancer medication called TLD1433, a ruthenium(II) complex that has entered Phase II trials for conditions such as non-muscle-invasive bladder cancer, is now being repurposed to address one of the biggest public health issues globally—bacterial infections. Despite being preventable or treatable in many cases, bacterial infections kill an estimated 7.7 million people each year, resulting in one in eight deaths worldwide. With these numbers, it stands as the second-leading cause of death on the planet.
June 8th, 2026 — Source

Health — Cancer — June 7th, 2026

AI predicts meningioma recurrence from routine pathology slides
Mayo Clinic researchers and collaborators have shown that artificial intelligence (AI) can analyze routine pathology slides to help classify meningiomas, the most common primary brain tumor in adults, and predict a patient's risk of tumor recurrence.
June 7th, 2026 — Source

Study proposes reconsidering how histone deacetylase inhibitors work in cancer treatment
Researchers at Baylor College of Medicine and collaborating institutions are challenging the traditional understanding of how cancer drugs called histone deacetylase (HDAC) inhibitors function. For decades, scientists believed that these drugs blocked HDAC enzymes, which drive cancer development by altering how genes are turned on and off.
June 7th, 2026 — Source

Health — Cancer — June 6th, 2026

Hair-size microrobots combine three cancer-fighting functions in preclinical animal tests
Imagine a future where cancer treatment affects only the tumor, where eye injections are no longer required and brain surgeries don't result in large incisions or long recovery times. That's the future researchers at Michigan State University are working toward.
June 6th, 2026 — Source

Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
Popular GLP-1 weight-loss drugs may have an unexpected bonus: a significantly lower risk of breast cancer.
June 6th, 2026 — Source

Health — Cancer — June 5th, 2026

Early immunotherapy aids in treating potentially fatal fungal pneumonias in preclinical models
A new study led by researchers at The University of Texas MD Anderson Cancer Center has shown that early administration of immunotherapy with standard antifungal treatment improved outcomes and largely alleviated immune system paralysis caused by fungal lung infections in preclinical models. These findings could herald new clinically relevant strategies for treating a variety of life-threatening invasive fungal pneumonias, which disproportionately affect immunocompromised cancer patients.
June 5th, 2026 — Source

Experimental drug combination shows early effectiveness in advanced kidney cancer
An experimental drug combination may help overcome treatment resistance in advanced kidney cancer, according to early results from a first-in-human clinical trial led by Mayo Clinic researchers.
June 5th, 2026 — Source

Worm tablet could be repurposed as brain cancer treatment
A drug widely used to combat intestinal worms has shown promise in treating brain tumors, with scientists calling for more trials to confirm it works in humans. A systematic review published in the British Journal of Clinical Pharmacology and co-authored by Bond University researchers found mebendazole (MBZ) consistently slowed tumor growth in laboratory and animal tests. It doubled survival rates in mice, and in one study, MBZ combined with radiotherapy left more than half of mice tumor-free over the long term.
June 5th, 2026 — Source

Health — Cancer — May 30th, 2026

Implanted collagen tiles double survival for brain metastasis patients
A multicenter clinical trial led by researchers at The University of Texas MD Anderson Cancer Center has found that implanting collagen tiles during brain surgery to deliver targeted radiation therapy dramatically improved tumor control, lowered the risk of recurrence and improved overall survival compared to current standard of care for patients with newly diagnosed brain metastases in need of surgical resection.
May 30th, 2026 — Source

Health — Cancer — May 29th, 2026

Study identifies protein that helps eye cancer spread to the liver
A study led by researchers at Moffitt Cancer Center helps explain why uveal melanoma, the most common form of eye cancer, often spreads to the liver. The uvea is the middle layer of the eye, including the iris.
May 29th, 2026 — Source

Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer
The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.
May 29th, 2026 — Source

Why metformin matters beyond diabetes: New target could reshape aging and cancer research
It turns out that metformin directly targets ATP5I, a small subunit of the enzyme that produces adenosine triphosphate (ATP), the energy-carrying molecule found in the cells of all living things, the UdeM researchers have found.
May 29th, 2026 — Source

Health — Cancer — May 28th, 2026

Common anemia drugs may help slow cancer growth and progression
Common medications used to treat anemia may also slow down cancer cell growth, according to new research from Finland. Researchers from the University of Oulu and the University of Eastern Finland discovered that these drugs affect cell metabolism and growth in ways previously unknown. The findings suggest that the drugs could benefit cancer patients who often suffer from anemia, potentially treating two problems at once.
May 28th, 2026 — Source

Finnish researchers use AI to accelerate colorectal cancer diagnostics
Researchers at the Faculty of Information Technology at the University of Jyväskylä have used artificial intelligence to speed up the analysis of colorectal cancer samples and predict the functioning of the cells' DNA repair mechanism. The AI model's analysis can help shorten diagnosis times, reduce costs, and improve the analysis's accuracy. The research was conducted in collaboration with the Central Finland Welfare Region and is co-funded by the European Union.
May 28th, 2026 — Source

Grant funds research on unique challenges facing young cancer survivors
Weill Cornell Medicine received a five-year, $5 million grant from the National Cancer Institute, part of the National Institutes of Health, to develop innovative support strategies for an understudied group of cancer patients: adolescents and young adults (AYAs). For these individuals, cancer survival often marks the beginning of lifelong challenges from treatment effects.
May 28th, 2026 — Source

Healthy lifestyle shown to lower risk of death after cancer diagnosis
New evidence shows that sticking to five lifestyle recommendations improves survival after a later cancer diagnosis. The findings provide encouraging evidence that simple, achievable habits established before a cancer diagnosis can play a role in improving long-term health and the health of those following a cancer diagnosis.
May 28th, 2026 — Source

Obesity may influence how breast cancer spreads
Obesity is a known risk factor for invasive breast cancer, but researchers have not fully understood how it helps early, noninvasive breast lesions become invasive cancer. These findings could help improve physicians' ability to predict and treat the disease.
May 28th, 2026 — Source

Researchers identify new target to prevent aggressive form of prostate cancer
Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease. The study published in the Journal of Experimental Medicine (JEM), shows that genetic or pharmacological inhibition of Sirtuin 1 prevents the growth of NEPC tumors in mice, and lays the groundwork for future clinical studies aimed at developing new treatments for NEPC in humans./span>
May 28th, 2026 — Source

Unexpected allies: Eosinophils may help predict cancer immunotherapy response and survival
Long regarded as cells involved primarily in allergic responses and antiparasitic defense, eosinophils are now drawing increasing attention in oncology. A review article led by Marie Gilon, an oncology resident physician and Ph.D. candidate at the University of Liège, synthesizes current knowledge on how these white blood cells interact with tumor biology and may inform the clinical management of cancer patients.
May 28th, 2026 — Source

Veterans with cancer face years of elevated suicide risk, with danger highest just after diagnosis
Veterans diagnosed with cancer face a higher risk of suicide attempts—especially in the months following diagnosis—and that risk can persist for years, found a large, national study led by Oregon Health & Science University and the Veterans Health Administration.
May 28th, 2026 — Source

Virtual AI mouse tests nanomedicine without using living animals
When a tumor manages to nestle itself in the brain of a living being, it has - from the tumor's perspective - done something particularly clever. It has hidden itself behind one of the most powerful barriers with which the body protects its most important organs: the blood-brain barrier, a highly selective filter that only allows certain substances to pass through. Most drugs are not among them, though. It is therefore a major challenge for biomedical research to find an effective chemotherapy for brain tumors.
May 28th, 2026 — Source

Health — Cancer — May 24th, 2026

DNA repair protein gene gone rogue may unlock new cancer treatments
When it comes to cancer, tumor suppressor genes are usually thought of as the "good guys." These genes make proteins that protect and repair DNA in cells. If they stop functioning or there's not enough, cancer risk goes up. But there can be too much of a good thing: when cells overexpress the gene EXO1—meaning that they make more of the protein than they should—it can degrade the DNA it's supposed to repair. This causes damage that can disrupt the genome, which is a hallmark of cancer, according to a team of researchers from Penn State College of Medicine.
May 24th, 2026 — Source

Scientists say house cats could help unlock new cancer treatments for humans
Scientists have uncovered surprising genetic links between cat and human cancers — and the discovery could reshape cancer treatment for pets and people alike.
May 24th, 2026 — Source

Health — Cancer — May 22nd, 2026

Cancer, mood, anxiety, sleep: It's all connected, and yoga eases symptoms for survivors
University of Rochester Medicine is in the spotlight at a national meeting for a new discovery in integrative oncology: A special yoga intervention goes a step further than other therapies to improve four domains of physical and psychological side effects that most cancer patients experience, including lifting mood and easing anxiety.
May 22nd, 2026 — Source

Genetic clues may reveal which rare solitary fibrous tumors are more aggressive, likely to spread
Specific genetic fusion patterns in solitary fibrous tumors may help identify which patients face a higher risk of metastasis, recurrence and more aggressive disease behavior, according to new research that could improve how physicians assess and eventually treat this rare cancer.
May 22nd, 2026 — Source

New AI tool may help personalize multiple myeloma treatment
An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are most likely to benefit from specific therapies, including immunotherapy and stem cell transplantation.
May 22nd, 2026 — Source

Ovarian cancer cells use stress hormone signaling to shut down immune system, research reveals
When activated in ovarian cancer cells, the receptor for the body's primary stress hormone alters the tumor environment in ways that blunt immune response, according to new research led by UT Southwestern Medical Center. The findings, published in Endocrinology, identify a previously unrecognized role for the glucocorticoid receptor (GR) in shaping the ovarian cancer tumor microenvironment.
May 22nd, 2026 — Source

Ozempic and other GLP-1 RAs could slow progression of some cancers, data suggest
Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 receptor (GLP-1R) expression was associated with overall survival, suggesting that GLP-1 signaling could be involved in the progression of these cancers.
May 22nd, 2026 — Source

Scientists uncover cancer-causing chemicals hidden in everyday foods
Researchers found cancer-causing chemicals hidden in many common foods, particularly those cooked at high temperatures.
May 22nd, 2026 — Source

Health — Cancer — May 21st, 2026

Brain's 'tumor hotspots' uncovered in fruit fly study
New research from Peter Mac has uncovered why some parts of the brain may be more vulnerable to tumor growth than others, offering new clues into how brain cancers begin and how they could one day be stopped. Published in the Proceedings of the National Academy of Sciences, the research by Professor Louise Cheng's lab, used fruit fly models to investigate why cancer-causing mutations can lead to tumors in some regions of the brain and not in others.
May 21st, 2026 — Source

Breast cancer drug is effective for treatment-resistant uterine cancer
Uterine cancer is the deadliest cancer of the female reproductive system. Currently, clinicians treat the disease by using a mix of surgery and chemotherapy. But not everyone responds to this line of treatment, and those who fail first-line therapies are often left without next steps. Research by the Yale School of Medicine (YSM) shows that a breast cancer drug could provide new options for people suffering from treatment-resistant uterine cancer.
May 21st, 2026 — Source

New marker identifies patients with advanced prostate cancer more likely to benefit from combination immunotherapy
Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment.
May 21st, 2026 — Source

Scientists discover hidden weakness shared by hundreds of cancer mutations
A new technology called PerturbFate may help scientists crack complex diseases by uncovering the hidden pathways that connect hundreds of different genetic mutations.
May 21st, 2026 — Source

Scientists identify brain circuit that helps us 'change gears'
Most people have experienced the feeling: switching from one task to another, only to find the brain momentarily stuck in the old mode of thinking. Sometimes, even after realizing a strategy no longer works, the mind keeps returning to it anyway.
May 21st, 2026 — Source

Study sheds light on how early pancreas lesions become cancerous
In an unexpected finding, a new study flips on its head researchers' understanding of how precancerous pancreas lesions evolve into pancreatic cancer. The paradigm-changing discovery has tremendous implications for identifying people at higher risk of cancer or even, potentially, stopping malignant transformation.
May 21st, 2026 — Source

Study targets alcohol marketing that downplays breast cancer risk
Memorial Day weekend, the unofficial start of summer, is a peak holiday for alcohol consumption, with nearly half of celebrants reporting they plan to buy alcoholic beverages. Public health experts are raising concern that only about 28% of people are aware that regular alcohol consumption increases risk for at least seven forms of cancer.
May 21st, 2026 — Source

Health — Cancer — May 18th, 2026

Blood test detects tumor DNA to guide advanced cancer treatment
A blood test that detects tumor DNA circulating in the bloodstream may help select the most effective treatment options for cancer patients whose tumors have started to spread, according to one of the largest randomized controlled trials of its kind presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026).
May 18th, 2026 — Source

ESTRO: Select breast cancer patients may be able to omit surgery following ablative radiation
A select group of patients with early-stage breast cancer were able to omit surgery with no tumor progression after three years, according to results of a Phase 2 trial of ablative radiation therapy and endocrine therapy led by researchers at The University of Texas MD Anderson Cancer Center.
May 18th, 2026 — Source

Understanding treatment response in high-risk bladder cancer
High-risk non--muscle-invasive bladder cancer returns after treatment in roughly 30% of patients and leads to death in about 10% within two years, even after tumor resection, intensive surveillance and treatment with the standard immunotherapy known as Bacillus Calmette-Guerin (BCG).
May 18th, 2026 — Source

Health — Cancer — May 17th, 2026

A revolutionary cancer treatment could transform autoimmune disease
Researchers are testing CAR T cell therapy as a way to reset the immune system.
May 17th, 2026 — Source

Cancer-driving MYC protein also helps tumors repair damaged DNA
A protein best known for driving cancer growth also helps damaged tumor cells survive by repairing their DNA, according to a new study that could influence how some cancers are treated.
May 17th, 2026 — Source

Fewer radiotherapy sessions for prostate cancer show minimal side effects
Two larger doses of radiotherapy for prostate cancer cause no additional side effects compared to the standard five doses of radiotherapy, according to results presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026). Experts say the research brings us one step closer to safe and effective radiotherapy in only two out-patient sessions.
May 17th, 2026 — Source

Just two radiotherapy sessions given over eight days can treat prostate cancer without any extra side effects
Two larger doses of radiotherapy for prostate cancer cause no additional side effects compared to the standard five doses of radiotherapy, according to results presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026). Experts say the research brings us one step closer to safe and effective radiotherapy in only two out-patient sessions.
May 17th, 2026 — Source

Targeted radiotherapy may delay progression in metastatic breast cancer patients
Treating breast cancer that has begun to spread around the body with targeted radiotherapy could help patients to live longer without their cancer getting worse, according to the results of a small randomised controlled trial presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026).
May 17th, 2026 — Source

Health — Cancer — May 16th, 2026

Blood test that detects tumor DNA could help guide treatment when cancer has spread
A blood test that detects tumor DNA circulating in the bloodstream may help select the most effective treatment options for cancer patients whose tumors have started to spread, according to one of the largest randomized controlled trials of its kind presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026).
May 16th, 2026 — Source< or Source

Cancer risk awareness and concrete plans boosted gastric screening during COVID-19
A study conducted by researchers at University of Tsukuba revealed that individuals with higher cancer-related health literacy, perceived susceptibility to gastric cancer, and encouragement from family members or health care providers demonstrated stronger intentions to undergo gastric cancer screening, even during the COVID-19 pandemic. These intentions were significantly associated with subsequent screening participation. In contrast, while fear of COVID-19 increased screening intention in the short term, over time it could suppress screening behavior.
May 16th, 2026 — Source

Common cancer protein may be therapeutic target, study finds
A protein doctors routinely use to measure how aggressively tumors are growing may also help prevent the chromosome errors that drive cancer, new research by academics at Brunel University of London suggests.
May 16th, 2026 — Source

Q&A: Examining the quality of life after esophageal and gastric cancer treatment
The survival rates of patients with esophageal and gastric cancers have improved. However, many survivors continue to experience long-term symptoms. On May 29, Kenneth Färnqvist will defend his thesis "The architecture of survivorship: patterns of quality of life, symptom dynamics, and self-care in esophageal and gastric cancer" in which he has investigated how quality of life, symptoms, and self-care develop over time.
May 16th, 2026 — Source

Health — Cancer — May 15th, 2026

How exercise influences cancer cell viability
My research focuses on understanding how exercise affects cancer cell behavior within the breast cancer microenvironment, specifically in the context of obesity. My team is investigating whether exercise can counteract the negative influence that fat cells have on cancer cell viability.
May 15th, 2026 — Source

New mechanism to enhance precision in cancer drug development
Researchers at The University of Texas Medical Branch (UTMB) have identified how a key enzyme called ATR protects DNA from breaking when cells copy damaged genetic material, a discovery that could affect how certain cancer drugs are developed.
May 15th, 2026 — Source

Nanometer-scale cell sugar mapping reveals internal states, from immune activation to cancer stages
Every human cell is surrounded by a sugar coating known as the glycocalyx. It not only interacts with its environment but also reveals a great deal about cells' internal states. Scientists at the Max Planck Institute for the Science of Light (MPL) have mapped sugar structures on cell surfaces using high-resolution microscopy.
May 15th, 2026 — Source

Scientists discover vitamin B2 may help cancer cells survive
Scientists have uncovered a surprising dark side to vitamin B2: it may help cancer cells stay alive. The vitamin supports a cellular shield that protects tumors from ferroptosis, a form of programmed cell death linked to cancer suppression. In lab tests, researchers used a vitamin B2-like compound called roseoflavin to break down that protection and trigger cancer cell death.
May 15th, 2026 — Source

Why breast cancer becomes more deadly with age
Researchers at Georgetown's Lombardi Comprehensive Cancer Center have identified a mechanism that may help explain a key reason why older people experience worse outcomes from breast cancer. The study implicates RAGE (Receptor for Advanced Glycation End-products), a cell surface receptor that amplifies inflammatory signaling, and which also becomes increasingly active with metastatic progression.
May 15th, 2026 — Source

Worse survival seen with tumor-infiltrating clonal hematopoiesis in patients with solid tumors
Dabin Yun, Pharm.D., from Chungbuk National University in South Korea, and colleagues characterized the prevalence of TI-CH in solid tumors and assessed its association with clinical factors and overall survival in a retrospective cohort study analyzing whole-genome sequencing data of a large cohort of patients with solid tumors. The prevalence of TI-CH was measured as the primary outcome, defined by somatic variants in 74 driver genes in tumor tissue.
May 15th, 2026 — Source

Health — Cancer — May 14th, 2026

Cancer fatigue may ease within weeks as common stimulant shows benefit
Cancer-related fatigue affects nearly three-quarters of people living with cancer, according to some estimates, yet it remains one of the most undertreated symptoms in oncology.
May 14th, 2026 — Source

Hidden genetic defect linked to Kaposi sarcoma for the first time
A new study has uncovered a genetic cause that may explain why some people develop Kaposi sarcoma despite having no apparent immune deficiency. The rare cancer, which forms in the cells lining blood vessels, is caused by human herpesvirus 8 (HHV-8), also known as Kaposi sarcoma--associated herpesvirus.
May 14th, 2026 — Source

Scientists develop a superior diagnostic tool to spot hidden gene fusions in pediatric cancer
Researchers have introduced a novel diagnostic method that can more sensitively detect gene fusions in B-cell acute lymphoblastic leukemia (B-ALL), the most common type of pediatric cancer, compared to other publicly available fusion detection algorithms.
May 14th, 2026 — Source

Scientists identify methylphenidate as an effective tool for combating chronic cancer-related fatigue
A new meta-analysis in the May 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants-a class of medication that increases dopamine and norepinephrine availability in the brain-can provide meaningful relief for cancer-related fatigue.
May 14th, 2026 — Source

Study shows that people who gain the most weight are at more than double the risk of certain cancers
New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) shows that people who gain the highest amount of weight across adulthood are at greatly increased risk of certain obesity-related cancers. The study is by Associate Professor Anton Nilsson and Associate Professor Tanja Stocks, Department of Translational Medicine, Lund University, Malmö, Sweden, and colleagues
May 14th, 2026 — Source

Health — Cancer — May 11th, 2026

A common cholesterol drug may weaken ovarian cancer's hidden shield
Ascites—the buildup of liquid in the belly—may be doing more than causing discomfort. A Duke University School of Medicine study finds this fluid helps cancer cells survive and spread—and that a decades-old cholesterol drug may be able to disrupt that protection.
May 11th, 2026 — Source

Depression may be overdiagnosed in patients with ovarian cancer
People with ovarian cancer could be being overdiagnosed with depression due to the physical symptoms they experience as part of the cancer, according to international researchers. In addition to causing mental symptoms such as sadness and despair, depression can cause physical sensations including fatigue, headaches, back pain, gastrointestinal issues, and sleep problems.
May 11th, 2026 — Source

Slow-dividing breast cancer cells may explain relapses decades after treatment
A new study by the Garvan Institute of Medical Research has uncovered a hidden mechanism explaining why breast cancer can return many years after successful treatment. Published in Nature Communications, the research reveals rogue cells that change their programming to allow them to divide at a remarkably slow pace, meaning they could form microscopic tumors that silently tick away in distant organs, evading detection for decades.
May 11th, 2026 — Source

Health — Cancer — May 9th, 2026

Public education key in new cervical cancer screening
As Canada moves to modernize cervical cancer screening, a new study suggests most women do not yet understand or trust the shift from the Pap test to human papillomavirus (HPV) based screening. The national survey, published in Current Oncology, examined women's preferences for cervical screening—including how they want to be screened and how they want information communicated—as Canada transitions from Pap tests to HPV testing.
May 9th, 2026 — Source

Health — Cancer — May 8th, 2026

IL-10 gene therapy boosts immune attack against liver cancer in mice
Researchers at National Taiwan University have developed a liver-directed IL-10 gene therapy that strengthens cancer-fighting immune cells and suppresses liver tumors in mice. The treatment also generated long-lasting immune memory cells that remained in the liver after tumors disappeared.
May 8th, 2026 — Source

Immunologist's lab demonstrates the power of B cells to gather and defend organs against cancer
Creativity and curiosity have always been central to the work of Joshua Moreau, Ph.D., an immunologist whose work at Oregon Health & Science University sits at the intersection of harnessing the immune system; delving into tissue biology; and, most recently, discovering a potentially powerful defense against the invasion of cancer cells.
May 8th, 2026 — Source

Nanoparticles that disable drug resistance before delivering chemo eliminate tumors in mice
A two-step nanoparticle system first blocks cancer cells' drug-expulsion mechanism, then releases chemotherapy combined with laser-driven heat to destroy resistant tumors.
May 8th, 2026 — Source or Source or Source

Technology receives FDA approval for breast cancer treatment
More than a decade ago, Yale chemist Craig Crews founded a biotechnology company in New Haven based on his pioneering research into PROTACs (or PROteolysis TArgeting Chimera), a technology that treats certain types of cancer and other diseases by degrading the proteins that cause them.
May 8th, 2026 — Source

Health — Cancer — May 7th, 2026

A new combined therapy to boost the immune system against cancer
Cancer immunotherapy is built on a simple but powerful idea: the immune system can recognize and destroy cancer cells if it is properly activated. In many patients, however, this response is too weak or too slow to be effective.
May 7th, 2026 — Source

Despite breakthroughs, many go without treatment for metastatic lung cancer
About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan and quality of life for many patients.
May 7th, 2026 — Source

Why unusually long telomeres could raise lymphoma risk and reshape cancer monitoring
Researchers at the Johns Hopkins Kimmel Cancer Center and the Telomere Clinic at Johns Hopkins have identified a genetic syndrome in which unusually long telomeres—the protective caps at the ends of chromosomes—allow immune cells to remain biologically "younger" for longer than normal, predisposing affected individuals to lymphoma and other cancers.
May 7th, 2026 — Source

Health — Cancer — May 4th, 2026

Mistletoe extract shows no effect in patients with advanced pancreatic cancer
New research shows that palliative patients with pancreatic cancer neither live longer nor experience improved quality of life when taking mistletoe extract in addition to standard cancer treatment, compared to placebo.
May 4th, 2026 — Source

New technique uses electronic jolt and nanoparticles to reveal early signs of pancreatic cancer
Scientists at Oregon Health & Science University have developed a new technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer.
May 4th, 2026 — Source

One missing metabolic step can turn cancer's DNA-copying machinery into a lethal weakness
Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, a study led by UT Southwestern Medical Center researchers shows.
May 4th, 2026 — Source

Proteins found in cancer extracellular vesicles could guide drug development
Cancer cells release tiny biological packages called extracellular vesicles (EVs) that help tumors grow and spread. A team led by Cedars-Sinai Health Sciences University investigators has now connected certain proteins carried in these EVs with poor patient outcomes in multiple cancer types.
May 4th, 2026 — Source

Some breast cancer survivors need closer heart disease monitoring
The racial makeup and socioeconomic status of early-stage breast cancer patients could offer clues about their risk for heart disease, the leading cause of death among breast cancer survivors. Results of a study led by a Cedars-Sinai breast oncologist and published in npj Breast Cancer identified several groups of patients who could benefit from closer monitoring after a breast cancer diagnosis.
May 4th, 2026 — Source

Health — Cancer — April 27th, 2026

As heart, kidney and metabolic health worsen, cancer risk may rise, research indicates
The biggest dangers from CKM syndrome are death and disability from heart disease and stroke. However, nearly every major organ system is affected by CKM syndrome, linking it to kidney failure, dementia, fatty liver disease, obstructive sleep apnea, and increased risk for cancer.
April 27th, 2026 — Source

Inside lungs, tumor position reveals immune shifts missed by other models
Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside lung tumors. By combining a patient-relevant mouse model with single-cell technologies, the team provides one of the most comprehensive immune maps to date of lung adenocarcinoma, which is the most common subtype of lung cancer.
April 27th, 2026 — Source

Mail-in test for colorectal cancer could help community health centers increase screening
Colorectal cancer (CRC) is the second most common cause of cancer death in the United States and disproportionately impacts people who receive care in under-resourced settings. Fortunately, several effective screening tests are available to detect cancer early when it is most treatable.
April 27th, 2026 — Source

Newer mail-in stool tests increase colorectal cancer screening completion rates
Colorectal cancer (CRC) is the second most common cause of cancer death in the United States and disproportionally impacts people who receive care in under-resourced settings. Fortunately, several effective screening tests are available to detect cancer early when it is most treatable. In partnership with community health centers (CHC), investigators from Mass General Brigham and UCLA Health mailed one of two stool-based screening tests to more than 5,000 participants from CHCs in Boston and Los Angeles.
April 27th, 2026 — Source

Pesticide exposure linked to 150% higher cancer risk in major study
A major new study finds that living in pesticide-heavy environments could raise cancer risk by up to 150%, even when the chemicals are considered "safe" on their own. The research suggests these mixtures may silently damage cells years before cancer appears.
April 27th, 2026 — Source

Researchers develop AI tool to assess lung cancer surgery complication risk
Researchers from the University at Buffalo and Roswell Park Comprehensive Cancer Center are developing an artificial intelligence tool to help surgeons better identify lung cancer patients at risk for postoperative complications. The work builds on a longstanding collaboration between the institutions, bringing together UB's strengths in AI and Roswell Park's expertise in thoracic oncology.
April 27th, 2026 — Source

Repurposed drugs may provide safer treatments for aggressive childhood leukemia
Three clinically available drugs could pave the way for safer and more effective treatments for one of the most aggressive forms of childhood leukemia, a new study suggests.
April 27th, 2026 — Source or Source

Scans uncover hidden prostate cancer progression when PSA stays stable
The findings, drawn from more than 2,500 patients, raise questions about how physicians monitor prostate cancer treatment response and suggest that relying solely on prostate-specific antigen (PSA) levels—the most commonly used blood biomarker for the disease—may leave some disease progression undetected.
April 27th, 2026 — Source

Turning immune cells into tumor allies: A cancer cell protein can reprogram frontline defenders
Cancer cells can disarm the immune system not just by hiding from it, but by actively reprogramming nearby immune cells into a suppressed state. This previously unrecognized molecular interaction, discovered by scientists at the University of Texas Southwestern Medical Center in Dallas, could become a new target to disable and potentially aid patients with cancers that defy the form of immunotherapy known as the checkpoint blockade.
April 27th, 2026 — Source

Health — Cancer — April 26th, 2026

Discovery of a novel vulnerability in aggressive lymphoma could change future therapy
A research team at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) has discovered that the protein cFLIP can be used to override the defenses of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. These defenses often cause treatments to be ineffective because they allow the cancer cells to survive. The results are especially relevant to ABC-DLBCL, a specific subtype of blood cancer that has poor patient prognosis and survival outcome.
April 24th, 2026 — Source

Stiffer tumor tissue may accelerate cancer spread and rewire nearby cells
The stiffness of tumor tissue plays a role in how cancer spreads. Furthermore, stiff tumor tissue leaves traces in the affected cells, according to two recent research studies from Lund University. "This helps us to better understand how the mechanical properties of the tumor microenvironment actively drive cancer development and spread," says Vinay Swaminathan, senior lecturer at Lund University.
April 24th, 2026 — Source

Health — Cancer — April 24th, 2026

Alcohol causes more cancers in Australia than previously thought
Alcohol consumption is likely to cause more cancer incidence in Australia than previously thought, according to new research from the University of Sydney. The new study, published in the British Journal of Cancer, analyzed alcohol consumption behavior among 225,000 people in the 45 & Up Study cohort in NSW—Australia's largest ongoing study of health and aging.
April 24th, 2026 — Source

Exploiting a new vulnerability that targets 'zombie' cells as an anticancer therapy
A new set of drugs exploit a recently revealed weakness in "zombie-like"—or senescent—cells that could lead to new treatments for cancer and age-associated diseases. The study from the MRC Laboratory of Medical Sciences (LMS) and Imperial College London shows that senescent cells walk a tightrope, risking cell death with high levels of iron and other damaging agents but compensating for this by overproducing a protective protein that staves off death.
April 24th, 2026 — Source or Source

Liquid metal nanoparticles freeze into spikes that kill drug-resistant cancer
Bismuth-doped gallium nanoparticles transform into cell-puncturing spikes under freezing, killing drug-resistant lung, colorectal, and ovarian cancer organoids through mechanical disruption rather than biochemistry.
April 24th, 2026 — Source

Mechanical forces from the beating heart may help prevent cancer cell growth
Scientists may have discovered another way the human body tries to protect itself from cancer. New research on mice suggests that the heart's constant beating may prevent tumor growth in cardiac tissue. Most organs are vulnerable to cancer, but the heart is something of an anomaly. While cancer can spread from other parts of the body to the heart, tumors rarely start there. It's a medical mystery that has puzzled scientists for years.
April 24th, 2026 — Source

New scoring tool shows radiation can reprogram pancreatic tumor environment
A new study by researchers at Fox Chase Cancer Center focusing on pancreatic cancer has shown that a new scoring system can provide a single numerical value that reflects whether the tumor microenvironment, the biological "neighborhood" surrounding a tumor, is working to suppress or support that tumor. The results of the laboratory study could ultimately help clinicians improve treatment offered to patients with pancreatic cancer.
April 24th, 2026 — Source

Study reframes Hodgkin lymphoma as a cancer of failed cell development
For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis." Normally, a B cell matures into a plasma cell that produces antibodies to fight infection, but in this case, the cells are trapped partway through the transition. They switch off key B cell features but never fully mature into functional plasma cells, instead surviving as malignant Hodgkin lymphoma cells, also called Reed-Sternberg cells.
April 24th, 2026 — Source

Health — Cancer — April 23rd, 2026

Bioengineered chewing gum reduces cancer-linked oral microbes
Researchers led by Henry Daniell of the School of Dental Medicine have shown that extracts from bioengineered chewing gum reduce the levels of three microbes known to be associated with head and neck squamous cell cancer (HNSCC), paving the way for more effective and affordable therapies. Their findings are published in Scientific Reports.
April 23rd, 2026 — Source

Can exercise or ibuprofen fight chemo brain?
A simple home-based exercise program may help counter "chemo brain," but adding ibuprofen does not boost the benefit and may even complicate memory outcomes, highlighting the need for larger trials.
April 23rd, 2026 — Source

Dual-pathway blockade therapy offers hope for rare, hard-to-treat gynecological clear cell cancers
Before her cancer diagnosis in early 2017, 48-year-old Caitlin Delaney, who is based in Australia, had been struggling with a troubling mix of symptoms comprising extreme fatigue, chronic sinusitis, and appetite changes including a sudden aversion to foods such as chocolate and alcohol. Detailed tests and scans eventually revealed the cause—an advanced stage of clear cell ovarian cancer. For another patient, Michelle (not her real name), aged 49, the road to diagnosis came in late 2022 after months of persistent acid reflux, bloating, and ongoing indigestion, which similarly pointed to the same cancer—clear cell carcinoma of the ovary.
April 23rd, 2026 — Source

Innovative light probes allow real-time visualization of cellular processes
Fluorescent proteins have revolutionized science, enabling researchers to tag and visualize individual molecules in living cells, tissues, and animals. Using these tools, researchers have watched viruses infect cells in real time, observed cellular trash collection, and tracked the signaling that spurs tumor growth.
April 23rd, 2026 — Source

Rectal cancer deaths in older millennials are rising rapidly
Rectal cancer deaths among older millennials are accelerating, with growth in mortality far outpacing colon cancer, suggesting primary care doctors should fully investigate early symptoms in patients under age 45, according to a study to be presented at Digestive Disease Week® (DDW) 2026.
April 23rd, 2026 — Source

Restoring gut microbiome may prevent liver cancer in mice
Restoring the gut microbiome to its youthful state may hold the key to slowing aging and preventing liver cancer, one of the fastest-growing cancers worldwide, according to a study to be presented at Digestive Disease Week® (DDW) 2026.
April 23rd, 2026 — Source

Study maps the evolution of myeloid leukemia in children with Down syndrome
It may be possible to identify which pre-cancerous cells will develop into a rare type of blood cancer, due to new research showing that a single genetic change drives myeloid leukemia in children with Down syndrome.
April 23rd, 2026 — Source or Source

Two-faced protein discovery may explain why leukemia drugs fail or succeed
A KAIST research team has identified the real reason why anticancer drugs kill cancer cells—targeted anticancer therapies do not simply block cancer proteins but rather shut down the "protein factories" inside the cells, forcing them to undergo self-destruction. Consequently, the "two-faced protein" that plays a key role in this process is gaining attention as a breakthrough for treating patients with drug resistance.
April 23rd, 2026 — Source

USC and Tempus AI partner to advance precision medicine
The Keck School of Medicine of USC and Keck Medicine of USC have launched collaborations with Tempus AI, Inc., a technology company at the forefront of applying AI to precision medicine, to integrate clinical care, clinical trials and research through a unified framework. The goal of this strategic collaboration, which will span the USC Norris Comprehensive Cancer Center, the Keck Hospital of USC, USC Verdugo Hills and all USC-affiliated hospitals and clinics across Southern California, is to enhance patient care and accelerate research and innovation.
April 23rd, 2026 — Source

Health — Cancer — April 21st, 2026

Extra chromosomes may help tumor cells move and engulf neighbors, study suggests
Extra chromosomes may help tumor cells move and engulf neighbors, study suggests
April 21st, 2026 — Source

Health — Cancer — April 17th, 2026

Catching a scramblase in the act could pave the way to improved blood disorder and cancer treatments
Weill Cornell Medicine investigators have revealed the detailed workings of a cell membrane protein that has essential roles in all animals. The discovery could lead to new therapeutic strategies for blood coagulation disorders, cancers and other conditions in which the protein, called a TMEM16 scramblase, works abnormally. Scramblases operate within cell membranes, where they alter or "scramble" the normal layered arrangement of lipid molecules—an essential step in many biological processes.
April 17th, 2026 — Source

Innovative surgery relieves chronic leg and arm swelling
Innovative surgery relieves chronic leg and arm swelling
April 17th, 2026 — Source

New guidance says all average-risk females aged 50--74 should undergo biennial mammography screening
New guidance from the American College of Physicians (ACP) says all average-risk females ages 50 to 74 should receive biennial screening mammography for breast cancer. Females between the ages of 40 and 49 should discuss with their doctor their risk for breast cancer and the benefits and harms of screening.
April 17th, 2026 — Source

Older mice may offer new insight into cancer and aging
Cancer risk increases with age and is often more aggressive and difficult to treat in older adults. However, fewer than 10% of mouse studies use aged animals, with most relying on mice roughly equivalent to humans in their early 20s. This discrepancy is one potential reason so many cancer drugs that show promise in preclinical models go on to fail in human trials.
April 17th, 2026 — Source

Researchers discover how cell membrane composition drives cancer proliferation
Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment. However, evidence has recently emerged suggesting that these membranes do more than simply provide protection - they also influence the behavior of the protein receptors embedded in them.
April 17th, 2026 — Source

Scientists find unexpected immune pathways for mRNA cancer vaccines
The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel-prize--winning technology is being adapted to fight cancer, with mRNA vaccines in clinical trials for melanoma, small cell lung cancer and bladder cancer, among others, opening the door to new ways of preventing and treating the disease.
April 17th, 2026 — Source

Health — Cancer — April 14th, 2026

Blocking a single protein supercharges the immune system against cancer
Scientists have discovered a way to supercharge the immune system's T cells by blocking a protein called Ant2, forcing the cells to rewire how they generate energy. This shift makes them more powerful, resilient, and effective at finding and destroying cancer cells.
April 14th, 2026 — Source

Combining new drug with chemotherapy extends survival of platinum-resistant ovarian cancer patients in clinical trial
Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases. In some patients, the disease returns or progresses within six months of the last platinum dose, a condition referred to as platinum-resistant cancer. This form of cancer is a leading cause of gynecological cancer-related mortality.
April 14th, 2026 — Source

Hidden tumor protein may help forecast immunotherapy success in colon and rectal cancer
Determining the presence of a protein in non-tumor cells within the cancer microenvironment could be one of the keys to establishing prognosis in patients with colon and rectal cancer. It may also help identify which patients could benefit from immunotherapy or from treatments aimed at inhibiting a specific protein linked to tumor proliferation.
April 14th, 2026 — Source

New drug doubles 1-year survival in pancreatic cancer trial
Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.
April 14th, 2026 — Source

Health — Cancer — April 13th, 2026

Young cancer survivors face double the risk of later cancers
Survivors of cancer in their teen and young adult years are at double the risk of most types of later cancers, according to research from Alberta published in CMAJ (Canadian Medical Association Journal)
April 13th, 2026 — Source

Health — Cancer — April 12th, 2026

Cancer Rates Are Higher Near Large Livestock Feeding Operations in 3 States, a New Study Finds
Researchers comparing maps of CAFOs with county-level disease data from California, Texas and Iowa found increased rates of all types of cancer, but said more research is needed to determine the cause.
April 12th, 2026 — Source

How aggressive breast cancer turns off the immune system
Researchers are launching a new project to crack the mystery of aggressive breast cancer, where predicting disease progression remains a major hurdle. By studying how tumors interact with and suppress the immune system, scientists aim to identify new biomarkers that reveal how the cancer evolves. Using real patient samples, the team hopes to turn earlier discoveries into practical clinical tools. The goal: more precise, personalized treatments that can outsmart even the most dangerous tumors.
April 12th, 2026 — Source

Health — Cancer — April 11th, 2026

Antidepressant unable to prevent chemotherapy-associated nerve damage
A randomized trial conducted by the Alliance for Clinical Trials in Oncology has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by chemotherapy in patients with colorectal cancer.
April 11th, 2026 — Source

Researchers map prostate immune niches, showing T cells persist months in mice
More than 35,000 men in the United States die from prostate cancer each year. Now, a new study reveals the immune cell weaponry we might use to save lives.
April 11th, 2026 — Source

Shifts in cancer mortality: Place of living increasingly determines where historic drop in cancer mortality reaches
In 1991, the U.S. experienced a significant shift in cancer death rates, as, for the first time, deaths began a steady decline that continues to the present day. Researchers at Mississippi State's Social Science Research Center, in partnership with scientists at Oak Ridge National Laboratory, examined this decline to identify where and who benefited the most from this dramatic improvement.
April 11th, 2026 — Source

Study finds no increased risk of respiratory cancers from asbestos-free talc exposure
In a systematic review and meta-analysis, researchers found that occupational exposure to talc that is not contaminated with asbestos is not associated with an increase in the risk of lung cancer, mesothelioma, or laryngeal cancer.
April 11th, 2026 — Source

Health — Cancer — April 9th, 2026

AI outperforms doctors at summarizing complex cancer pathology reports
AI models can generate more complete summaries of complex cancer pathology reports than physicians, according to a new Northwestern Medicine study that tested six models developed by Meta, Google, DeepSeek and Mistral AI.
April 9th, 2026 — Source

Brain tumors: 3D experimental system to evaluate candidate drugs against glioma
Glioma is a tumor of the central nervous system that originates from glial cells, which support neurons in the brain. In the less aggressive, slow-progressing forms, gliomas are often found in children and youth. Glial tumors alone make up almost 40% of all tumors of the central nervous system. Low grade gliomas are less aggressive than others, but still difficult to interpret biologically.
April 9th, 2026 — Source

How an overactive immune system can drive cancer
The immune system is designed to protect us against viruses and bacteria. In autoimmune diseases, however, the immune system instead attacks the body's own cells. Conditions such as systemic lupus erythematosus (lupus) and rheumatoid arthritis are well-known examples. It is estimated that just under 250,000 people in Norway live with some form of autoimmune disease, with approximately 8% to 10% of the population worldwide.
April 9th, 2026 — Source

Long non-coding RNA may be a promising therapeutic target for cancer
Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways in prostate cancer cells and drives tumor progression, underscoring its potential as a therapeutic target, according to a recent study published in Nature Communications. Rendong Yang, Ph.D., associate professor of Urology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was co-corresponding author of the study.
April 9th, 2026 — Source

New method provides clearer view of how genome functions in cancer
Researchers at the University of Minnesota Medical School have developed a new method called PARTAGE that provides a clearer picture of how the genome is regulated and disrupted in diseases like cancer.
April 9th, 2026 — Source

New tool offers personalized approach to blood cancer care
Researchers have developed a new tool to help clinicians tailor personalized treatment plans for patients with a rare blood cancer called chronic myelomonocytic leukemia (CMML). The tool, called the international CMML Prognostic Scoring System (iCPSS), may help improve a patient's chance of survival.
April 9th, 2026 — Source

Octopus-shaped nanomachine reprograms ATP flow to starve cancer cells
An octopus-shaped nanomachine hijacks tumor ATP leakage to power a self-amplifying cycle of membrane damage, drug delivery, and metabolic collapse in cancer cells.
April 9th, 2026 — Source

OICR funds four Ontario teams to develop next-generation cancer therapies
Better cancer care depends on better treatment options. That's why the Ontario Institute for Cancer Research (OICR) is supporting four Ontario-based research teams working to develop the next generation of cancer therapies that are designed to be more effective at destroying tumors, have reduced side effects, and make cancer less likely to return. These projects take aim at breast and ovarian cancers, a hard-to-treat form of leukemia, the most aggressive form of the most common childhood brain cancer and a 'master regulator' protein that plays a role in many different cancers.
April 9th, 2026 — Source

Precision medicine tools offer hope for patients with rare blood cancers
Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas - blood cancers that arise in immune cells called B cells - yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.
April 9th, 2026 — Source

Study explains why current BET inhibitors fail in cancer treatment
For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that "Bromo- and Extra-Terminal domain" (BET) proteins help activate, so blocking BET proteins should slow tumor growth. In the lab, it often did. In patients, results were mostly disappointing: limited responses, significant side effects, and no clear way to predict which tumors would respond at all.
April 9th, 2026 — Source

Why anti-cancer drugs do not always live up to expectations
For more than a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that "Bromo- and Extra-Terminal domain" (BET) proteins help activate, so blocking BET proteins should slow tumor growth.
April 9th, 2026 — Source

Health — Cancer — April 8th, 2026

A urine test that could change the course of bladder cancer care
Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in the United States. Most patients are diagnosed at an early stage called non-muscle invasive bladder cancer (NMIBC), in which the tumors are confined to the inner layers of the bladder. Despite early detection, the disease frequently returns.
April 8th, 2026 — Source

Clusterin inhibition offers new hope for treating cervical gastric-type adenocarcinoma
Gastric-type adenocarcinoma (GAS) is one of the most aggressive non-human papillomavirus (HPV)-associated cervical adenocarcinomas and remains especially difficult to diagnose and treat. It is often missed because it can arise high in the cervical canal, test negative for HPV, and resemble benign lesions. Clinically, it is more invasive, more likely to metastasize, and linked to poorer survival than usual-type endocervical adenocarcinoma. Standard treatments such as radiotherapy and chemotherapy often work poorly, while the biological basis of its resistance has remained unclear. Although genomic studies have provided partial clues, they have not fully explained how GAS builds such a malignant and treatment-refractory microenvironment. Based on these challenges, deeper research is needed on the tumor microenvironmental mechanisms driving GAS progression and therapeutic resistance.
April 8th, 2026 — Source

Duloxetine fails to prevent nerve damage caused by chemotherapy
A randomized trial conducted by the Alliance for Clinical Trials in Oncology with support from the National Cancer Institute has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by chemotherapy in patients with colorectal cancer.
April 8th, 2026 — Source

Future CAR therapy expands beyond T cells to treat diverse diseases
CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies. However, its limitations remain evident. In solid tumors, engineered T cells often struggle with trafficking, persistence, antigen heterogeneity, and the immunosuppressive tumor microenvironment. Toxicities such as cytokine release syndrome and neurotoxicity remain serious concerns, while autologous manufacturing is slow, expensive, and difficult to scale. These shortcomings have pushed researchers to rethink CAR not as a single-cell solution, but as a broader therapeutic platform. Based on these challenges, deeper research into diverse CAR systems is needed.
April 8th, 2026 — Source

Never married adults face higher risk of developing cancer
Adults who have never been married face a significantly higher risk of developing cancer than those who have been married, according to a large U.S. study of more than 4 million cases. The increased risk spans nearly every major cancer type and is especially pronounced for preventable cancers-those linked to infections, smoking and reproductive factors. Led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the study appears in the April 8 issue of Cancer Research Communications.
April 8th, 2026 — Source or Source

Study reveals how hyperdiploidy creates rare pre-leukemic clones in children
B-cell acute lymphoblastic leukemia is the most common form of childhood cancer. In this type of cancer, which affects blood cells, one of the most common abnormalities is the presence of cells with an excess of chromosomes (hyperdiploidy), a condition that leads to chromosomal instability. Now, a study published in Cell Reports reveals that this chromosomal instability caused by hyperdiploidy reduces the proliferation of the affected cells, delays their differentiation and allows some to persist as rare, long-lived clones in the bone marrow, but without triggering leukemia.
April 8th, 2026 — Source

Health — Cancer — April 6th, 2026

About 80% of breast cancer biopsies turn out benign. New imaging tool promises clearer diagnoses and fewer biopsies
Ultrasound is widely used in breast cancer diagnosis. While it can effectively show that a lump is filled with fluid—indicating it is unlikely to be cancer—it cannot reliably determine whether a solid mass is benign or cancerous. This often leads doctors to order breast biopsies to confirm the presence of cancer.
April 6th, 2026 — Source

Diabetes drug metformin may echo the benefits of exercise in prostate cancer care
A new study has found that metformin, a widely prescribed diabetes drug, may mimic one of exercise's core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive. The findings suggest that metformin could help counter the metabolic strain of hormone therapy, when fatigue and other side effects often limit physical activity.
April 6th, 2026 — Source

Electroacupuncture may ease 'brain fog' in breast cancer survivors, small trial finds
Researchers at the University of California, Irvine have found that electroacupuncture may help improve cognitive function and reduce psychological distress among breast cancer survivors experiencing persistent neuropsychiatric symptoms.
April 6th, 2026 — Source

Examining evolving trends in oral cavity cancer among younger adults
April marks Head and Neck Cancer Awareness Month, a national campaign encouraging early detection and raising awareness of cancers affecting the mouth, throat, and related structures. This crucial message about early detection is reinforced by new original research published in Otolaryngology--Head and Neck Surgery.
April 6th, 2026 — Source

JMIR Publications' new article showcases the transformative potential of precision oncology
JMIR Publications today announced the release of a timely new article in its News and Perspectives section, showcasing the transformative potential of precision oncology. The article, "Further Promise and Potential for Precision Medicine in Oncology," details how shifting from a "one-size-fits-all" approach to individualized, multi-drug regimens can significantly improve outcomes for patients with aggressive, advanced cancers.
April 6th, 2026 — Source

Mayo Clinic researchers develop experimental nanotherapy to treat aggressive brain tumors
Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, according to a study published in Communications Medicine. The strategy extended survival in preclinical models of glioblastoma, the most aggressive form of brain cancer.
April 6th, 2026 — Source

Metformin mimics exercise-related metabolic effects in prostate cancer patients
A new study has found that metformin, a widely prescribed diabetes drug, may mimic one of exercise's core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive. The findings suggest metformin could help counter the metabolic strain of hormone therapy, when fatigue and other side effects often limit physical activity.
April 6th, 2026 — Source

Precision oncology success: Individualized multi-drug therapy outperforms standard care
A new article in the News and Perspectives section of the Journal of Medical Internet Research showcases the transformative potential of precision oncology. The article, "Further Promise and Potential for Precision Medicine in Oncology," details how shifting from a "one-size-fits-all" approach to individualized, multi-drug regimens can significantly improve outcomes for patients with aggressive, advanced cancers.
April 6th, 2026 — Source

Princeton researchers reveal new links between high-fat diets and aggressive breast cancer
Princeton researchers have revealed new links between high-fat diets and aggressive breast cancer, demonstrating the important role fat plays in making some cancers more invasive.
April 6th, 2026 — Source

Rates of secondary blood-related cancers that develop due to chemotherapy or radiation may be rising
Some therapies used to treat cancer may increase the risk of later developing cancers that affect the blood. A population-based study in Japan has revealed a gradual increase in the rates of therapy-related acute myeloid leukemia (tAML) in recent years, especially after breast cancer treatment.
April 6th, 2026 — Source

Study finds increasing rates of therapy-related acute myeloid leukemia
Some therapies used to treat cancer may increase the risk of later developing cancers that affect the blood. A population-based study in Japan has revealed a gradual increase in the rates of therapy-related acute myeloid leukemia (tAML) in recent years, especially after breast cancer treatment. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
April 6th, 2026 — Source

Targeted nanoparticle therapy doubled survival rates in aggressive brain cancer models
Targeted liposomal nanoparticles successfully cross the blood brain barrier to treat glioblastoma and doubled survival rates in preclinical brain cancer models.
April 6th, 2026 — Source

Health — Cancer — April 3rd, 2026

Cellular pathways that drive precancerous lesions to form pancreatic tumors identified
Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer and has a low five-year survival rate. It begins with a reversible state called acinar-to-ductal metaplasia, where cells can heal after injury or inflammation. If there are cancer-causing mutations, metaplasia can continue progressing toward cancer.
April 3rd, 2026 — Source

Childhood cancer is a substantial contributor to global childhood mortality and global cancer burden
Childhood cancer is the eighth-leading cause of childhood death globally and causes more deaths than measles, tuberculosis and HIV/AIDS, with outcomes largely determined by resource availability, according to the latest findings from the Global Burden of Disease (GBD) 2023 study published today in The Lancet. The estimates show that while mortality has declined globally, children in low- and middle-income countries (LMICs) face the most severe consequences from cancer.
April 3rd, 2026 — Source

COCOON trial protocol halves skin toxicities in lung cancer treatment
A new research perspective was published in Volume 13 of Oncoscience on March 11, 2026, titled "Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC."
April 3rd, 2026 — Source

Health — Children & Teenagers — April 3rd, 2026

An injectable particle could make surgery safer for infants
Biomedical researchers have designed an injectable microgel to help reduce bleeding in infants who require surgical care. In an animal model, the engineered microgel reduced bleeding by at least 50%. The paper, "Hemostatic B-Knob Triggered MicroGels (BK-TriGs) to Address Bleeding in Neonates," is published in the journal Science Advances.
April 3rd, 2026 — Source

Children living near the Salton Sea in Southern California show slower lung function growth
Children who live within 11 kilometers of the Salton Sea, a drying body of water with a high concentration of salts and contaminants in Imperial Valley, California, have slower lung function growth between ages 10 and 12 than children who live farther away. The impact is comparable to living within 500 meters of a freeway and could affect respiratory health into adulthood.
April 3rd, 2026 — Source

How calcium channel mutations disrupt early brain development in childhood epilepsy
Researchers at Baylor College of Medicine have uncovered a previously unrecognized mechanism by which inherited calcium channel mutations disrupt early brain development and predispose children to epilepsy and related cognitive challenges. The findings, published in Neuron, shed new light on how subtle genetic changes can alter brain circuits long before seizures begin.
April 3rd, 2026 — Source

Vapes replace cigarettes as the top nicotine threat to young children
While cigarette exposures are decreasing for young children, electronic nicotine products are putting toddlers at new risk of inhalation, according to Rutgers Health researchers. Their study, published in JAMA Network Open, was the first to assess trends in young children's nicotine exposures across all types of products.
April 3rd, 2026 — Source

Health — Cancer — April 2nd, 2026

A redesigned endoscope offers a new way to look for early signs of ovarian cancer
Ovarian cancer remains the deadliest gynecologic cancer, largely because it is rarely found early. Symptoms are often vague, and existing screening approaches—such as blood tests and transvaginal ultrasound—can miss the disease at stages when treatment is most effective. In recent years, research has reshaped understanding of how many aggressive ovarian cancers begin, pointing not to the ovary itself, but to the fallopian tubes. That shift has created a need for tools that can safely examine these narrow structures for early changes linked to cancer.
April 2nd, 2026 — Source

Blood-based test could personalize treatment for patients with HPV-associated throat cancer
Researchers at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) are advancing the understanding of a promising blood test that could personalize treatment and surveillance for patients with human papillomavirus (HPV)-associated throat cancer.
April 2nd, 2026 — Source

First-in-class dual HIF inhibitors eliminate tumors in mice when combined with immunotherapy
Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be "master regulators" of cancer progression.
April 2nd, 2026 — Source

How pancreatic tumors thwart an iron-driven demise
Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be harnessed for cancer therapy. Given that more than 95% of pancreatic ductal adenocarcinomas (PDACs) harbor such mutations, one might expect these tumors to be similarly vulnerable. Yet, in keeping with PDAC's notorious intractability, its tumors show no such vulnerability. Why this is so has been something of a mystery.
April 2nd, 2026 — Source

International researchers set new standards for studying tumor microbiota
Recent research shows that tumors in different organs host microbial communities capable of influencing cancer biology, immune responses, and the effectiveness of therapies, highlighting the need to standardize methods for studying intratumoral microbes.
April 2nd, 2026 — Source

Leukemia study restores silenced gene in mice. Could it point to new treatments for humans?
A key cancer-fighting gene in leukemia is switched off—not broken—and scientists from The Jackson Laboratory (JAX) have found a way to switch it back on. In a study published in Science Translational Medicine, the team reveals not only a potential new way to treat acute myeloid leukemia (AML) without harsh chemotherapy, but also a promising strategy to study more gene-silencing mechanisms in other diseases.
April 2nd, 2026 — Source

Lung cancer surgery safe for many patients over 80, study finds
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have found that adults aged 80 and older with early-stage lung cancer can safely undergo surgery and achieve outcomes comparable to younger patients, challenging longstanding assumptions about age and cancer treatment.
April 2nd, 2026 — Source

NCCN grants funding to five oncology leaders of the future
The National Comprehensive Cancer Network® (NCCN®)-an alliance of leading cancer centers-announces the 2026 recipients for the annual NCCN Foundation® Young Investigator Awards. The awards grant early career investigators funding to advance research on important issues in oncology. The recipients were selected by the NCCN Oncology Research Program (ORP), which will provide oversight and guidance across the two-year program.
April 2nd, 2026 — Source

New dual drugs eliminate tumors when combined with immunotherapy
Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be "master regulators" of cancer progression. The study, to be published April 2 in the Journal of Experimental Medicine (JEM), shows that these drugs, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice, suggesting that they could eventually be used to treat a broad range of cancers in humans.
April 2nd, 2026 — Source

New research investigates cancer survivors' 'symptom burden'
A declaration of remission doesn't mean a cancer patient's illness is fully gone. Many cancer survivors face lingering symptoms that lead to both physical discomfort and mental strain. Even though there are some commonalities, the symptoms themselves are highly variable between individuals and difficult to predict, says Marilyn Hammer, professor of nursing at Northeastern University.
April 2nd, 2026 — Source

Radiation therapy improves outcomes for 'supermassive' bile duct tumors
A new study from researchers at The University of Texas MD Anderson Cancer Center demonstrates that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with large bile duct tumors in the liver, known as intrahepatic cholangiocarcinoma.
April 2nd, 2026 — Source

Study introduces biomarker to characterize aggressiveness of brain tumors
Researchers from the Biomedical Data Science Laboratory (BDSLab) at the ITACA Institute of the Universitat Politècnica de València have developed a new method based on magnetic resonance imaging that enables objective quantification of the growth of the most aggressive brain tumors, particularly glioblastoma.
April 2nd, 2026 — Source

Health — Cancer — April 1st, 2026

Pesticides and cancer: Study reveals the biological mechanisms behind an environmental health risk
A new study, published in Nature Health, reveals a strong link between exposure to agricultural pesticides in the environment and the risk of developing cancer. By combining environmental data, a nationwide cancer registry, and biological analyses, researchers from the IRD, the Institut Pasteur, the University of Toulouse, and the National Institute of Neoplastic Diseases (INEN) in Peru have shed new light on the role of pesticide exposure in the development of certain cancers.
April 1st, 2026 — Source

Scientists discover hidden "winds" inside cells that could explain cancer spread
Cells have their own hidden "wind system" that turbocharges movement—and could reshape cancer research.
April 1st, 2026 — Source

'Smart' drugs to fight cancer
Scientists have designed a molecular system that distinguishes and neutralises cancer cells with unprecedented precision, paving the way for autonomous, self-regulating drugs.
April 1st, 2026 — Source or Source

Health — Cancer — March 31st, 2026

3 million-cell map shows menopause reshapes breast tissue, possibly raising cancer risk
Scientists have created the most detailed map to date, comprised of over 3 million cells, showing how breast tissue changes as women age—including dramatic changes during menopause.
March 31st, 2026 — Source

Prioritizing potentially cancer-causing mutations in real-world cancer genomics
Hiroshima University researchers have developed a practical framework to identify candidate pathogenic variants hidden among the large number of variants of uncertain significance (VUS) detected in comprehensive genomic profiling (CGP) of cancers. This framework could improve the accuracy of precision oncology by more reliable prioritization of VUS.
March 31st, 2026 — Source

Strongest evidence yet that vaping likely causes cancer
As early as the 1880s, there was evidence that smoking tobacco damaged your lungs. But it took almost 100 years to definitively show that smoking causes lung cancer.
March 31st, 2026 — Source

Unexpected findings on lung cancer CT scans may point to other non-lung cancers
When doctors review diagnostic medical scans for lung cancer, they sometimes spot abnormalities unrelated to the lungs. New research shows that some of those abnormalities could be signs of other undiagnosed cancers. The study, led by researchers at the Brown University School of Public Health, analyzed lung screening data from more than 26,000 people who took part in the landmark National Lung Screening Trial. This large federal study helped establish computerized tomography (CT) scans as a standard way to screen people at high risk for lung cancer—especially longtime smokers.
March 31st, 2026 — Source

Health — Cancer — March 24th, 2026

A protein may help revive exhausted T cells in cancer immunotherapy
Immunotherapy has been one of the most transformative treatments for cancer patients in recent decades, shifting the emphasis from the broad-spectrum approach of chemotherapy to prompting the immune system's boldest warriors—its T cells—to target only the infiltrating tumor.
March 24th, 2026 — Source

Agent Orange linked to aggressive bone marrow cancer in Vietnam veterans
More than 50 years after Agent Orange was used in Vietnam, a new national study published in Blood Advances highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes (MDS), a group of bone marrow cancers that can progress to acute leukemia. The findings shed light on why some veterans develop more severe bone marrow cancers and will hopefully help these individuals obtain access to needed, service-connected care.
March 24th, 2026 — Source

Immune cell 'bloodhounds' track cancer cells' unique metabolic signatures and eliminate tumors in mice
A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered immunotherapy for solid tumors, according to a new study by Stanford Medicine researchers. The approach equips certain types of immune cells with proteins on their surfaces that can recognize byproducts of cancer cells' abnormal metabolism diffusing in the spaces between cells and stimulates the immune cells to migrate toward the tumor.
March 24th, 2026 — Source

Repurposed cancer drug shows promise against drug-resistant herpes infections
UIC researchers have successfully repurposed an FDA-approved cancer drug, doxorubicin, to treat drug-resistant strains of herpes. Their work appears in the journal Drug Resistance Updates.
March 24th, 2026 — Source

Health — Cancer — March 22nd, 2026

A lysosome switch could reshape research on cancer and neurodegenerative disease
An international research team from Bielefeld University and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has uncovered a previously unknown regulatory mechanism in human cells. For the first time, they demonstrate how a key molecular switch regulates the cell's "recycling centers." The findings, published in Nature Communications, provide important insights into the understanding of cancer and neurodegenerative diseases.
March 22nd, 2026 — Source

Cancer vaccines could transform treatment and prevention, but misinformation about mRNA abounds
Scientists are making rapid progress toward a long-awaited goal that could help to reshape cancer care: mRNA cancer vaccines with the potential to significantly boost the immune system's ability to fight and eliminate tumors.
March 22nd, 2026 — Source

Could Ozempic help people whose cancer has spread to the brain?
Weight-loss injections that have become famous for helping people shed pounds may also help some patients with advanced cancer live longer when the disease has spread to the brain, according to a new study.
March 22nd, 2026 — Source

Hepatitis C drug may prevent hepatitis E virus replication
A drug that is already in clinical trials against hepatitis C virus can also prevent hepatitis E virus from replicating.
March 22nd, 2026 — Source

HPV-positive cancers hide from the immune system, but blocking a single protein could make the tumors treatable
A team of scientists at Henry Ford Health + Michigan State University Health Sciences have uncovered a mechanism that allows certain head and neck cancers to hide from the immune system, a discovery that could change how some of the most treatment-resistant tumors are approached.
March 22nd, 2026 — Source

Not all cancer mutations are equal: Mutation strength in a single gene shapes tumor behavior
Cancer is often thought of as a single disease. Yet even tumors that arise in the same organ can follow very different genetic paths. A new study shows that these differences can sometimes be traced back to tiny changes in a single gene. Research led by senior researcher Dr. Derya Deniz Özdemir from Koç University School of Medicine and the Research Center for Translational Medicine (KUTTAM), published in Nature Genetics, reveals that mutations in one of the most frequently altered genes in cancer do not all have the same effect.
March 22nd, 2026 — Source

Q&A: What to know about colorectal cancer and its recent prevalence among young people
Colorectal cancer, a type of cancer that affects the colon or rectum, is the second leading cause of cancer-related death and the third most common cause of death or type of cancer. It is the No. 1 cause of cancer-related death for men and women under 50. Roughly one in 24 people will develop colorectal cancer. Though declining in older adults due to screening, cases are rising by nearly 3% per year in adults under 50. While often asymptomatic in early stages, it is highly preventable through screening and highly treatable if detected early.
March 22nd, 2026 — Source

Health — Cancer — March 21st, 2026

A blood test may tailor breast cancer treatment for older women
For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions. In a study published today in Clinical Cancer Research, scientists at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine found that a blood-based test may help guide treatment decisions for a carefully selected group of women age 70 and over who have estrogen receptor--positive breast cancer, who were considering endocrine (or hormone-blocking) therapy as the primary treatment and forgoing surgery and radiation.
March 21st, 2026 — Source

How exercise can lower your cancer risk
Exercise. It can be hard for a lot of us to get started. Regardless of how you feel about physical activity, it comes with various benefits. One benefit of exercise that is not often recognized is its assistance in lowering cancer risk.
March 21st, 2026 — Source

New AI tool predicts cancer spread with surprising accuracy
A new AI tool can predict which cancers will spread—before it's too late.
March 21st, 2026 — Source

Study finds FGFR1 boosts cholesterol uptake in prostate cancer cells
The study, led by Ziying Liu '25, a former student in the lab of Fen Wang at the Institute of Biosciences and Technology and the Naresh K. Vashisht College of Medicine, found that a cell-signaling receptor called fibroblast growth factor receptor 1 (FGFR1) helps prostate cancer cells increase their internal supply of cholesterol. Cholesterol is a key building block for steroid hormones and cell membrane that can fuel tumor growth.
March 21st, 2026 — Source

Health — Cancer — March 18th, 2026

Antioxidant serves as an unexpected food source for tumors, scientists discover
Researchers have discovered an antioxidant, glutathione, that cancer cells appear to be "addicted to" as fuel, opening new pathways for investigation and a potential drug that can restrict the way tumors use this nutrient.
March 20th, 2026 — Source

Cellular stress signal found to drive immune exhaustion and weaken cancer therapy
Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet how metabolic stress translates into stable transcriptional reprogramming remained unclear.
March 20th, 2026 — Source

Cholecystokinin, not insulin, may be key hormone in obesity-driven pancreatic cancer
Obesity increases the body's need for insulin, forcing cells in the pancreas known as beta cells to ramp up insulin production to maintain blood sugar levels. Scientists have thought that this excessive insulin secretion is one of the factors that drives the development of obesity-induced pancreatic cancer.
March 20th, 2026 — Source

Combination therapy shows promise for leptomeningeal metastasis in breast cancer
Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.
March 20th, 2026 — Source

Hope for preventing stomach cancer: Drug candidate proves extremely effective against H. pylori
Researchers at the Technical University of Munich (TUM) have increased the effectiveness of a standard antibiotic by a factor of 60 through targeted chemical modifications. In laboratory and animal studies, the new drug candidate successfully combats the bacterium Helicobacter pylori, which is closely associated with the development of stomach cancer.
March 20th, 2026 — Source

Long dismissed in adult health, the thymus may be critical for longevity and cancer treatment
Two new studies from investigators at Mass General Brigham challenge a decades-old assumption that the thymus, an organ best known for its role in establishing immune function in childhood, becomes irrelevant in adulthood. Using artificial intelligence (AI) to analyze routine CT scans, researchers uncovered that adults with a healthy thymus had increased longevity and reduced risk for cardiovascular disease and cancer.
March 20th, 2026 — Source

New study identifies how obesity-related liver cancer becomes more aggressive and resistant to treatment
A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to conventional treatments. The study reveals that a specific signaling pathway involving endotrophin—a protein secreted during liver fibrosis—and the receptor protein CD44 promotes tumor malignancy and drug resistance.
March 20th, 2026 — Source

Prodrug lipid nanoparticle could unlock universal immunotherapy for solid cancers
Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors, including common variants such as cancers of the breast, liver, and colon.
March 20th, 2026 — Source

Scientists create cancer-fighting immune cells right in the body
For years, one of the most powerful weapons against certain blood cancers, called CAR-T cell therapy, has required an elaborate process: Doctors extract a patient's immune cells, ship them to a specialized facility where they're genetically reprogrammed to fight cancer, then ship them back for infusion back into the patient's bloodstream. This has revolutionized cancer treatment, but it takes weeks and can cost hundreds of thousands of dollars, placing it out of reach for many of the patients who need it most.
March 20th, 2026 — Source

Study identifies inflammatory immune pathway driving immunotherapy resistance in bladder cancer
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well to immunotherapy. Their findings, published in Cancer Discovery, show that common signs of inflammation in the blood are linked to immune cells inside tumors that block the body's ability to fight cancer.
March 20th, 2026 — Source

Health — Cancer — March 16th, 2026

Clinical trial tests a newer, targeted therapy for IDH mutant astrocytoma
A new clinical trial led by the Alliance for Clinical Trials in Oncology will investigate if a combination of drug therapies after radiation therapy improves outcomes for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma, a type of brain cancer. Supported in part by a grant from the National Cancer Institute, the study (Alliance A072301) will look at whether adding the oral medication vorasidenib to the standard oral chemotherapy can help keep the cancer from coming back after radiation.
March 16th, 2026 — Source

Here's what you need to know about cancer vaccine development
Cancer is the second-leading cause of death in the United States, accounting for over 613,000 fatalities in 2023, per the Centers for Disease Control. But the field of cancer vaccines, which can be used as a form of treatment, is rapidly growing. More than 400 trials testing this form of therapy have been initiated globally over the last 3 years, per data from the National Library of Medicine.
March 16th, 2026 — Source

Light and nanomaterials could detect cancer years before diagnosis
Researchers combine photonics and nanotechnology to identify molecular cancer signals five to eight years earlier than traditional diagnostic tools.
March 16th, 2026 — Source

Microfluidic chip tracks cancer relapse by measuring white blood cell adhesion
A new microfluidic technology that leverages immune cell behavior is set to transform cancer monitoring, thanks to researchers at UNIST. Led by Professor Joo Hun Kang in the Department of Biomedical Engineering at UNIST, the team has introduced a novel diagnostic chip that analyzes the adhesion properties of leukocytes, or white blood cells, to detect cancer recurrence and evaluate the effectiveness of chemotherapy.
March 16th, 2026 — Source

Mutant gene behind aggressive adult leukemia offers new clues for treatment
Imagine a tiny superhero inside every cell of your body whose job is to stop damaged cells before they turn dangerous. That superhero is a gene called TP53, and for decades scientists have known it as the "guardian of the genome." But what happens when the guardian breaks?
March 16th, 2026 — Source

Photonics and nanotech could spot cancer signals 5 to 8 years earlier
Timing is critical in diagnosing diseases such as cancer. Researchers within The Grainger College of Engineering at the University of Illinois Urbana-Champaign used a historically underappreciated tiny powerhouse to detect diseases sooner.
March 16th, 2026 — Source

Protein MIIP suppresses colorectal cancer by regulating immune cell signaling
Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and limited responses to immunotherapy in most patients. Although immune checkpoint inhibitors have transformed treatment for certain tumor subtypes, the majority of colorectal cancers remain "immune-cold," meaning they fail to trigger effective anti-tumor immunity. Increasing evidence suggests that tumor-associated macrophages, especially the M2 subtype, actively promote tumor growth, invasion, and immune suppression. However, the molecular signals that drive macrophage polarization within colorectal tumors remain poorly understood. Understanding how tumor cells reshape immune behavior is therefore essential for improving therapy outcomes.
March 16th, 2026 — Source

Researchers develop targeted delivery system for poorly soluble cancer drugs
Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high therapeutic efficacy. However, many of these compounds possess properties that make them difficult to handle, such as poor water solubility and large molecular weights. This leads to poor absorption in the body and difficulty in achieving sufficient therapeutic effects. Further, the drugs distribute to normal tissues, which lead to severe side effects. Fortunately, active research is underway to develop drug delivery systems (DDS) that effectively solubilize these compounds and efficiently deliver them to cancerous tissues.
March 16th, 2026 — Source

The cost of survival: Women more likely to survive cancer but suffer more severe side effects
Women are more likely to survive cancer than men but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study from Adelaide University. Conducted in partnership with international collaborators and published in the JNCI: Journal of the National Cancer Institute the research identified consistent differences between male and female cancer patients in both survival and treatment toxicity.
March 16th, 2026 — Source

The shot that could stop cancer before it begins, and why getting it early matters
When 12-year-olds receive a letter from the school nurse about the HPV vaccine, their reactions are often mixed. Some students worry about the needle. Others wonder why they need a vaccine for something they have never heard of.
March 16th, 2026 — Source

Health — Cancer — March 13th, 2026

A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices
A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Research Center at The Institute of Cancer Research, London (ICR) and the Breast Cancer Now Research Unit at King's College London, have uncovered a new weakness in triple negative breast cancer linked to a gene called HORMAD1 and a way to target it.
March 13th, 2026 — Source

ESMO and EURACAN call for policy action to standardize care for patients with rare cancers
Adherence to Clinical Practice Guidelines in the management of rare cancers remains inconsistent across Europe despite demonstrably improving patient outcomes, shows an analysis jointly conducted by ESMO and EURACAN, the European Reference Network (ERN) for rare cancers. The results, presented today at the ESMO Sarcoma and Rare Cancers Congress 2026, reveal an opportunity for doctors and public health policymakers to improve outcomes by standardizing and centralizing care for patients with rare malignancies, who taken together represent over 650,000 new cases annually, or a quarter (24%) of all cancer diagnoses in Europe each year.
March 13th, 2026 — Source

Fertility treatments linked to small increases in some cancers
A study of more than 400,000 women finds medically assisted reproduction is associated with small increases in certain cancers. However, overall cancer risk remains comparable to that of the general population.
March 13th, 2026 — Source

Severe COVID or flu may raise lung cancer risk years later
A severe case of COVID-19 or influenza could increase the risk of lung cancer later on, according to new research. Scientists discovered that serious viral infections can alter immune cells in the lungs, leaving behind chronic inflammation that may help tumors develop months or years later. The increased risk was seen mainly after severe infections that required hospitalization. Vaccination, however, appears to prevent the dangerous lung changes.
March 13th, 2026 — Source

Sonodynamic therapy is safe and well-tolerated in high-grade gliomas, first-in-human trial suggests
High-grade gliomas, especially glioblastoma (GBM) and others, remain among the most aggressive brain cancers, with few effective treatment options after the tumor recurs. Even with maximal surgical resection, radiotherapy, and chemotherapy, outcomes are poor, underscoring the need for noninvasive, tumor-specific strategies that can spare healthy tissue.
March 13th, 2026 — Source

Study finds two types of colon polyps can raise bowel cancer risk fivefold
Researchers studying over 8,400 colonoscopies discovered that having both adenomas and serrated polyps in the bowel can raise the risk of serious precancerous changes by up to five times. These two polyp types may represent separate cancer pathways that can occur at the same time. Nearly half of patients with serrated polyps also had adenomas, making this high-risk combination more common than expected. The results emphasize the importance of early detection and regular colonoscopy monitoring.
March 13th, 2026 — Source

Uncovering a key signaling pathway linking liver cancer and fibrosis
New molecular insights into the link between hepatocellular carcinoma and intratumoral fibrosis could lead to better treatment strategies, report researchers from Institute of Science Tokyo. Through a comprehensive analysis involving clinical data and in vitro and in vivo experiments, they revealed that the SPP1--CD44--Hedgehog signaling pathway is a key driver of fibrosis in liver tumors, hinting at its potential as a therapeutic target.
March 13th, 2026 — Source

Health — Cancer — March 12th, 2026

Combat Medical raises £2.6 million Series A to advance treatment of BCG unresponsive bladder cancer
Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to advance its hyperthermic intravesical chemotherapy treatment, HIVEC® through phase 3 clinical trials and toward FDA registration. The round was led by T&J Meyer Family Foundation, and included investment from Varia Ventures, NW Angel Fund and non-institutional family offices and individuals.
March 12, 2026 — Source

Diatom-based microrobots show promise for targeted photodynamic therapy of glioblastoma
Researchers in China have developed magnetically controlled microrobots made from diatoms for the treatment of glioblastoma using photodynamic therapy. These microrobots exhibit excellent magnetic responsiveness and programmable motion capabilities, enabling them to precisely target and navigate to glioblastoma lesion areas. Once positioned at the tumor site, the diatom-based microrobots can be activated by laser irradiation, triggering a photodynamic therapeutic effect.
March 12, 2026 — Source

Novel tool measures how cancer cells rewrite genetic instructions to aid growth and survival
Cancer is caused by faulty genes, but what also shapes a cancer cell's behavior is how a gene's instructions are trimmed and rearranged before they are turned into the proteins that keep a cell alive. A study published in Nature Communications reveals a new way of measuring that editing process, known as splicing, directly. It is the first time scientists have been able to get a clear view of how tumors systematically rewire their genetic instructions to aid growth and survival, and it may point toward new ways of controlling the disease.
March 12, 2026 — Source

Personalized support program improves smoking cessation for cervical cancer survivors
A new study led by UCLA researchers suggests that a personalized counseling program can significantly help women who have survived cervical precancer or cervical cancer to quit smoking—and does so at a cost that researchers say represents good value for health care systems.
March 12, 2026 — Source

Structured exercise programs may help combat 'chemo brain' according to new study
New research suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks, work, and social activities through chemotherapy treatment delivered on an every two-week cycle. This first-of-its-kind, nationwide, multicenter, Phase III trial randomized patients to receive an exercise prescription, Exercise for Cancer Patients (EXCAP), which included individually tailored walking and simple resistance band exercises, along with their usual chemotherapy treatment.
March 12, 2026 — Source

VALANX Biotech secures €3 million to advance LIV-1 ADC for metastatic triple-negative breast cancer
VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured €3 million to advance its lead antibody-drug conjugate (ADC) program. The round includes Foundation Fournier-Majoie and FUJIFILM Corporation as new investors, joining existing VC investors xista science ventures, tecnet equity, SOSV and angel investors Urs Spitz and SkyGene.
March 12, 2026 — Source

Health — Cancer — March 11th, 2026

Distinct tumor 'neighborhoods' could guide more targeted treatments in aggressive childhood brain cancer
New research published in Nature finds that tumor cells within supratentorial ependymomas (SE)—an aggressive childhood brain cancer—cluster into distinct tumor cell populations. Much like a neighborhood, each cell subtype within these "communities" has a specific (and previously unappreciated) role to play.
March 11, 2026 — Source

Study links migration transition to changing cancer incidence patterns
North Korean defectors who resettled in South Korea share genetics but markedly contrasting early-life exposures with South Korean residents. Research published in the Journal of Internal Medicine compared overall and site-specific cancer incidence rates between North Korean defectors and native South Koreans.
March 11, 2026 — Source

Turning cancer's protein machinery against itself to boost immunity
A new study led by Pierre Close's team (GIGA, Laboratory of Cancer Signaling, and WELRI Investigator) reveals how subtly disrupting the way tumors produce their proteins can trigger a potent antitumor immune response. Researchers from the University of Liège and international collaborators have discovered an unexpected way to stimulate the immune system against cancer: by subtly disrupting how tumor cells manufacture their proteins.
March 11, 2026 — Source

Health — Cancer — March 5th, 2026

A nanoplatform turns mild heat into a gene-editing trigger that disarms tumor defenses
Bismuthene nanodiscs use mild heat to switch on gene editing that dismantles a tumor's heat defenses, creating a feedback loop that kills cancer cells more effectively.
March 5, 2026 — Source

AI blood test detects early pancreatic cancer with over 90 percent accuracy
PanMETAI combines AI and NMR metabolomics to detect early-stage pancreatic cancer from a blood sample, achieving 93 percent sensitivity in clinical validation.
March 5, 2026 — Source or Source

Cryotherapy could be a game changer for patients with early-stage kidney cancer
Today, small kidney tumors are most often treated with a minor operation in which all or part of the kidney is removed. However, in many cases, these small tumors can be treated with targeted cryotherapy, which destroys the cancer cells.
March 5, 2026 — Source

Distinct spatial tumor--immune ecosystems predict lung cancer treatment response
Researchers at Moffitt Cancer Center have identified distinct spatial tumor--immune ecosystems that predict whether patients with advanced non--small cell lung cancer will benefit from immunotherapy. The findings, published in Cancer Research, show that analyzing how tumor and immune cells are organized and interact within the tumor microenvironment may predict disease progression more accurately than PD-L1 status alone. The paper was featured on the cover of the publicationand is also part of its Data Science special series.
March 5, 2026 — Source

GI cancers to double by 2050, experts warn
Gastrointestinal cancer cases are expected to double worldwide by 2050, according to a multi-institutional study co-led by Cedars-Sinai. The projections, based on 2022 data and published in the journal Cancer, conclude that the biggest increases will be in pancreatic cancer diagnoses and colorectal cancer deaths.
March 5, 2026 — Source

Molecular target drives immunogenicity in cancer immunotherapy
Researchers at the National University of Singapore (NUS) have identified a protein called tyrosine phosphatase 1B (PTP1B) as a potential "switch" that can modulate a type of cancer cell death known as immunogenic cell death (ICD).
March 5, 2026 — Source

New AstroID database integrates clinical and genetic data for large-scale cancer studies
Researchers from the Johns Hopkins Kimmel Cancer Center and The Johns Hopkins University have created a novel database structure that allows investigators anywhere to more easily study multiple types of cancer data - including laboratory results, genetic sequencing and imaging data - in one setting.
March 5, 2026 — Source

Scientists develop nanomaterial that targets cancer cells while sparing healthy tissue
Enhancing chemodynamic therapy techniques to target and wipe out cancer
March 5, 2026 — Source

Study maps US diabetes--cancer hotspots
A new University of Kentucky study has mapped areas across the U.S. where high rates of diabetes and deaths from diabetes-related cancers overlap. The UK Markey Cancer Center and Barnstable Brown Diabetes Center research reveals patterns that could help target life-saving interventions.
March 5, 2026 — Source

Study on Alt-Med Breast Cancer Treatments Finds a Grim Side Effect: Death
Over a five-year span, women who used complementary and alternative medicine had a greater mortality rate than those who relied on traditional care.
March 5, 2026 — Source

Health — Cancer — March 4th, 2026

A questionnaire allows for reliable measurement of cancer patients' concerns
The fear that cancer will progress or worsen is one of the most common concerns among people living with the disease. Identifying and measuring this concern is key to providing appropriate psychological care and improving patients' quality of life. Now, a study led by the University of Barcelona in collaboration with the Rovira i Virgili University and CEU San Pablo University has validated, for the first time in the Spanish population, the Spanish version of the Assessment of Survivor Concerns (ASC) questionnaire, a tool designed specifically to assess cancer- and health-related concerns.
March 4, 2026 — Source

AI could help us more accurately screen for breast cancer—new research
At least 20,000 Australian women are diagnosed with breast cancer each year. And more than 3,300 die from the disease. To save women's lives, we need to detect breast cancer early. Breast screening, which halves women's risk of dying from breast cancer, is key to that.
March 4, 2026 — Source

CAR T-cell therapy improves survival in relapsed or refractory lymphoma
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma, according to a recent clinical trial published in The Lancet. Marginal zone lymphoma (MZL) is a group of rare and slow-growing non-Hodgkin lymphomas that develop from B-cells and then spread into lymphoid tissues, including lymph nodes, as well as stomach tissue and bone marrow.
March 4, 2026 — Source

Distinct tumor-immune ecologies can help predict immunotherapy response in lung cancer
Researchers at Moffitt Cancer Center have identified distinct spatial tumor--immune ecosystems that predict whether patients with advanced non--small-cell lung cancer will benefit from immunotherapy. The findings, published in Cancer Research, show that analyzing how tumor and immune cells are organized and interact within the tumor microenvironment may predict disease progression more accurately than PD-L1 status alone. The paper was featured on the cover of the publication and is also part of its Data Science special series.
March 4, 2026 — Source

Gaps in lung cancer treatment persist, study finds
In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically improved outcomes. But according to new research from Yale, published in JAMA Network Open, one thing has barely changed: who receives curative care.
March 4, 2026 — Source

Glucose drives STAT3 activation in colorectal cancer cells, leading to tumor growth
Colorectal cancer is the third most common cancer in the United States. Although screening has led to a decrease in incidence over the past 20 years, early-onset colorectal cancer has been rising. Despite advances in surgery and therapies, patients with metastatic colorectal cancer continue to have poor outcomes, highlighting the need for novel treatments.
March 4, 2026 — Source

Good vibrations: Playing music to cells reduces laryngeal cancer aggressiveness in lab tests
The continuous movement of the vocal cords weakens and eventually stops as laryngeal cancer progresses. Researchers have, for the first time, discovered that restoring cellular vibration reduces the aggressiveness of advanced vocal cord cancer. When cancer cells were exposed to sound-wave vibration, a protein that promotes cancer growth and severity decreased.
March 4, 2026 — Source

How AI could speed treatment for patients with this deadly cancer
Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an assistant research professor in bioengineering at Northeastern University, says that AML also has a high recurrence rate and no one-size-fits-all treatment option.
March 4, 2026 — Source

Nanoparticle vaccine approach takes on a new target: Hepatitis C virus
Hepatitis C virus (HCV) infects an estimated 50 million people worldwide, according to the World Health Organization, and remains a leading cause of cirrhosis and liver cancer. While antiviral drugs can cure most infections, global access remains limited and these drugs do not stop reinfection.
March 4, 2026 — Source

New AI tool predicts best pancreatic cancer treatment
A new tool co-developed by investigators from Cedars-Sinai Health Sciences University can predict which of two available chemotherapy options for pancreatic cancer would be more effective for an individual patient.
March 4, 2026 — Source

One-hour saliva test spots biomarker linked to several cancers
The paper is titled "Label free paper sensor and light driven material for the rapid screening of S100P cancer biomarker in saliva." Corresponding author, Associate Professor Emad Kiriakous, from QUT's School of Chemistry and Physics, said this technology could pave the way for simple, low-cost, point-of-care screening tools to help identify and treat cancer early.
March 4, 2026 — Source

Open source cancer database created for easier disease study
Researchers from the Johns Hopkins Kimmel Cancer Center and The Johns Hopkins University have created a novel database structure that allows investigators anywhere to more easily study multiple types of cancer data—including laboratory results, genetic sequencing and imaging data—in one setting.
March 4, 2026 — Source

Restoring cellular vibration reduces aggressiveness of advanced vocal cord cancer
The continuous movement of the vocal cords weakens and eventually stops as laryngeal cancer progresses. Researchers have, for the first time, discovered that restoring cellular vibration reduces the aggressiveness of advanced vocal cord cancer. When cancer cells were exposed to sound-wave vibration, a protein that promotes cancer growth and severity decreased.
March 4, 2026 — Source

Vaginal estrogen therapy is safe for young endometrial cancer survivors, study finds
Despite the increased incidence of endometrial cancer in younger women, there is limited research regarding the safety of local, low-dose vaginal estrogen therapy (ET) for survivors. A new study suggests that this form of estrogen is not only effective in relieving numerous menopause symptoms but also does not seem to increase a woman's risk of cancer recurrence. Study results are published online today in Menopause, the journal of The Menopause Society.
March 4, 2026 — Source

Why some tiny tumors vanish and others grow: Discovery could help treat cancer at very earliest stages
Cambridge scientists have shown that when tumors first emerge, interactions with healthy cells in the underlying supportive tissue determine their ability to survive, grow, and progress to advanced stages of disease.
March 4, 2026 — Source

Health — Cancer — March 3rd, 2026

A new target in melanoma? Disrupting macrophage vesicles could break a tumor-fueling cycle
Pro-inflammatory M1 macrophages involved in immune responses accelerate the progression of melanoma through the extracellular vesicles they secrete, a study from the University of Eastern Finland shows.
March 3, 2026 — Source

Chemically 'stapled' peptides used to target difficult-to-treat cancers
Researchers at the University of Bath have developed a new technology that uses bacteria to build, chemically stabilize, and test millions of potential drug molecules inside living cells, making it much quicker and easier to discover new treatments for difficult-to-treat cancers.
March 3, 2026 — Source

High-fat diet accelerates triple-negative breast cancer growth in engineered tumors
A multidisciplinary team of researchers at Princeton University conducted a study to find out what patients diagnosed with breast cancer should eat to ensure the best prognosis. "We took the approach of building identical engineered tumors and culturing them in conditions that mimic the blood composition of patients under different dietary states," author Celeste M. Nelson said. "We were hoping to identify dietary conditions that would slow tumor growth. Instead, we found one dietary condition—a high-fat diet—that sped up tumor growth."
March 3, 2026 — Source

Inflammatory signals from vesicles increase cancer cell aggressiveness and invasiveness
The study explored the molecular mechanisms by which extracellular vesicles secreted by pro-inflammatory M1 macrophages affect melanoma cells. Extracellular vesicles are small membrane-bound particles secreted by cells and used for intercellular communication. All cells secrete extracellular vesicles; however, they seem to play a particularly important role in intercellular communication in the tumor microenvironment.
March 3, 2026 — Source

Minimally invasive procedure effectively treats small kidney cancers
A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive procedure called ablation is as effective as surgery for treating small kidney cancers, with faster recovery and fewer complications. Results of the study are published in Radiology.
March 3, 2026 — Source

Scientists find the genetic switch that makes pancreatic cancer resist chemotherapy
Scientists have identified a crucial molecular switch that decides whether pancreatic cancer cells resist chemotherapy or respond to it. The key player, a gene called GATA6, keeps tumours in a more structured and treatable form—but it gets shut down by an overactive KRAS-driven pathway. When researchers blocked that pathway, GATA6 levels rebounded and cancer cells became more sensitive to chemo. The discovery could help turn some of the toughest pancreatic tumours into ones doctors can better control.
March 3, 2026 — Source

Strong alcohol labeling and pricing policy could reduce cancer in Canada
If Canadian jurisdictions mandated warning labels on alcohol and minimum pricing tied to the number of standard drinks in a container, it could prevent hundreds of cancer diagnoses and deaths, according to a new study led by University of Victoria's Canadian Institute for Substance Use Research (CISUR).
March 3, 2026 — Source

Study finds stress-related nerves may fuel pancreatic cancer growth
Oregon Health & Science University researchers have found that certain nerves that play an integral role in the body's "fight or flight" stress response can support pancreatic tumor growth. These nerves, called sympathetic nerves, grow directly into pancreatic tumors and communicate with cancer cells and nearby support cells known as cancer-associated fibroblasts. This communication can change the tumor's behavior in ways that help pancreatic cancer grow.
March 3, 2026 — Source

UH Cancer Center data breach affects nearly 1.2 million people
The University of Hawaii has confirmed that a ransomware gang stole the data of nearly 1.2 million individuals after breaching its Cancer Center's Epidemiology Division in August 2025.
March 3, 2026 — Source

Work exploring role of the mannose pathway in regulating cell fate decisions may hold promise for cancer therapy
A research team has conducted a study exploring the role of the mannose pathway in regulating cell fate decisions in low glucose environments. Their work may hold potential for novel therapeutic strategies in cancer treatments.
March 3, 2026 — Source

Health — Cancer — March 2nd, 2026

A lopsided nanoparticle detects cancer markers in blood 100 times better than today's rapid tests
A self-propelled nanoparticle engineered through computer simulation could bring laboratory-grade cancer detection to paper-based bedside tests.
March 2, 2026 — Source

A molecular 'switch' could make pancreatic cancer more treatable
Scientists at Duke-NUS Medical School have identified a molecular "switch" that determines whether pancreatic cancer cells resist chemotherapy or respond to it—a finding that could help convert some of the most treatment-resistant tumors into forms that are more manageable with existing drugs.
March 2, 2026 — Source

AI cancer tools may rely on 'shortcut learning' rather than genuine biological signals
Artificial intelligence tools are increasingly being developed to predict cancer biology directly from microscope images, promising faster diagnoses and cheaper testing. But new research from the University of Warwick, published in Nature Biomedical Engineering, suggests that many of these systems may be using visual shortcuts rather than true biology—raising concerns that some AI pathology tools are currently too unreliable for real-world patient care.
March 2, 2026 — Source

AI model to improve prostate cancer care
Researchers and clinicians from six leading medical centers and academic institutions—including the University of California San Diego—have collaborated to develop a new artificial intelligence model of the male urinary tract that could make prostate cancer radiation therapy more precise and help reduce side effects, such as urinary complications.
March 2, 2026 — Source

AI tool could help predict side effects from lung cancer treatment
Radiation therapy is a cornerstone of lung cancer treatment. But even when delivered with precision, radiation can damage healthy lung tissue. "Try as we might, when we deliver radiation to a cancer, some goes to surrounding organs and patients can have side effects including lung inflammation, coughing and feeling short of breath," says medical physicist Yevgeniy Vinogradskiy, Ph.D.
March 2, 2026 — Source

AI cancer tools may be using visual shortcuts rather than true biology
New research warns that popular deep learning systems trained for cancer pathology may be relying on hidden shortcuts rather than genuine biological signals.
March 2, 2026 — Source

Belzutifan+pembrolizumab post-surgery helps kidney cancer patients at high risk for relapse stay cancer-free longer
Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination regimen that includes belzutifan, a HIF-2α inhibitor, given with standard immune therapy pembrolizumab.
March 2, 2026 — Source

Biomarkers indicating higher liver cancer risk in chronic hepatitis B patients identified
Chronic hepatitis B is a viral disease that affects the liver and greatly increases the risks of liver cirrhosis and hepatocellular cancer (HCC, liver cancer). It affects approximately 296 million people worldwide. Hepatitis B is treatable; with the advent of nucleoside (nucleotide) analog (NA) therapy, viral replication is suppressed, reducing the risk of disease progression.
March 2, 2026 — Source

Engineered immune cells show promise against brain metastases in preclinical study
A new study by researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain metastases, one of the most challenging and deadly complications of lung cancer. The research team developed a highly specialized type of immune cell, called a CAR macrophage, or CARMA, designed to find and attack tumor cells that spread to the brain. These engineered macrophages were able to enter the brain, seek out cancer cells, and slow tumor growth in preclinical models.
March 2, 2026 — Source

Experts call for rapid improvements in diagnosis, treatment of bile duct cancer
The international group of experts, including Professor John Bridgewater (UCL Cancer Institute), is calling for rapid improvements in diagnosis, treatment and research for cholangiocarcinoma, also known as bile duct cancer.
March 2, 2026 — Source

Experts call to improve survival rates for bile duct cancer patients
The international group of experts, including Professor John Bridgewater (UCL Cancer Institute), is calling for rapid improvements in diagnosis, treatment and research for cholangiocarcinoma, also known as bile duct cancer. Bile duct cancer is a rare but aggressive disease that starts in the small tubes that carry digestive fluid from your liver to intestines. These tumors usually develop and progress silently, meaning most people are diagnosed at a late stage when treatment options are limited.
March 2, 2026 — Source

How financial and practical stressors can affect emotional health during cancer care
A cancer diagnosis changes almost everything—but it doesn't stop life's other responsibilities. Bills still arrive. Work still needs attention. Family routines keep going. Trying to keep up with it all while managing treatment can be overwhelming.
March 2, 2026 — Source

No matter your age, don't ignore these colorectal cancer symptoms, surgeons say
Colorectal cancer is now the leading cause of cancer deaths in people younger than 50. While routine screening is recommended beginning at age 45 for those at average risk, certain symptoms at any age warrant a conversation with a health care provider.
March 2, 2026 — Source

Precision tumor imaging with a fluorescence probe and engineered enzymes—selective activation enables easy visibility
Cancer is a universal issue which affects many people around the world. Many will turn to surgery in the hope a surgeon will be able to completely remove a tumor, leaving healthy tissues unaffected. Various tools and techniques have been developed over the years to improve the way these surgeries are performed, and visual imaging methods such as glowing dyes have proven to be very useful.
March 2, 2026 — Source

Registry data address major gaps in rare eye cancer
Eye experts at Flinders University have released new global findings that reveal how a rare eye cancer first appears, offering vital insights that will help doctors diagnose the disease earlier and improve care for patients around the world. The research draws on the International Vitreoretinal B‑Cell Lymphoma Registry, the world's largest global project dedicated to understanding this aggressive eye cancer.
March 2, 2026 — Source

Study shows the heart can be protected during chemotherapy without reducing antitumor efficacy
Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective anticancer drugs—a class of medicines called anthracyclines—can cause serious damage to the heart. In some patients, this cardiac damage appears months or even years after treatment and has a major impact on quality of life.
March 2, 2026 — Source

Tracking mysteries of loss of Y chromosome, cancer
The Y chromosome is among the smallest in the human body and carries the fewest genes. Researchers are paying renewed attention to its role in cancer—specifically, what happens when it vanishes.
March 2, 2026 — Source

Health — Cancer — February 24th, 2026

Histotripsy can safely target the pancreas in laboratory study
Pancreatic cancer continues to be a devastating disease, with an overall 5-year survival rate of around 13%. Accounting for about 3% of all cancers, it is the third leading cause of cancer death in the United States. Difficulties in diagnosis—due to the anatomic location of the pancreas and patients being asymptomatic or having ambiguous symptoms in early stages—cause treatment options to be limited. Surgical resection, chemotherapy, radiotherapy, and other interventions present significant challenges, prompting researchers to continue to seek new alternatives.
February 24, 2026 — Source

New strategy grabs cancer's 'undruggable' proteins and throws them in the cellular trash
When cancer-driving proteins resist various treatments, Northwestern University scientists have uncovered a new solution. Don't fight them—throw them in the cellular trash. In a new study published in Nature Communications, scientists developed protein-like polymers (PLPs) capable of grabbing proteins and directing them to the cell's waste-disposal machinery. From there, the proteins are degraded and disposed of, triggering cancer cell death.
February 24, 2026 — Source

Health — Cancer — February 17th, 2026

A yeast-derived genetic tool offers hope for mitochondrial disorders and cancer
Nucleotide synthesis-the production of the basic components of DNA and RNA-is essential for cell growth and division. In most animal cells, this process depends closely on properly functioning mitochondria, the organelles responsible for respiration and energy production. When mitochondrial respiration fails-a common feature of mitochondrial diseases and several forms of cancer-cells lose the ability to proliferate normally. A new study published in Nature Metabolism now shows that this dependence is not irreversible.
February 17, 2026 — Source

Cornell study finds existing drug could boost liver cancer immunotherapy
Immunotherapy -- which activates the body's own immune system to kill cancer cells -- has not worked well against a rare and fatal liver cancer, but a new Cornell University study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment.
February 17, 2026 — Source

Early study connects dogs' cancer survival with their gut microbiome composition
Canine cancer patients receiving a new form of immunotherapy lived longer or shorter depending on the composition of their microbiome, the community of organisms living in their gut. Results of the clinical trial led by Oregon State University scientists were published in Veterinary Oncology.
February 17, 2026 — Source

FDA-approved drug may reverse T-cell exclusion in fibrolamellar liver cancer
Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment. Fibrolamellar carcinoma primarily affects children and young adults and accounts for up to 2% of all liver cancers. It currently has no cure and has often metastasized by the time it is detected, leaving patients with a short life expectancy.
February 17, 2026 — Source

Mysterious RNA led scientists to a hidden layer of cancer
A mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across dozens of tumor types. These molecules form unique molecular signatures that identify cancer type and subtype with remarkable accuracy. Some even drive tumor growth and metastasis. Because many are released into the bloodstream, a simple blood test can track how patients respond to treatment and predict survival.
February 17, 2026 — Source

The Link Between GLP-1 Drugs and Thyroid Cancer Could Be Smoke and Mirrors
A new review finds no convincing evidence that drugs like Ozempic raise people's risk of common thyroid cancers.
February 17, 2026 — Source

Why are more under-50s getting colorectal cancer? 'We don't know'
The death of US actor James Van Der Beek was just the latest reminder that colorectal cancer has been surging among people under 50 in recent years—and no one knows why.
February 17, 2026 — Source

Health — Cancer — February 15th, 2026

Scientists find nerves actively fuel pancreatic cancer
Scientists have uncovered a hidden partnership between pancreatic cancer and the nervous system. Support cells in the pancreas lure nerve fibers, which then release signals that accelerate early cancer growth. This creates a self-sustaining loop that helps tumors take hold. Blocking the nerve activity significantly reduced tumor growth in experiments, suggesting a new treatment strategy.
February 15, 2026 — Source

Health — Cancer — February 14th, 2026

DNA nanomachine inside living cells measures how aggressive a cancer is
A DNA nano-harvester stays on its track inside tumor cells, measuring cancer aggressiveness by detecting a key microRNA biomarker.
February 14, 2026 — Source

Health — Cancer — February 13th, 2026

Colorectal cancer is increasing among young people, James Van Der Beek's death reminds
An increasing number of people are dying of colorectal cancer at a young age, including those as young as 20. Actor James Van Der Beek, who was diagnosed with colorectal cancer in 2023, died at age 48 on Feb. 11, 2026, bringing the disease back into the limelight.
February 13, 2026 — Source

Combating leukemia by stopping stem cells from turning cancerous
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in Norway. Men are affected slightly more often than women. Fewer than 5 in 100 patients over the age of 65 survive.
February 13, 2026 — Source

How pancreatic cancer prepares the tumor environment: A possible biomarker for the earliest stage of development
Even before a tumor in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment and creates an inflammatory and immune-defensive microenvironment in which the carcinoma can grow. This has been shown by an international research team led by Ulm University in a pioneering study. The scientists' study opens up new possibilities for developing personalized intervention strategies—before a difficult-to-treat tumor even develops.
February 13, 2026 — Source

NHS updates bladder cancer chemotherapy guidelines
Hundreds of people with advanced bladder cancer across the UK can now receive three rather than six chemotherapy cycles following research by Queen Mary University of London which has led to a change to NHS treatment guidelines. For people with the condition, this means fewer toxic side effects and a better quality of life during treatment.
February 13, 2026 — Source

Siemens Healthineers and Mayo Clinic expand partnership to fight neurodegenerative disease, cancer
Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care for neurodegenerative disease and the management of prostate cancer and metastatic liver tumors. The two organizations have signed an agreement that will improve care for people with those diseases and expand access to new imaging and interventional technologies.
February 13, 2026 — Source

Study identifies a new class of drug targets for aggressive leukemia
Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is deleted or removed, the cancer cells are sent into overdrive and die, finds a Yale-led study published in Science Signaling.
February 13, 2026 — Source

The 'zombie cell' effect: New study explains chemotherapy resistance in lung and ovarian cancers
Researchers have identified a biological mechanism that helps explain why some lung and ovarian cancers become resistant to chemotherapy, offering insight into why cancers recur. The study, published in Nature Aging this month, investigated how platinum-based chemotherapies such as cisplatin negatively affect tumor behavior in non-small cell lung cancer (NSCLC) and high-grade serous ovarian cancer (HGSOC). Although these treatments are widely used, their long-term effectiveness is often limited when tumors return or stop responding.
February 13, 2026 — Source

Time of radiotherapy influences cancer treatment response
A team of researchers from the Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER) and the University of Seville, in collaboration with the Virgen Macarena University Hospital, have identified a fundamental mechanism that links the 24-hour circadian cycle to the precise repair of DNA breaks. This study, which focused on the circadian protein Cryptochrome1 (CRY1), suggests that the time of day when radiotherapy is administered can significantly influence the effectiveness of treatment for certain types of cancer.
February 13, 2026 — Source

Health — Cancer — February 11th, 2026

Light-based sensor can detect low concentrations of cancer biomarkers in the blood
Researchers have developed a highly sensitive light-based sensor that can detect extremely low concentrations of cancer biomarkers in the blood. The new technology could one day make it possible to spot early signs of cancer and other conditions using a simple blood test.
February 12, 2026 — Source or Source

Study strengthens evidence supporting lung-sparing surgery, offering hope for mesothelioma patients
A new study from the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center finds that pleurectomy/decortication, a lung-sparing surgery, can be performed safely with low mortality in carefully selected patients with pleural mesothelioma, a rare and aggressive cancer most often caused by asbestos exposure.
February 12, 2026 — Source

Unraveling the mystery of why some cancer treatments stop working
Cancer researchers working on immunotherapies have made a big discovery: SLAMF6, a molecule on the surface of immune cells that prevents T cells from effectively attacking tumors—and, in mice, they've found a way to neutralize it.
February 12, 2026 — Source

Health — Cancer — February 11th, 2026

Aggressive brain tumors build protective 'sugar shield' to survive extreme stress
For the first time, researchers have identified a previously unrecognized metabolic defense mechanism in aggressive brain tumors: a sugar-rich shield that surrounds tumor cells and protects them against a particularly destructive form of cell death.
February 11, 2026 — Source

A single oncolytic virus injection may help T cells infiltrate glioblastoma
A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has shown that a single injection of an oncolytic virus—a genetically modified virus that selectively infects and destroys cancer cells—can recruit immune cells to penetrate and persist deep within brain tumors. The research, which is published in Cell, provides details on how this therapy prolonged survival in patients with glioblastoma, the most common and malignant primary brain tumor, in a recent clinical trial.
February 11, 2026 — Source

DNA barcoding can be used to track cancer cells in solid and liquid biopsies
Australian scientists have discovered that DNA barcoding can be used to track cancer cells in solid and liquid biopsies, empowering future research into more reliable breast cancer diagnosis and treatment strategies.
February 11, 2026 — Source or Source

Does a past abortion or miscarriage affect a woman's risk of developing breast cancer?
A prior abortion or miscarriage was not linked with an increased risk of developing pre- or postmenopausal breast cancer in a study published in Acta Obstetricia et Gynecologica Scandinavica.
February 11, 2026 — Source or Source

Established cancer drug can reactivate immunotherapy
Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune cells recognize gradually vanish. Researchers at the Technical University of Munich (TUM) have now identified one of the molecular mechanisms behind this process. In an initial study, they succeeded in blocking it using an existing cancer drug.
February 11, 2026 — Source

Harnessing antiviral memory to fight tumors: Redirected antibodies show promise
Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a major target of cancer immunotherapy. Unfortunately, drugs that target it do not trigger especially strong anticancer immune responses. New research published in Advanced Science reveals a promising strategy that harnesses preexisting antiviral immunity to boost antitumor responses.
February 11, 2026 — Source

Investigators study ivermectin's 'ability to kill cancer cells'
The National Cancer Institute, the federal research agency charged with leading the war against the nation's second-largest killer, is studying ivermectin as a potential cancer treatment, according to its top official.
February 11, 2026 — Source

Key gene behind drug resistance in small cell lung cancer identified
A research team has discovered a crucial mechanism that underlies chemotherapy resistance and metastasis in small cell lung cancer (SCLC). Their study shows that the silencing of the RASA4 gene through epigenetic mechanisms plays a crucial role in driving disease progression.
February 11, 2026 — Source

New strategy harnesses pre-existing antiviral immunity to boost anti-tumor responses
Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a major target of cancer immunotherapy. Unfortunately, drugs that target it do not trigger especially strong anti-cancer immune responses. New research published in Advanced Science reveals a promising strategy that harnesses pre-existing antiviral immunity to boost anti-tumor responses.
February 11, 2026 — Source

Review calls for risk-based screening as never-smoker lung cancers rise
Lung cancer patients who have never smoked make up a significant and growing share of global lung cancer cases, yet remain an understudied group, according to a new review written by UCL (University College London) researchers.
February 11, 2026 — Source

Rural cancer patients do just as well when having surgery close to home
Adults living in rural communities often travel long distances when seeking treatment for cancer, but distant travel may not always be necessary to receive high-quality surgical care, according to a new analysis published in the Journal of the American College of Surgeons.
February 11, 2026 — Source

Study finds immune markers at two months tied to longer survival in glioblastoma trial
Researchers at The University of Texas MD Anderson Cancer Center have identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus, Delta-24-RGD, that targets and eliminates cancer cells.
February 11, 2026 — Source

Study of tumor environment is first to show how vesicles are exchanged in tissue
A new study may change the way scientists think about the distance traveled by tiny bubbles carrying signals between cells that are embedded in tissue. These particles, called extracellular vesicles, are known to safely carry signaling cargo as a communication method between cells in bodily fluids and within tissue, and to influence health and disease. Understanding how the properties of these vesicles differ in normal versus diseased tissue could make them outstanding biomarkers for early disease detection, researchers say.
February 11, 2026 — Source

Tiny organism offers insight into neurological side effects of chemotherapy
Chemotherapy remains one of the most powerful tools in the fight against cancer, yet it often comes with significant long-term side effects that can dramatically affect patients' quality of life. Among the most debilitating is Chemotherapy-Induced Peripheral Neuropathy, which impacts both the central and peripheral nervous systems and affects up to 85% of cancer patients and survivors.
February 11, 2026 — Source or Source

Health — Cancer — February 6th, 2026

ABCA1 protein releases molecular brakes on solid tumor immunotherapy, study finds
In recent years, cancer researchers have made major breakthroughs by using the body's immune system to fight cancer. One of the most promising approaches, known as immune checkpoint blockade, works by releasing molecular "brakes" on T cells. This allows them to better recognize and attack cancer cells. While these therapies can be very effective for some patients, many solid tumors, including most forms of breast cancer, remain largely unaffected. Cancer Center at Illinois (CCIL) Program Co-leader Erik Nelson and his research group are working to understand why these treatments fail.
February 6, 2026 — Source

Americans prefer to screen for cervical cancer in-clinic versus at home, finds study
American women now have the option of screening for cervical cancer at home, using newly approved self-collection tools. While experts hope this will increase uptake in the under-screened population, a first-of-its kind study by researchers from The University of Texas MD Anderson Cancer Center found the majority (60.8%) still prefer to see a medical professional in-clinic.
February 6, 2026 — Source

Can chemo-resistant cancer cells be resensitized?
Overcoming tumor resistance to chemotherapy drugs has long been a challenge for oncology clinicians and researchers. Now, a new study suggests that blocking a key protein, p300, may force damaged cancer cells into a state of uncontrolled transcriptional activity, thereby creating a novel form of cellular stress that can make even chemo-resistant tumors sensitive again to treatment.
February 6, 2026 — Source

CRISPR approach turns oncogene amplification into a weakness in multiple solid tumors
The onset and aggressiveness of cancer are related to the abnormal behavior of certain genes, known as oncogenes. The best-known of these alterations is mutation, but it is not the only one. Sometimes, within a cell, a very high number of copies of the oncogene appear—tens or even hundreds. This amplification of oncogenes occurs in a significant proportion of solid tumors and may make the tumor more aggressive and prevent the body's defenses from detecting it, contributing to the development of resistance to treatments.
February 6, 2026 — Source

Dual-action molecule design concentrates cancer treatment in tumor cells to allow higher doses
Wistar scientists have combined a promising cancer therapy with a molecule that targets tumors to treat cancer more effectively. The new approach could be a way to deliver treatment directly to tumors at higher doses, while reducing side effects in healthy tissue.
February 6, 2026 — Source

European collaboration transforms immune cell data into cancer biomarkers
World Cancer Day, marked on 4 February, is an international day dedicated to raising awareness of cancer, and to encouraging its prevention, detection and treatment. To recognise the efforts of researchers in this area, we are publishing a success story about the COST Action, which examined immune cells as mediators of diseases associated with chronic inflammation and cancer.
February 6, 2026 — Source

Experimental bioadhesive patch sticks to wet brain tissue and wipes out most glioblastoma cells
Glioblastoma is the most prevalent and aggressive brain tumor. It proliferates very rapidly, is highly invasive, and there is currently no treatment capable of halting its progression or curing it, which means life expectancy after diagnosis is very short. The standard procedure involves surgical resection of the tumor followed by radiotherapy and chemotherapy, but even with this aggressive treatment, recurrences are very common, often within a year.
February 6, 2026 — Source

How GE HealthCare uses theranostics in cancer care
Sergio Calvo, general manager of theranostics at GE HealthCare, joins MobiHealthNews to discuss how combining molecular imaging and targeted therapy is personalizing cancer care.
February 6, 2026 — Source

New tool spots early signs of infection after breast cancer reconstruction
In the U.S., one in eight women will get breast cancer in their lifetime, and about half of them will have mastectomies. Many of those women opt to have their breasts surgically reconstructed, most commonly with implants, but a relatively high percentage develop infections after implant surgery, requiring intravenous antibiotics and often removal of the implant. This can lead to additional surgeries, delays in cancer care and increased costs, as well as added emotional distress for women already under strain from cancer diagnosis and treatment.
February 6, 2026 — Source

Scientists now know why ovarian cancer spreads so rapidly in the abdomen
Ovarian cancer kills more women than any other gynecological cancer. Most patients receive their diagnosis only after the disease spreads throughout the abdomen. Until now, scientists have never fully understood why this cancer advances so fast.
February 6, 2026 — Source

Senescent neutrophils promote tumor survival across cancer types
Renowned as first responders to threatening infections, neutrophils also happen to feature prominently in the microenvironment of tumors, where they and other immune cells play opposing and frequently mutable roles in promoting-or resisting-cancer progression. Though they've been linked to the growth of multiple cancers, including those of the lung and breast, neutrophils can assume multiple functional states, only some of which have such an effect. Identifying those states has, for technical reasons, proved to be quite a challenge.
February 6, 2026 — Source

'Sticky coat' boosts triple negative breast cancer's ability to metastasize
Researchers at Baylor College of Medicine have uncovered a strategy that triple negative breast cancer (TNBC) cells use to boost their ability to metastasize, or spread to other organs. Metastasis is the leading cause of cancer-related deaths and scientists are investigating ways to prevent it.
February 6, 2026 — Source

Understanding how cancer cells use water pressure to move through the body
Cancer is one of the leading causes of death worldwide, marked by the uncontrolled growth of abnormal cells. What makes it more dangerous is the ability of cancer cells to move quickly through the body, allowing them to invade surrounding tissues. While this behavior is well known, the mechanism behind this rapid spread remains unclear. Researchers from Kyushu University set out to fill this gap and unveiled a new physical process that helps cancer cells move rapidly throughout the body.
February 6, 2026 — Source

Why colorectal cancer breaks the immune system's rules
Colorectal cancer has long baffled scientists because, unlike most tumors, patients often do better when their cancers are packed with immune-suppressing regulatory T cells. New research finally explains why. Scientists discovered that these T cells aren't all the same: one subtype actually helps keep tumors in check, while another shields cancer from immune attack. The balance between these "good" and "bad" cells can determine whether a tumor grows or shrinks.
February 6, 2026 — Source

Health — Cancer — February 4th, 2026

A double-edged sword: Chronic cellular stress promotes liver cancer—but also makes tumors vulnerable to immunotherapy
A key molecular mechanism drives the growth of liver cell cancer while simultaneously suppressing the body's immune response to the tumor. This has been published in the journal Nature by a team led by researchers from the German Cancer Research Center (DKFZ), the University Hospital of Tübingen, and the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California. However, the results also show that this very mechanism could help identify patients who respond particularly well to immunotherapy in the future, thus opening up new therapeutic approaches.
February 4, 2026 — Source

An off-the-shelf immunotherapy for targeting solid tumors: Ready-to-use CAR-NKT cells show promise
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The study focused on engineered invariant natural killer T cells, or NKT cells—powerful immune cells with a unique ability to infiltrate solid tumors—and systematically compared four targeting systems, called chimeric antigen receptors, or CARs, that direct these cells to attack cancer.
February 4, 2026 — Source

Could fecal transplants be the new way to fight cancer?
One person's waste could be another's shot at fighting cancer. The idea may sound far-fetched, but it is gaining momentum in cancer care. Researchers are testing fecal microbiota transplants as a way of changing the gut's microbes. This could help treatments, such as immunotherapy, work better, and it could be especially significant for hard-to-reach cancers. These fecal microbiota could also help deliver longer-lasting benefits for more patients.
February 4, 2026 — Source

Doctors hope UK archive can solve under-50s bowel cancer mystery
In a dusty hospital basement on the outskirts of London, over 100 years of medical history lines the shelves, neatly arranged in row after row of cardboard specimen boxes.
February 4, 2026 — Source

Engineered yeast cells accelerate testing of cancer immunotherapies
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster, benefiting patients.
February 4, 2026 — Source

High intake of ultraprocessed foods increases risk of both all-cause and cancer-specific death
Bottom line: Cancer survivors who consumed higher amounts of ultraprocessed foods as part of their diet had a significantly increased risk of both all-cause and cancer-specific death.
February 4, 2026 — Source

Scientists use RNA nanotechnology to program living cells, opening a new path for cancer cure
Scientists at Rutgers University--Newark have developed a first-of-its-kind RNA-based nanotechnology that assembles itself inside living human cells and can be programmed to stop propagation of harmful cells. The findings, recently published in Nature Communications, represent a major breakthrough in biomedical research. The researchers are now in the midst of testing the technology on human cancer cells as a potential cure for the disease but have not yet finished the study or published results.
February 4, 2026 — Source

Self-collected HPV tests match clinical screening
New national data from Australia show that opening self-collected HPV testing to everyone dramatically increases uptake among those least likely to be screened, and preserves the clinical power needed to drive cervical cancer elimination.
February 4, 2026 — Source

Small molecule targets glioblastoma oncogene in preclinical studies
UVA Comprehensive Cancer Center scientists have identified a molecule that blocks the gene responsible for glioblastoma, raising hopes that the molecule could become a much-needed new treatment for the deadliest brain cancer.
February 4, 2026 — Source

Health — Cancer — February 2nd, 2026

A 'window to the brain': Chip tracks glioblastoma treatment response using tumor vesicles in blood
Technology created at the University of Queensland could improve the odds of surviving brain cancer and change how we treat a range of neurological conditions. Dr. Richard Lobb and Dr. Zhen Zhang from UQ's Australian Institute for Bioengineering and Nanotechnology have opened a "window to the brain" with a new diagnostic device that can tell how deadly brain tumors respond to treatment from a simple blood test.
February 2, 2026 — Source

How early pregnancy impacts aging: Implications for breast-cancer risk
A new study by cell biologists at the University of California, Santa Cruz, suggests that an early first pregnancy may protect against breast cancer decades later by preventing age-related changes in breast cells that are linked to tumor formation. Using a mouse model designed to mimic human aging and reproductive history, researchers found that pregnancy fundamentally alters how mammary tissue ages—reducing the buildup of abnormal cells that have the ability to change their identity in a way that could seed cancer in later life.
February 2, 2026 — Source

Improving nursing support for fertility preservation in women with cancer
Hiroshima University researchers developed a three-factor, 12-item, questionnaire-based scale to systematically assess nursing practices that support fertility preservation decision-making in women with cancer. They show that such decision-making can be clearly defined, measured, and improved.
February 2, 2026 — Source

Mutation map shows how key cancer gene drives tumor growth
Scientists have created a complete map showing how hundreds of possible mutations in a key cancer gene influence tumor growth. The study focused on CTNNB1, a gene that produces the protein &beta-catenin, which helps regulate tissue growth and repair. When &beta-catenin is disrupted, cells can begin uncontrolled growth—a hallmark of cancer.
February 2, 2026 — Source

New treatment approach boosts survival in young leukemia patients
An Australian research collaboration has led to a major leap forward in the treatment of acute lymphoblastic leukemia (ALL). Recently published clinical trial results have shown evidence that switching part of the standard chemotherapy protocol for a targeted immunotherapy, can significantly improve outcomes for young people living with the disease.
February 2, 2026 — Source

Randomized trial finds drug therapy reduces hot flashes during prostate cancer treatment
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the placebo in men receiving hormone therapy for prostate cancer. This primary analysis of Alliance A222001 is published in the Journal of Clinical Oncology.
February 2, 2026 — Source

Scientists create new map showing how cancer gene mutations influence tumor growth
Scientists have created a complete map showing how hundreds of possible mutations in a key cancer gene influence tumor growth.
February 2, 2026 — Source

Taming tumor chaos: Researchers uncover key to improving glioblastoma treatment
A study by Brown University Health researchers has identified a crucial factor that may help improve treatment for glioblastoma, one of the most aggressive and common forms of adult brain cancer. The findings, published in Cell Reports, reveal how differences among cells within a single tumor influence the cancer's response to chemotherapy, and introduce a promising new therapy designed to tip the odds in the patients' favor.
February 2, 2026 — Source

Health — Cancer — January 31st, 2026

Additional lymph node evaluation needed during surgery to accurately identify lung cancer spread
Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to accurately identify cancer spread.
January 31, 2026 — Source

AI support spots 9% more breast cancers without raising false positives
Artificial intelligence helps doctors spot more cases of breast cancer when reading routine scans, a world-first trial found Friday.
January 31, 2026 — Source

Eosinophils suppress tumor growth and recurrence in chordoma
Chordoma is a rare tumor characterized by poor prognosis, limited therapeutic options, and a high rate of recurrence. Despite advances in oncology, effective treatments for chordoma remain limited. Resistance to conventional radiotherapy and chemotherapy restricts therapeutic options, and surgical treatment is often challenging due to the tumor's proximity to critical anatomical structures. Consequently, identifying novel therapeutic targets is essential for improving chordoma diagnosis, treatment strategies, and outcome prediction.
January 31, 2026 — Source

Findings support additional lymph node evaluation to better detect lung cancer spread
Globally, surgical standards vary on the number and location of lymph nodes that should be removed and assessed for metastasis in patients with clinically node-negative NSCLC, cancer that imaging shows has not spread. In North America, surgical standards developed in 2021 call for assessment of three N2 nodes in the mediastinum between the right and left lungs, and one N1 node in the root of the lung.
January 31, 2026 — Source

Genetic ancestry influences tumor biology and survival in head and neck cancers
Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African-American patients survive for half as long as their counterparts of European ancestry, according to a new review study led by researchers from the University of Maryland School of Medicine's (UMSOM) Institute for Genome Sciences (IGS) and the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC).
January 31, 2026 — Source

New AI tool helps determine the risk of secondary heart attacks in cancer patients
University researchers have pioneered a new tool to determine the risk of secondary heart attacks in cancer patients using Artificial Intelligence.
January 31, 2026 — Source

Health — Cancer — January 30th, 2026

AI tool predicts six-month risks for cancer patients after heart attack
Cancer patients who suffer a heart attack face a dangerous mix of risks, which makes their clinical treatment particularly challenging. As a result, patients with cancer have been systematically excluded from many clinical trials and available risk scores. Until now, doctors had no standard tool to guide treatment in this vulnerable group.
January 30, 2026 — Source

AI-supported mammography improves early detection of breast cancer
Artificial intelligence (AI)-supported mammography identifies more cancers during screening and reduces the rate of breast cancer diagnosis by 12% in the years following, finds the first randomised controlled trial of its kind involving over 100,000 Swedish women published in The Lancet journal.
January 30, 2026 — Source

Gut bacteria may tip the balance between feeding tumors and fueling immunity
A new study reveals how bacteria in the gut can help determine whether the amino acid asparagine from the diet will feed tumor growth or activate immune cells against the cancer, according to researchers at Weill Cornell Medicine. This casts the gut microbiome, comprising the trillions of microorganisms that live in the intestine, as a central player in the body's response to cancer and to modern cancer treatments like immunotherapies.
January 30, 2026 — Source

Researchers develop blood test to find pancreatic ductal adenocarcinoma
National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer. The new test could improve survival rates from pancreatic cancer, which tends to be diagnosed at late stages when therapy is less likely to be effective. The findings were published in Clinical Cancer Research.
January 30, 2026 — Source

Researchers discover genetic ancestry is a critical component of assessing head and neck cancerous tumors
Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African-American patients survive for half as long as their counterparts of European ancestry, according to a new review study led by researchers from the University of Maryland School of Medicine's (UMSOM) Institute for Genome Sciences (IGS) and the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC).
January 30, 2026 — Source

Researchers identify new blood markers that may detect early pancreatic cancer
NIH-funded, four-marker panel could one day help catch one of deadliest cancers at more treatable stages.
January 30, 2026 — Source

Scientists find hidden pathways pancreatic cancer uses to spread
Researchers have discovered how pancreatic cancer reprograms its surroundings to spread quickly and stealthily. By using a protein called periostin, the tumor remodels nearby tissue and invades nerves, which helps cancer cells travel and form metastases. This process also creates a tough, fibrous barrier that makes treatments less effective. Targeting periostin could help stop this invasion before it starts.
January 30, 2026 — Source

Time of radiotherapy can influence the effectiveness of cancer treatment
A team of researchers from the Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER) and the University of Seville, in collaboration with the Virgen Macarena University Hospital, have identified a fundamental mechanism that links the 24-hour circadian cycle to the precise repair of DNA breaks. This study, which focused on the circadian protein Cryptochrome1 (CRY1), suggests that the time of day when radiotherapy is administered can significantly influence the effectiveness of treatment for certain types of cancer.
January 30, 2026 — Source

Health — Cancer — January 19th, 2026

A new nanorobot designed to improve immune cell recognition could help treat colorectal cancer
Colorectal cancer, the abnormal growth of cancerous cells in the large intestine or the rectum, is one of the most common types of cancers worldwide. Available treatments for this type of cancer include chemotherapy, radiation therapy, surgery and interventions designed to strengthen patients' immune system (i.e., immunotherapies).
January 19, 2026 — Source

A new playbook for cancer prevention in Africa begins with everyday infections
Wits scientists have identified a "microbial watchlist" of bacteria, viruses, fungi and parasites that could cause cancer.
January 19, 2026 — Source

Aging, smoking, oral bacteria and genetic mutations linked to higher stomach cancer risk
Scientists at Duke-NUS Medical School and the National University Health System (NUHS), together with an international team of researchers, have uncovered a complex interplay of factors that increase the risk of developing stomach cancer (gastric cancer).
January 19, 2026 — Source

Lung cancer deaths leveling off for EU women, except in Spain
After increasing for more than 25 years, lung cancer death rates are finally levelling off among women in European Union (EU) countries apart from Spain, according to predictions of mortality rates from the disease for 2026.
January 19, 2026 — Source

New study exposes a targetable vulnerability in acute myeloid leukemia
New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway involved in the body's inflammation response. Their preclinical evidence suggests that blocking this pathway with a new drug compound can weaken acute myeloid leukemia during critical stages, paving the way for more effective and targeted treatments for this hard-to-treat disease.
January 19, 2026 — Source

Plasma protein profiling can help detect cancer in patients with non-specific symptoms
A simple blood test can help detect cancer in patients with non-specific symptoms such as fatigue, pain or weight loss. This is according to a Swedish study from Karolinska Institutet, Danderyd Hospital and others, published in Nature Communications.
January 19, 2026 — Source

Reprogramming the cancer messenger: A new era of tumor extracellular vesicle engineering
Researchers at National Taiwan University have developed a modular platform to reprogram tumor-derived extracellular vesicles (EVs), transforming them from oncogenic messengers into safe, customizable drug delivery vehicles through precise molecular editing.
January 19, 2026 — Source

Spreading drug costs over the year may ease financial burden for Medicare cancer patients
A new study examines the potential impact of the Medicare Prescription Payment Plan (M3P)—an opt-in policy implemented in 2025 under the Inflation Reduction Act that allows beneficiaries to spread out-of-pocket (OOP) costs over the calendar year—on Medicare Part D beneficiaries with cancer who face high out-of-pocket (OOP) prescription drug costs.
January 19, 2026 — Source

Study examines potential impact of the Medicare Prescription Payment Plan on cancer patients
A new study examines the potential impact of the Medicare Prescription Payment Plan (M3P) - an opt-in policy implemented in 2025 under the Inflation Reduction Act that allows beneficiaries to spread out of pocket (OOP) costs over the calendar year - on Medicare Part D beneficiaries with cancer who face high out-of-pocket (OOP) prescription drug costs. Many cancer patients enrolled in Part D incur thousands of dollars in OOP expenses at the start of the year to quickly reach the catastrophic coverage threshold, after which cost-sharing drops to zero. For patients living on fixed or limited incomes, these large upfront payments can be unmanageable, contributing to delayed treatment initiation, medication nonadherence, financial distress and poorer health outcomes.
January 19, 2026 — Source

Weight loss in cancer: Organs respond to the disease in a coordinated way, study finds
Cachexia is a metabolic disorder that causes uncontrolled weight loss and muscle wasting in chronic diseases and cancer.
January 19, 2026 — Source

Health — Cancer — January 14th, 2026

Bacterial toxin can counteract colorectal cancer growth
A toxin secreted by cholera bacteria can inhibit the growth of colorectal cancer without causing any measurable damage to the body. This is shown by a new study by researchers at Umeå University, Sweden. Systemic administration of the purified bacterial substance changes the immune microenvironment in tumors, and the results may open the way for research into a new type of cancer treatment.
January 14, 2026 — Source

Blood test predicts which patients with lung cancer will benefit from newly approved immunotherapy drug
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab.
January 14, 2026 — Source

ctDNA levels after neoadjuvant therapy may predict breast cancer recurrence better than pathologic complete response
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted worse outcomes than in those patients without ctDNA, even in patients with a pathologic complete response (pCR), according to a study published in Cancer Research Communications.
January 14, 2026 — Source

Novel liquid biopsy technology could advance cancer diagnostics and monitoring
A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing challenge of simultaneously achieving high sensitivity, broad coverage, and simple workflow. A team of researchers from Genomill Health Inc., the University of Turku, and the TYKS Turku University Hospital, Finland, benchmarked this new method, Bridge Capture, against two market-leading tools Their analysis, appearing in The Journal of Molecular Diagnostics, published by Elsevier, highlights the method's simplicity, cost-efficiency, reproducibility, and scalability, making it well suited for routine clinical testing, disease monitoring, and treatment selection.
January 14, 2026 — Source

Scientists identify pre-cancerous states in seemingly normal aging tissues
A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.
January 14, 2026 — Source

Health — Cancer — January 9th, 2026

Deep learning creates virtual multiplexed immunostaining to improve cancer diagnosis
Researchers at the University of California, Los Angeles (UCLA), in collaboration with pathologists from Hadassah Hebrew University Medical Center and the University of Southern California, have developed a deep learning--based method that can digitally generate multiple immunohistochemical stains from a single, unstained tissue section.
January 9, 2026 — Source

Immune cell atlas may improve survival predictions, guide treatment decisions in multiple myeloma
A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell atlas, which includes robust patient outcome data, provides unparalleled new insights into how the immune system interacts with cancerous plasma cells and can be used to determine how aggressive a patient's multiple myeloma is likely to be.
January 9, 2026 — Source

Inflammatory immune cells predict survival and relapse in multiple myeloma
A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell atlas, which includes robust patient outcome data, provides unparalleled new insights into how the immune system interacts with cancerous plasma cells and can be used to determine how aggressive a patient's multiple myeloma is likely to be.
January 9, 2026 — Source

Mapping metastasis—how nutrient availability shapes breast cancer's spread
Breast cancer can spread—or metastasize—to many different parts of the body, but it's not well understood why tumors grow better in some organs than others.
January 9, 2026 — Source

New research decodes the bacterial "zip code" of colorectal cancer for prediction and survival
A recent study shows that bacteria living inside colorectal tumors form distinct ecosystems that are closely linked to how the disease progression and patient outcomes. These "tissue-resident" microbes appear to play an integral role in shaping tumor biology, and can help predict patient survival more accurately than standard clinical factors alone.
January 9, 2026 — Source

Origin cells for common malignant brain tumor in young adults uncovered
IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young adults under the age of 50. It is a refractory brain cancer that is difficult to treat due to its high recurrence rate.
January 9, 2026 — Source

Personalizing cancer treatments significantly improves outcomes in clinical trial
Researchers at University of California San Diego School of Medicine have led the first clinical trial in the world to show that cancer drug treatments can be safely and effectively personalized based on the unique DNA of a patient's tumor.
January 9, 2026 — Source

Scientists Found a Way to Supercharge the Immune System Against Cancer
Scientists have engineered next-generation antibodies that rally the immune system to hit cancer harder and more effectively.
January 9, 2026 — Source

Single-cell analysis illuminates myeloma immune landscape
Scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research Foundation (MMRF) and in collaboration with leading institutions across the country, have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma, a blood cancer that, while treatable, remains incurable. The findings, published in Nature Cancer, provide unprecedented insight on immune dysfunction in myeloma and could lead to improved tools for predicting which patients are at higher risk of relapse after treatment.
January 9, 2026 — Source

Targeting IDO1 for cancer: Novel degraders show promise in preclinical studies
Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these escape mechanisms. However, such therapies are not always successful. A research team led by Herbert-Waldmann at the Max Planck Institute for Molecular Physiology in Dortmund and Georg Winter at the AITHYRA Institute in Vienna has now developed a new class of compounds that specifically target and destroy the enzyme IDO1—a key molecular switch that tumours use to suppress immune responses
January 9, 2026 — Source

Health — Cancer — January 8th, 2026

A double-pronged attack on malignant B cells with improved immunotherapy
Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that recognizes two distinct features of malignant cells to destroy the cancer more effectively.
January 8, 2026 — Source

Bowel preparation for colonoscopies may temporarily alter gut balance, preclinical study suggests
New preclinical research suggests that bowel preparation procedures for colonoscopies may temporarily alter gut balance, culminating in unappreciated effects in patients with compromised gastrointestinal health.
January 8, 2026 — Source

Colonoscopy bowel prep temporarily weakens gut defenses against infection, study finds
New preclinical research suggests that bowel preparation procedures for colonoscopies may temporarily alter gut balance, culminating in unappreciated effects in patients with compromised gastrointestinal health.
January 8, 2026 — Source

Easy-to-use tool can identify high- and low-risk metastatic prostate cancer patients earlier
A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with aggressive disease.
January 8, 2026 — Source

Engineered protein complex could help immunotherapies target hard-to-treat neuroblastoma
Researchers from Children's Hospital of Philadelphia (CHOP) have developed a method to help cancer immunotherapies reach otherwise "invisible" tumors by helping guide therapies to their appropriate targets. This could be particularly useful for very difficult-to-treat tumors like neuroblastoma. The findings appear in Science Advances.
January 8, 2026 — Source

FDA misses deadline to ban formaldehyde in hair straighteners
The U.S. Food and Drug Administration (FDA) has again missed a deadline to propose a ban on chemicals in hair-straightening products that may pose a serious cancer risk.
January 8, 2026 — Source

Juggling two worlds: Caregivers of leukemia patients struggle to balance care and daily life
Caregivers of individuals diagnosed with acute leukemia face a difficult balancing act: meeting the urgent demands of cancer care while managing their daily responsibilities. A new qualitative study published in the journal Leukemia Research highlights the profound toll of this dual role and underscores the need for caregiver support as an essential part of cancer care.
January 8, 2026 — Source

Just 10 minutes of exercise can trigger powerful anti-cancer effects
A brief, intense workout may do more than boost fitness—it could help fight cancer. Researchers found that just 10 minutes of hard exercise releases molecules into the bloodstream that switch on DNA repair and shut down cancer growth signals. When these molecules were applied to bowel cancer cells, hundreds of cancer-related genes changed activity. The discovery helps explain how exercise lowers cancer risk and hints at future therapies inspired by movement.
January 8, 2026 — Source

Hidden blood mutations linked to higher heart disease risk after cancer treatment
About one in five patients with cancer who undergo genetic testing are incidentally found to have mutations in their blood called clonal hematopoiesis of indeterminate potential (CHIP). A study by Vanderbilt Health researchers reveals that it puts them at increased risk for heart disease following cancer treatment.
January 8, 2026 — Source

Multi-pronged antibodies could boost immune response to cancer
Researchers at the University of Southampton have developed a promising new way to bolster the body's immune system response to cancer.
January 8, 2026 — Source

Novel antisense oligonucleotide shows promise against aggressive pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the disease. Potential treatments typically target a key mutated oncogene called KRAS. In some cases, PDAC tumors with these mutations have resisted therapeutic efforts. However, combination therapies involving alternative drug targets may one day help clinicians overwhelm these defenses.
January 8, 2026 — Source

Radiotracers could improve choice of bladder cancer therapies
A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that can visualize tumors that carry the cell surface protein Nectin-4. This primarily occurs in the body in cases of urothelial carcinoma, a common form of bladder cancer.
January 8, 2026 — Source

Recent advances in CAR-NK cell therapy could revolutionze cancer treatment
Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, manufacturing complexity, and limited effectiveness against solid tumors. CAR-T cell therapy, while highly effective in certain blood cancers, is frequently associated with cytokine release syndrome, neurotoxicity, and prolonged production timelines. These challenges highlight the need for alternative immune cell platforms that retain antitumor potency while reducing clinical risk. Natural killer cells possess inherent cytotoxicity, do not require antigen presentation through major histocompatibility complexes, and rarely cause graft-versus-host disease.
January 8, 2026 — Source

Researchers develop enhanced antibodies to unleash the immune system against cancer
Researchers at the University of Southampton have developed a promising new way to bolster the body's immune system response to cancer.
January 8, 2026 — Source

Seattle's Alpenglow moves 3D microscope tech from lab to clinic to help modernize cancer diagnostics
Seattle-based Alpenglow Biosciences today announced a partnership with PathNet, a leading U.S. pathology laboratory, to help commercialize use of the startup's 3D microscope technology in clinical settings. The effort aims to modernize critical diagnostic tests for prostate and bladder cancers.
January 8, 2026 — Source

Short-circuiting pancreatic cancer: A potential RNA therapy
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the disease. Potential treatments typically target a key mutated oncogene called KRAS. In some cases, PDAC tumors with these mutations have resisted therapeutic efforts. However, combination therapies involving alternative drug targets may one day help clinicians overwhelm these defenses.
January 8, 2026 — Source

Unveiling IDH-mutant glioma's roots: A new path for early diagnosis
IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young adults under the age of 50. It is a refractory brain cancer that is difficult to treat due to its high recurrence rate. Until now, treatment has focused primarily on removing the visible tumor mass. However, a Korean research team has discovered for the first time that normal brain cells acquire the initial IDH mutation and spread out through the cortex long before a visible tumor mass harboring additional cancer mutations forms, opening a new path for early diagnosis and treatment to suppress recurrence.
January 8, 2026 — Source

UVA researcher wins $700,000 for promising ovarian cancer research
Promising ovarian cancer research by Melanie Rutkowski, PhD, at the University of Virginia Comprehensive Cancer Center has won $700,000 in support from the Victoria's Secret Global Fund for Women's Cancers in partnership with Pelotonia and AACR, the American Association for Cancer Research.
January 8, 2026 — Source

Walking eases fatigue among colon cancer patients
Regular physical activity—especially walking—can significantly reduce fatigue among people with colon cancer, a new study says.
January 8, 2026 — Source

Health — Cancer — January 7th, 2026

A cancer 'flashlight' helps physicians determine who can benefit from targeted treatments
To determine who could benefit from targeted cancer treatments, a researcher at the University of Missouri has put tumors under a spotlight.
January 7, 2026 — Source

A fresh energy supply may shield nerves from diabetic or chemo-induced neuropathy
Researchers demonstrate that transferring healthy mitochondria from support glial cells to nerve cells could reduce nerve pain and degeneration.
January 7, 2026 — Source

Algorithm matches drugs to glioblastoma's diverse cell types, offering hope for individualized therapies
Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for treating glioblastoma, a lethal brain tumor. This approach enabled them to predict more effective treatment combinations to fight the disease on an individualized basis.
January 7, 2026 — Source

An electronic health record-integrated AI agent advances personalized prostate cancer education
Mayo Clinic researchers have developed and evaluated MedEduChat, an electronic health record (EHR) that works with a large language model to provide accurate, patient-specific prostate cancer education.
January 7, 2026 — Source

Artificial saliva with sugarcane protein shields teeth after cancer treatment
An artificial saliva in the form of a mouthwash, produced with the CANECPI-5 protein extracted from sugarcane and modified in a laboratory, can aid in treating teeth in patients with head and neck cancer. In these cases, radiotherapy very close to the mouth can destroy salivary glands and compromise saliva production, which is essential for controlling bacteria and disease.
January 7, 2026 — Source

BATF2: A novel tumor suppressor silenced by glutamine in head and neck cancer
A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
January 7, 2026 — Source

Brazilian study shows liquid biopsies can expedite lung cancer care
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for expediting diagnoses and guiding patient treatment. A study supported by FAPESP and published in the journal Molecular Oncology showed that it is possible to identify relevant mutations in blood samples from patients with non-small cell lung cancer (NSCLC) using a commercial multigene panel. Conducted at Hospital de Amor de Barretos, a national oncology reference center, the research evaluated the presence of circulating tumor DNA (ctDNA) in different patient groups, including asymptomatic individuals.
January 7, 2026 — Source

Breakthrough treatment for advanced prostate cancer could eliminate severe side effects
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving therapy.
January 7, 2026 — Source

Can 'Fibermaxxing' Reduce Your Risk of Colorectal Cancer? Registered Dietitians Weigh In
Many Americans aren't getting enough fiber, while colorectal cancer rates are increasing in younger adults. Is fibermaxxing the solution?
January 7, 2026 — Source

Cholesterol-lowering drug can overcome chemotherapy resistance in triple-negative breast cancer, researchers discover
Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy. Despite initial responsiveness, many patients experience rapid relapse driven by cancer stem-like cells that survive chemotherapy and seed metastasis.
January 7, 2026 — Source or Source

Colon cancer rates are spiking among young people: Here's why, and how to lower the risk
Dr. Bethany Malone has treated a lot of colorectal cancer patients. The youngest, not counting those with genetic conditions, was 19 years old.
January 7, 2026 — Source

Cornell-developed nanoparticles improve cancer immunotherapy effectiveness
A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy, according to a new study led by Weill Cornell Medicine and Cornell Engineering researchers.
January 7, 2026 — Source

Cracking prostate cancer's code: An enzyme's central role in controlling subtypes and improving therapeutic response
A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at EPFL, and Eneda Toska at Johns Hopkins University have identified the enzyme KMT2D as a key epigenetic regulator in prostate cancer. Their study published in Cancer Research reveals that KMT2D plays a central role in shaping how prostate tumors grow, survive, and respond to therapy.
January 7, 2026 — Source

High glutamine levels suppress immune response in head and neck cancer tumors
A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
January 7, 2026 — Source

Magnetic nanoparticles fight bone cancer and help healing
Researchers have developed a magnetic nanomaterial that can kill bone cancer cells and support bone regeneration at the same time. The material heats up under a magnetic field to destroy tumors, while its bioactive coating helps it bond to bone and stimulate healing. Tests showed rapid formation of bone-like minerals, a key sign of successful integration. The breakthrough could lead to smarter, less invasive treatments for bone tumors.
January 7, 2026 — Source

MD Anderson and SOPHiA GENETICS join forces to accelerate data-driven cancer care
The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.
January 7, 2026 — Source

Novel approach uncovers possible drugs based on specific cellular targets for treating glioblastom
Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for treating glioblastoma, a lethal brain tumor. This approach enabled them to predict more effective treatment combinations to fight the disease on an individualized basis. This laboratory and computational research effort was led by scientists at Georgetown's Lombardi Comprehensive Cancer Center.
January 7, 2026 — Source

Ozempic, Wegovy might lower colon cancer risk
Ozempic and Wegovy might help people avoid colon cancer as well as promote weight loss or control diabetes, a new study says.
January 7, 2026 — Source

Q&A: How tumor support cells help lung cancer evade targeted therapy
A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated fibroblasts, can help lung cancer cells survive targeted drug therapy by activating multiple survival routes that allow tumors to evade treatment.
January 7, 2026 — Source

Study links dozens of blood proteins to prostate cancer risk across populations
A large-scale study has identified dozens of blood proteins linked to prostate cancer risk, some shared across populations, some unique to specific groups.
January 7, 2026 — Source

Treatment developed for advanced prostate cancer that could eliminate severe side effects
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving therapy.
January 7, 2026 — Source

Uncovering why cancer immunotherapy leads to heart inflammation
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by using the patient's own T-cells to target tumors. However, they can cause rare, but potentially fatal cardiac inflammation known as ICI-myocarditis. This is particularly true in the most recent ICI combination treatment of targeting proteins LAG-3 and PD-1, according to new research.
January 7, 2026 — Source

Young cancer survivors may face faster aging and possible early-onset dementia
Adolescent and young adult cancer survivors age faster than their peers who did not have cancer, according to a new study, which also describes how accelerated aging occurs both at the cellular level and in brain function, such as memory, attention, and ability to process information.
January 7, 2026 — Source

Health — Cancer — January 6th, 2026

AI-designed nanosensors could enable at-home testing for early cancer detection
Nanoparticles coated with molecular sensors could be used to develop at-home tests for many types of cancer.
January 6, 2026 — Source

Immune sabotage: How a Vitamin A byproduct compromises the body's normal anti-cancer response
Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have identified novel mechanisms by which a metabolic derivative of vitamin A—all-trans retinoic acid—compromises both the body's normal anti-cancer immune response and, in a different context, the efficacy of a promising type of cancer vaccine.
January 6, 2026 — Source

Nanoparticles Show Unexpected Ability to Activate Immune System Against Melanoma
Cornell-developed "prime dots" trigger immune activation by reshaping the tumor microenvironment.
January 6, 2026 — Source

Nanoparticles with AI-crafted sensors open paths to at-home cancer screening
Detecting cancer in the earliest stages could dramatically reduce cancer deaths because cancers are usually easier to treat when caught early. To help achieve that goal, MIT and Microsoft researchers are using artificial intelligence to design molecular sensors for early detection.
January 6, 2026 — Source

Novel analysis shows promise for revealing early ovarian cancer signals
University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for providing insights into molecular changes linked to early ovarian cancer development.
January 6, 2026 — Source

Seeing thyroid cancer in a new light: When AI meets label-free imaging in the operating room
Thyroid cancer is the most common endocrine cancer, affecting more people each year as detection rates continue to rise. During tumor excision, surgeons often struggle to determine exactly how much tissue should be removed, as distinguishing cancer from healthy tissue in real time is challenging and nearby structures are extremely delicate.
January 6, 2026 — Source

Streptococcus anginosus metabolites fuel gastric cancer
A recent study published in the medical journal Gut has revealed a novel cancer-promoting mechanism of Streptococcus anginosus (Sa). The research shows that methionine metabolites produced by this bacterium can significantly contribute to the development of gastric cancer.
January 6, 2026 — Source or Source

Study confirms high cost effectiveness of prostate cancer screening
A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has demonstrated that prostate-specific antigen (PSA) screening for men aged 45 and above can significantly reduce the incidence of advanced-stage prostate cancer from 39% to approximately 1%, and lower the mortality rate from 6.14% to 2.85%.
January 6, 2026 — Source

Study underscores role of sleep in reducing toll of social adversity on breast cancer survivors' health
Where someone lives can affect their health. For breast cancer survivors, their neighborhood can influence their recovery from treatment.
January 6, 2026 — Source

Ultrasmall silica nanoparticles boost immune response against melanoma
A class of ultrasmall fluorescent core-shell silica nanoparticles is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy.
January 6, 2026 — Source

US backs at-home HPV testing to boost cervical cancer screening
Federal health officials say self-collected vaginal samples can now be used to screen for cervical cancer, and most private insurance plans will be required to cover the testing without charging patients out of pocket.
January 6, 2026 — Source

Using contrast-enhanced ultrasound to distinguish hepatic PEComa from HCC without high-risk factors
Announcing a new article publication for BIO Integration journal. Hepatic perivascular epithelioid cell tumor (PEComa) is a rare tumor with malignant potential that is frequently misdiagnosed as hepatocellular carcinoma (HCC), despite requiring distinct treatment approaches. This study retrospectively investigated the imaging characteristics of PEComa and HCC without high-risk factors using conventional ultrasound (CUS) and contrast-enhanced ultrasound (CEUS) to improve preoperative diagnostic accuracy.
January 6, 2026 — Source

Health — Cancer — January 5th, 2026

Combination therapy against brain cancer proves effective in preclinical models
Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could modernize treatment for glioblastoma. In a study published in Proceedings of the National Academy of Sciences, they found that combining a common chemotherapy drug with a chemical called EdU provided unprecedented survival and cancer remission in various preclinical glioblastoma models.
January 5, 2026 — Source

Fatigue before cancer treatment linked to adverse events
Fred Hutchinson Cancer Center-led investigators found that higher patient-reported fatigue before cancer treatment aligned with higher odds of severe, life-threatening, and fatal treatment-related toxic effects.
January 5, 2026 — Source

For the first time, a mechanism enabling breast cancer to metastasize to the brain has been deciphered
A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv University, has uncovered a mechanism that allows breast cancer to send metastases to the brain—a highly lethal occurrence for which there is currently no effective treatment. The findings could enable the development of new drugs and personalized monitoring for early detection and treatment of brain metastases.
January 5, 2026 — Source

Hot flash drug shows added anti-cancer effect in breast cancer treatment
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-estrogen treatment for women with breast cancer, a new Cambridge-led trial has found.
January 5, 2026 — ASUS unveils ROG XREAL R1 AR gaming glasses offering 171-inch virtual screen for handhelds, PCs and consoles
ASUS is bringing XREAL-branded AR gaming glasses to CES with the ROG XREAL R1. ASUS says the glasses use a 240Hz micro-OLED display with FHD (1920×1080) resolution, aimed at turning a PC, console, or handheld into a large virtual screen.
January 5, 2026 — Source

Inhalable nanotherapy can activate the immune system against checkpoint-resistant melanoma
Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the body's own cells. Cancer cells can use these checkpoints to hide from the immune system, making them a key focus for treatments that boost the immune response against cancer. Immune checkpoint inhibitors are proteins that release this brake on the immune system and unleash our immune cells to attack tumors.
January 5, 2026 — Source or Source

Molecular mechanism reveals how viral infection triggers aggressive leukemia
Researchers at Kumamoto University have uncovered a previously unknown molecular mechanism by which human T-cell leukemia virus type I (HTLV-1) drives the development of adult T-cell leukemia-lymphoma (ATL), one of the most aggressive and difficult-to-treat blood cancers. The findings provide critical insight into why only a small fraction of HTLV-1 carriers develop leukemia—and point toward new strategies for targeted therapy.
January 5, 2026 — Source

Retrotransposon drives cancer by altering 3D genome structure
Scientists at St. Jude Children's Research Hospital have revealed previously unappreciated roles for the retrotransposon LINE-1 in shaping the cancer genome structure and regulation. Retrotransposons are mobile DNA pieces, comprising much of the human genome. These so-called "jumping genes" can copy and insert themselves throughout the genome, contributing to various diseases, including cancer.
January 5, 2026 — Source

Tiny fluorescent core-shell silica nanoparticles supercharge cancer immunotherapy
A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy, according to a new study led by Weill Cornell Medicine and Cornell Engineering researchers.
January 5, 2026 — Source

Health — Cancer — January 2nd, 2026

A mathematical solution for precise control of cellular "noise"
Why does cancer sometimes recur after chemotherapy? Why do some bacteria survive antibiotic treatment? In many cases, the answer appears to lie not in genetic differences, but in biological noise - random fluctuations in molecular activity that occur even among genetically identical cells.
January 2, 2026 — Source

AI detects stomach cancer risk in remote communities from upper endoscopic images
In many regions, doctors practice in settings with limited medical resources. Advanced tests, specialist support, and expert guidance for complex decisions are often unavailable. Under these circumstances, accurate automated systems, especially AI, can help close the gap between limited resources and clinical needs.
January 2, 2026 — Source

AI model predicts B cell reactivity to neoantigens for improved cancer vaccines
Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move beyond one-time attacks and short-term memory to become a long-term immunity that "remembers" cancer, effectively preventing recurrence. KAIST's research team has developed an AI-based personalized cancer vaccine design technology that makes this possible and optimizes anticancer effects for each individual.
January 2, 2026 — Source

Elevated bacteria levels in tumors weaken immune response, studies show
Cleveland Clinic researchers have discovered that bacteria inside cancerous tumors may be key to understanding why immunotherapy works for some patients but not others.
January 2, 2026 — Source

Nanoparticle therapy reprograms tumor immune cells to attack cancer from within
Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable to perform their roles properly due to suppression by the tumor. A KAIST research team led by Professor Ji-Ho Park of the Department of Bio and Brain Engineering have overcome this limitation by developing a new therapeutic approach that directly converts immune cells inside tumors into anticancer cell therapies.
January 2, 2026 — Source

Newly identified rare genetic variant reduces the risk of leukemia
A newly identified and rare genetic variant slows the growth of mutated blood stem cells, researchers report, and it reduces the risk of leukemia. The findings offer insight into why some people are naturally more resistant to clonal expansion and age-related blood cancers despite acquiring risky mutations. As tissues age, they quietly accumulate many mutations that can drive cancer. In the blood-forming, or hematopoietic, system, such mutations often appear in otherwise healthy individuals as clonal hematopoiesis (CH), a process in which certain blood stem cell (HSC) clones gain a growth advantage over non-mutated clones, allowing them to expand steadily over time.
January 2, 2026 — Source

New therapeutic approach converts immune cells inside tumors into anticancer cell therapies
Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable to perform their roles properly due to suppression by the tumor. KAIST researchers have overcome this limitation by developing a new therapeutic approach that directly converts immune cells inside tumors into anticancer cell therapies.
January 2, 2026 — Source

Short, intensive workouts can help fight bowel cancer
As many of us embark on an exercise or gym routine for the new year, research reveals that just 10 minutes of intense exercise could help fight cancer.
January 2, 2026 — Source

Tumor bacteria linked to immunotherapy resistance in head and neck cancer
Cleveland Clinic researchers have discovered that bacteria inside cancerous tumors may be key to understanding why immunotherapy works for some patients but not others.
January 2, 2026 — Source

Health — Cancer — December 26th, 2025

Nanosensors reveal if immunotherapy is working days before tumors respond
Gold nanoparticles that cluster in response to T cell enzymes can predict cancer immunotherapy success days before tumors begin to shrink.
December 26, 2025 — Source

Health — Cancer — December 25th, 2025

Scientists develop targeted therapy for T-cell lymphomas and leukemias
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors.
December 25, 2025 — Source

Health — Cancer — December 21st, 2025

A new tool is revealing the invisible networks inside cancer
A new open-source tool is peeling back cancer's genetic "black box," revealing hidden molecular networks that shape survival and disease progression.
December 21, 2025 — Source

Accelerated cancer drug approvals yield modest survival gains at significant Medicare cost
Researchers found that between 2012 and 2020, 178,000 Medicare beneficiaries received early access to cancer drugs through the FDA's accelerated approval pathway. While the pathway aims to give patients faster access to promising treatments, fewer than half of these drugs were later shown to help people live longer.
December 21, 2025 — Source

Health — Cancer — December 19th, 2025

30-year smoking duration-based criteria could increase lung cancer screening
Thirty-year smoking duration-based criteria could reduce eligibility gaps for all races relative to whites, while improving six-year lung cancer detection sensitivity, according to a study published online Dec. 16 in the Annals of Internal Medicine.
December 19, 2025 — Source

Cancer's hidden 'safety switch': Silencing TAK1 gene could boost immunotherapy performance
Australian researchers have discovered that the TAK1 gene helps cancer cells survive attack from the immune system, revealing a mechanism that may limit the effectiveness of immunotherapy treatments.
December 19, 2025 — Source

Comprehensive study settles debate over diet safety for patients with cancer
For decades, patients undergoing blood cancer treatment have been told to avoid certain foods to reduce infection risk, guidance that some physicians hoped could safely be relaxed. Now, a University of Florida study offers clear evidence that a diet designed to limit exposure to foodborne microbes results in fewer serious infections, confirming it is still the safest choice.
December 19, 2025 — Source

Discovery turns household plastic recycling into anti-cancer medication
A discovery led by the University of St Andrews has found a way to turn ordinary household plastic waste into the building block for anti-cancer drugs.
December 19, 2025 — Source

Genomic test helps flag early aggressive prostate cancer in African American patients
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after treatment, particularly African American men who face the highest burden from this disease.
December 19, 2025 — Source

Prostate cancer cells use unique metabolic pathway to thrive in bone tissue
A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in bone tissue, offering a potential new treatment target for patients with advanced disease.
December 19, 2025 — Source

Health — Cancer — December 15th, 2025

Blood test may help identify which colon cancer patients benefit from NSAIDs
A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery, according to a study appearing in JAMA Oncology. Based on data from an Alliance for Clinical Trials in Oncology study, this finding could lead to more personalized treatments and better outcomes for patients.
December 15, 2025 — Source

Cancer disrupts brain's day-night rhythm, altering stress hormone cycles in mice
"The brain is an exquisite sensor of what's going on in your body," says Cold Spring Harbor Laboratory Assistant Professor Jeremy Borniger. "But it requires balance. Neurons need to be active or inactive at the right times. If that rhythm goes out of sync even a little bit, it can change the function of the entire brain."
December 15, 2025 — Source

Cannabis compounds show unexpected power against ovarian cancer
Cannabis compounds CBD and THC show early but compelling promise as a future ovarian cancer therapy.
December 15, 2025 — Source

Fertility gene helps glioblastoma tumors survive chemotherapy and return after treatment, researchers discover
Research by University of Sydney scientists has uncovered a mechanism that may explain why glioblastoma returns after treatment, offering new clues for future therapies which they will now investigate as part of an Australian industry collaboration.
December 15, 2025 — Source

New guideline maps care for pregnant women with blood cancers
A new guideline from the American Society of Clinical Oncology (ASCO) offers clear, evidence-based direction for treating blood cancers during pregnancy and shows that many patients can safely receive timely cancer care without compromising fetal health. The guideline underscores that survival outcomes for pregnant patients with leukemia or lymphoma can match those of non-pregnant patients when treatment follows established protocols.
December 15, 2025 — Source

Health — Cancer — December 12th, 2025

Acupuncture improves breast cancer survivors' perceived cognitive impairment
Real and sham acupuncture were more effective at improving breast cancer survivors' perceived cognitive impairment compared with usual care, while real acupuncture was superior to sham acupuncture in improving objective cognitive function, according to results from the randomized ENHANCE phase II clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
December 12, 2025 — Source or Source

Adding antibody treatment to chemo boosts outcomes for children with rare cancer
Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical trial.
December 12, 2025 — Source

It's being used to fight cancer, flu and the next pandemic, but what exactly is mRNA?
Aside from maybe high school biology classes, the first time many people heard of mRNA was during the pandemic because of the vital role MRNA technology played in COVID-19 vaccines.
December 12, 2025 — Source

Menopausal hormone therapy shows no added breast cancer risk for BRCA carriers
Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched prospective analysis presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
December 12, 2025 — Source or Source

Mini-tumors combine synthetic and real cells to simulate immune responses
Normally, the immune system recognizes and eliminates abnormal cells. However, cancer cells can develop strategies to evade this control: they block defense mechanisms or send inhibitory signals. In this way, tumors can grow unchecked. In a collaborative study, research teams from Germany, the United Kingdom, and Hungary have tackled this challenge by creating artificial tumor models in which synthetic cells mimic immune responses.
December 12, 2025 — Source

Mobile health tool may improve quality of life for adolescent and young adult breast cancer survivors
Incidence of breast cancer in women between the ages of 15 and 39 has risen on average 0.6% each year between 1975 and 2022.
December 12, 2025 — Source or Source

New immunotherapy targets for glioblastoma identified by mapping cell interactions
Glioblastoma is the most common form of brain cancer in adults, and its consequences are usually quick and fatal. After receiving standard-of-care treatment (surgery followed by radiation and chemotherapy), fewer than half of patients will survive longer than 15 months. Only 5% of patients survive longer than five years.
December 12, 2025 — Source

Study shows IL-36 gamma 'armored' CAR T cells can eradicate solid tumors
A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric antigen receptor (CAR) T-cell therapy in solid-tumor cancers, resulting in their eradication. Led by Renier Brentjens, MD, Ph.D., Deputy Director and Chair of the Department of Medicine at Roswell Park and a pioneer in the field of CAR T-cell therapy, the research represents a hopeful new step toward achieving the same success in solid tumors that the treatment has realized in hematologic malignancies.
December 12, 2025 — Source

Tanning Beds Are Giving Us Skin Cancer Where the Sun Doesn't Shine
New research highlights the unique dangers of the UV radiation provided by tanning beds.
December 12, 2025 — Source or Source

Health — Cancer — December 11th, 2025

Antibody formulation could enable simple injections instead of lengthy hospital infusions
Antibody treatments for cancer and other diseases are typically delivered intravenously, because of the large volumes that are needed per dose. This means the patient has to go to a hospital for every treatment, where they may spend hours receiving the infusion.
December 11, 2025 — Source

Blocking collagen signaling boosts drug delivery in pancreatic cancer
Pancreatic cancer is one of the deadliest malignancies, with survival rates remaining dismally low despite major advances in oncology. One of the key reasons lies in the disease's unique fibrotic microenvironment—a dense, collagen-rich tissue that acts as a physical and biochemical barrier, preventing drugs from reaching tumor cells effectively.
December 11, 2025 — Source or Source

CAR-T therapy yields long-term survival for patients with lymphoma
A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult patients with relapsed or refractory large B-cell lymphoma, even years after treatment.
December 11, 2025 — Source

Even moderate drinking carries a bigger cancer risk than you think
Alcohol's cancer risk is shaped by a powerful mix of biology, behavior, and social factors—often in ways people don't expect.
December 11, 2025 — Source

Frequency and quantity of alcohol consumption influence cancer risk
As Americans gear up for the holiday season, new research offers a timely reminder to reflect on the long-term health effects of raising a celebratory glass -- or two. Alcohol is known to increase the risk of several cancers even at moderate levels. Yet drinking remains widespread, and important questions persist about how both the frequency and amount of alcohol people consume shape their cancer risk.
December 11, 2025 — Source

Imaging study solves a long-standing gap in metastatic breast cancer research and care
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an improved method for predicting treatment benefits in patients with hormone receptor-positive (HR+) metastatic breast cancer that has spread primarily or exclusively to the bones.
December 11, 2025 — Source

Phase I trial finds breast cancer vaccine triggers an immune response and is safe
Cleveland Clinic researchers are presenting final Phase I data from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
December 11, 2025 — Source

Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer
Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of the phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
December 11, 2025 — Source

Researchers discover the enzyme responsible for chromothripsis in cancer
University of California San Diego researchers have discovered the enzyme responsible for chromothripsis, a process in which a single chromosome is shattered into pieces and rearranged in a scrambled order, allowing cancer cells to rapidly evolve and become resistant to treatment. Since its discovery more than a decade ago, chromothripsis has emerged as a major driver of cancer progression and treatment resistance, but scientists haven't learned what causes it. Now, UC San Diego scientists have solved this longstanding mystery in cancer biology, opening up new possibilities for treating the most aggressive cancers.
December 11, 2025 — Source

Scientists uncover key driver of treatment-resistant cancer: Genome-scrambling enzyme points to new treatments
University of California San Diego researchers have discovered the enzyme responsible for chromothripsis, a process in which a single chromosome is shattered into pieces and rearranged in a scrambled order, allowing cancer cells to rapidly evolve and become resistant to treatment.
December 11, 2025 — Source

Skipping sentinel lymph node biopsy may be safe for some early-stage breast cancer patients
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up, according to results from the BOOG 2013-08 phase III clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.
December 11, 2025 — Source

Software Mogul/Secretary of (*checks notes) the Interior Says AI Will Cure Cancer
"This is the miracle of AI. We can actually manufacture intelligence."
December 11, 2025 — Source

Tricking tumors into marking themselves for destruction with focused ultrasound
The research team from USC Viterbi's Wang Lab used focused ultrasound waves to "prime" tumor cells so they can be more easily recognized and attacked by chimeric antigen receptor (CAR) T-cells, the engineered immune cells that have revolutionized treatment for blood cancers but have until now struggled against solid tumors.
December 11, 2025 — Source

Trump Rules Force Cancer Registries To 'Erase' Trans Patients From Public Health Data
LISTEN: "People get better care when we know who they are." That belief is at the heart of why scientists and LGBTQ+ health advocates oppose a new rule that makes it harder to collect data on trans patients with cancer. KFF Health News correspondent Rachana Pradhan appeared on WAMU's Health Hub on Dec. 10 about the change from the Trump administration.
December 11, 2025 — Source

Valvular heart disease is common in cancer patients but interventions can improve survival
Valvular heart disease, identified through cardiovascular imaging, is common in cancer patients. Interventions to treat valvular heart disease significantly improved survival.
December 11, 2025 — Source

Health — Cancer — December 5th, 2025

AI brain scan model identifies stroke, brain tumors and aneurysms
A new AI model could help radiologists identify brain abnormalities in MRI scans for all conditions including stroke, multiple sclerosis and brain tumors.
December 5, 2025 — Source

Gut bacteria's hidden toxin acts as DNA glue, fueling colorectal cancer risk
Colibactin is a powerful toxin produced by Escherichia coli and other bacteria living in the human gut. This highly unstable bacterial product causes mutations in DNA that have been linked to colorectal cancer. Because it breaks down quickly, isolating and studying it has been difficult, but now scientists in the U.S. have discovered exactly how colibactin attacks DNA.
December 5, 2025 — Source

New atomic structure reveals how NBCn1 transporter protein aids breast cancer cell survival
UCLA scientists have characterized the structure and function of a key survival protein in breast cancer cells that helps explain how these tumors resist environmental stress and thrive in acidic, low-oxygen environments that would normally be toxic to healthy cells.
December 5, 2025 — Source

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows
Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an aggressive form of brain cancer, live longer.
December 5, 2025 — Source

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer
A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs. The findings were published in the December issue of The Journal of Nuclear Medicine.
December 5, 2025 — Source

Next gen cancer drug shows surprising anti aging power
A next-gen drug and a surprising enzyme system reveal new clues about how aging may be slowed.
December 5, 2025 — Source

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other breast cancers treatable with targeted therapies. Even when patients initially respond to treatment, the cancer often returns and is more resistant than before.
December 5, 2025 — Source

Order of cancer-driving mutations affects the chance of tumor development, study shows
The order of cancer-driving mutations—genetic changes—plays an important role in whether tumors in the intestine can develop, new research reveals.
December 5, 2025 — Source

Saliva and plasma at the core of cancer detection and treatment
Saliva and plasma could be crucial in detecting recurrences or relapses of head and neck cancers, negating the need for a painful and invasive biopsy.
December 5, 2025 — Source

Structure of protein reveals how breast cancer cells survive in hostile conditions
UCLA scientists have characterized the structure and function of a key survival protein in breast cancer cells that helps explain how these tumors resist environmental stress and thrive in acidic, low-oxygen environments that would normally be toxic to healthy cells.
December 5, 2025 — Source

Health — Cancer — December 3rd, 2025

A common childhood virus can drive bladder cancer development
Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research.
December 3, 2025 — Source

A personalized approach to treating pancreatic cancer
It's not surprising that pancreatic cancer is often referred to as a silent killer. With few early symptoms and an aggressive nature, it has one of the lowest survival rates of all cancers.
December 3, 2025 — Source

Breast cancer reshapes lymphatic vessels to support its spread
Breast cancer is able to modify the lymphatic vessels through which it travels to the draining lymph nodes. From there, it can then spread to other parts of the body. A new finding by Finnish researchers may help develop targeted therapies that could prevent this spread.
December 3, 2025 — Source or Source

Chemists synthesize a fungal compound that holds promise for treating brain cancer
For the first time, MIT chemists have synthesized a fungal compound known as verticillin A, which was discovered more than 50 years ago and has shown potential as an anticancer agent.
December 3, 2025 — Source

New investment aims to accelerate treatments for low-grade brain tumors
Researchers focused on accelerating and testing new treatments for low-grade brain tumors are set to receive a transformative £2.8 million to drive their future work.
December 3, 2025 — Source

Newly defined benign soft tissue tumor with bony shell may mimic malignancy
It's not often that a pathologist gets to make a diagnosis that works for the patient by preventing treatment from occurring. But thanks to a Johns Hopkins Medicine doctor and his newly reported definition and classification of a previously unknown, novel type of benign soft tissue tumor, that's exactly the desired outcome.
December 3, 2025 — Source

Researchers reveal complex interactions between heart disease and cancer
A surprising new discovery by Prof. Ami Aronheim and his team at the Technion--Israel Institute of Technology shows that in the absence of anti-cancer treatments, cancer development may actually improve heart function and reduce fibrosis—the scarring process that stiffens the heart muscle.
December 3, 2025 — Source

Small team, big impact: Automation helps relieve symptoms to keep cancer patients out of the ER
For many people living with cancer, symptoms such as pain, anxiety or insomnia can quickly spiral into an emergency room visit. Such visits can be financially costly and take an emotional toll on patients and their caregivers.
December 3, 2025 — Source

Sneaky senescent cells that resist cancer treatment can provide druggable lung cancer target
Senescent fibroblasts are aging cells that no longer divide and protect against tumor development. Yet two decades have gone by since cell biologist Judith Campisi, Ph.D., paradoxically demonstrated that these same cells can promote cancer growth in a laboratory setting. Until now, it has not been clear whether this occurs inside the body.
December 3, 2025 — Source

Two genes found to suppress colorectal cancer spread in preclinical models
Cancer is a leading cause of death worldwide, and among all cancers, colorectal cancer ranks second in mortality, responsible for more than 900,000 deaths in 2020.
December 3, 2025 — Source

Women who receive mammograms also undergo lung scans if notified of eligibility
While most women over age 50 schedule mammograms for breast cancer, only a minority who are also eligible for low-dose CT scans for lung cancer undergo those potentially lifesaving screenings. A new study shows that targeted outreach can close the gap.
December 3, 2025 — Source

Health — Cancer — November 30th, 2025

Your skin has a built-in cancer defense and sunlight turns it off
Scientists have uncovered how too much sunlight can flip a hidden switch inside skin cells that makes inflammation spiral out of control and increases the risk of cancer. Their research reveals that UV radiation breaks down a protective protein called YTHDF2, which normally prevents a small RNA signal from activating an immune sensor linked to dangerous inflammation. Once that protection is lost, a surprising chain reaction unfolds inside the cell, turning ordinary sun damage into a potential cancer trigger.
November 30, 2025 — Source

Health — Cancer — November 29th, 2025

Predicting a rare but life-altering complication of common cancer treatment
A new study published in the Journal of Clinical Investigation has identified biomarkers that predict the likelihood of a patient developing checkpoint inhibitor-associated autoimmune diabetes before they are treated with immune checkpoint inhibitors. Australian researchers say identifying those at high risk of the condition would allow for earlier and closer monitoring and potentially reduce the number of people presenting with serious complications like diabetic ketoacidosis.
November 29, 2025 — Source

Health — Cancer — November 26th, 2025

AI tops density in predicting breast cancer risk
An image-only artificial intelligence (AI) model for predicting the five-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a study presented at the annual meeting of the Radiological Society of North America (RSNA).
November 23, 2025 — Source

Copper nanoparticles emerge as a strong metal platform for UV SERS
Researchers show copper nanoparticles power UV SERS to detect key biochemical markers, a discovery that could pave the way to fast and reliable skin cancer diagnostics.
November 23, 2025 — Source or Source

High risk of metastatic recurrence found among young cancer patients
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence—a condition associated with significantly worse survival outcomes. Metastasis is when cancer cells spread from the initial or primary site to other parts of the body. It comes with significantly worse survival outcomes.
November 23, 2025 — Source

Missing cancer gene explains why some lung tumors respond well to immunotherapy
For some patients with the most common type of lung cancer, known as lung adenocarcinoma, there's new hope. In a new study published in Cell Reports, Mayo Clinic researchers have found several previously unknown genetic and cellular processes that occur in lung adenocarcinoma tumors that respond well to immunotherapy.
November 23, 2025 — Source

New microprotein can help cancer cells overcome stress
Cell stress and protein misfolding are involved in many diseases, including cancer and neurodegenerative disorders, and the study could one day contribute to new therapeutic strategies.
November 23, 2025 — Source

Rare inherited variants shape risk and outcomes in pediatric brain and spinal cord tumors
Researchers at Children's Hospital of Philadelphia (CHOP) and Children's National Hospital in Washington D.C. are uncovering how rare inherited genetic variants contribute to the development of brain and spinal cord tumors in children. The findings, published in the journal Nature Communications, provide new insights into how a child's genetic makeup influences cancer risk and outcomes.
November 23, 2025 — Source

Study finds uneven burden of brain and nervous system cancers across US
A new nationwide study has revealed striking differences in how brain and nervous system cancers affect Americans depending on where they live, as well as their age, sex and socioeconomic status, according to the study published in JAMA Neurology.
November 23, 2025 — Source

Health — Cancer — November 22nd, 2025

Experts launch digital hub to transform bowel cancer prevention and care
World-leading experts have launched an online platform to enable the public to shape the future of bowel cancer research and patient care.
November 22, 2025 — Source

Intranasal nanomedicine shows promise against glioblastoma
Researchers at Washington University School of Medicine in St. Louis, along with collaborators at Northwestern University, have developed a noninvasive approach to treat one of the most aggressive and deadly brain cancers. Their technology uses precisely engineered structures assembled from nano-size materials to deliver potent tumor-fighting medicine to the brain through nasal drops. The novel delivery method is less invasive than similar treatments in development and was shown in mice to effectively treat glioblastoma by boosting the brain's immune response.
November 22, 2025 — Source

New nasal nanodrops wipe out brain tumors in mice
A nasal-delivered nanotherapy turns silent glioblastoma tumors into immune-targeted ones—and destroys them in mice.
November 22, 2025 — Source or Source

Health — Cancer — November 21st, 2025

A drug already in trials may stop chemotherapy nerve damage
Researchers discovered that chemotherapy can accidentally trigger a stress alarm in immune cells, causing inflammation that damages nerves. Blocking this alarm protected mice from nerve pain and kept their nerves healthier. A drug already being tested for cancer may help do the same in people. Early blood tests suggest it may even be possible to predict who will develop these symptoms before they happen.
November 21, 2025 — Source

After series of denials, his insurer approved doctor-recommended cancer care. It was too late.
For nearly three years, Eric Tennant endured chemotherapy infusions, rounds of radiation, biopsies, and hospitalizations that left him weak and depleted.
November 21, 2025 — Source or Source

AI can help cancer patients better understand CT reports
Medical reports written in technical terminology can pose challenges for patients. A team at the Technical University of Munich (TUM) has investigated how artificial intelligence can make CT findings easier to understand. In the study, reading time decreased, and patients rated the automatically simplified texts as more comprehensible and more helpful.
November 21, 2025 — Source

Cancer stole her voice. She used AI, curse words, and kids' books to get it back.
When doctors told her they had to remove her tongue and voice box to save her life from the cancer that had invaded her mouth, Sonya Sotinsky sat down with a microphone to record herself saying the things she would never again be able to say.
November 21, 2025 — Source or Source

CT colonography cost-effective for CRC screening in Black adults
Szu-Yu Zoe Kao, from Siemens Medical Solutions U.S. Inc., in Malvern, Pennsylvania, and colleagues examined the cost-effectiveness of CTC for CRC screening by race (Black and White) and gender in a microsimulation model. The model incorporated 2010 to 2019 U.S. data on disease progression and real-world screening adherence for colonoscopy and the fecal immunochemical test (FIT). Status quo (choice between colonoscopy and FIT), CTC every five years, colonoscopy every 10 years, annual FIT, and multitarget stool DNA test every three years were compared.
November 21, 2025 — Source

Diagnostics for pancreatic cancer can improve with the help of AI
Pancreatic cancer is the deadliest form of cancer worldwide, mainly because the disease is often discovered late. Symptoms associated with these tumors are often non-specific, so patients and doctors do not immediately suspect cancer. Moreover, these tumors are difficult to detect in the early stages on abdominal CT scans. Once the diagnosis is made, curative treatment is usually no longer possible. Only 10% of patients survive beyond five years.
November 21, 2025 — Source

Genetic events that can trigger leukemia in patients with a rare disorder deciphered
Two parallel and complementary studies conducted by the IDIBELL team led by Dr. Alessandra Giorgetti have succeeded in recreating models of GATA2 deficiency disease, a rare genetic disorder that affects fewer than 1 million people worldwide. Thanks to these new models developed by Dr. Giorgetti's team, we now have a clearer understanding of the molecular process by which the hematopoietic stem cells of these patients become cancerous.
November 21, 2025 — Source

Global collaboration accelerates progress toward eliminating cervical cancer
Cervical cancer will be the first human cancer eliminated through coordinated global action. A new special issue of Cancer Biology & Medicine brings together leading experts from around the world to examine progress, challenges, and innovations in prevention, screening, and treatment. From policy frameworks and epidemiological insights to digital health tools and therapeutic vaccines, the collection provides a timely resource for accelerating the World Health Organization's 2030 targets for cervical cancer elimination and advancing women's health equity worldwide.
November 21, 2025 — Source

Marine bacteria show potent antitumor effects against colorectal cancer
A research team led by Professor Eijiro Miyako at the Graduate School of Advanced Science and Technology, Japan Advanced Institute of Science and Technology (JAIST), has discovered that the marine bacterium Photobacterium angustum demonstrates remarkable therapeutic efficacy against colorectal cancer.
November 21, 2025 — Source

Marine bacterium shows powerful therapeutic effects against colorectal cancer
A research team led by Professor Eijiro Miyako at the Graduate School of Advanced Science and Technology, Japan Advanced Institute of Science and Technology (JAIST), has discovered that the marine bacterium Photobacterium angustum demonstrates remarkable therapeutic efficacy against colorectal cancer.
November 21, 2025 — Source

New study highlights key findings on lung cancer surveillance rates
Despite recommendations for posttreatment surveillance in lung cancer patients, there is wide variability in the follow-up care that lung cancer patients receive. A recent study, led by senior author Leah Backhus, MD, MPH, Professor of Cardiothoracic Surgery (Thoracic Surgery) in the Stanford Department of Cardiothoracic Surgery, offers new insights on patient care and lung cancer surveillance rates.
November 21, 2025 — Source

Protein droplets in the nucleus guard against cancer, researchers discover
Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have discovered how a gene-regulating protein forms tiny liquid-like droplets inside the cell nucleus (the compartment that stores and manages DNA) to guard against cancer. Their study, published in Nature Communications, shows that these protein droplets act as control centers that keep tumor-suppressor genes switched on.
November 21, 2025 — Source

The Covid Contrarian Clubhouse Makes Its Mark on Trump's Washington
There are countless think tanks in the U.S. seeking to influence local, state, and national policy. A relatively new one is making its mark in President Donald Trump's Washington: the Texas-based Brownstone Institute.
November 21, 2025 — Source

Three times as many lung cancer deaths could be prevented with one simple step
Three times as many lung cancer deaths could be prevented if everyone eligible for screening got a chest CT scan, a new study says.
November 21, 2025 — Source

Understanding intrinsically disordered protein regions and their roles in cancer
Every function in a cell is associated with a particular protein or group of proteins, typically in a well-defined three-dimensional structure. However, intrinsically disordered regions of proteins defy this structure-function paradigm.
November 21, 2025 — Source

US Cancer Registries, Constrained by Trump Policies, To Recognize Only 'Male' or 'Female' Patients
The top authorities of U.S. cancer statistics will soon have to classify the sex of patients strictly as male, female, or unknown, a change scientists and advocates say will harm the health of transgender people, one of the nation's most marginalized populations.
November 21, 2025 — Source

US lung cancer screening fails most patients, according to study
In a study of nearly 1,000 consecutive patients treated for lung cancer at Northwestern Medicine, researchers discovered only 35% would have qualified for screening, according to the U.S. Preventive Services Task Force (USPSTF) screening criteria. The two-thirds of patients who would have been excluded were disproportionately women and never-smokers.
November 21, 2025 — Source

Health — Cancer — November 20th, 2025

A microRNA cocktail weakens brain tumors in preclinical trials
A patented RNA-based cocktail developed at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has emerged as a promising active agent against tumors of the central nervous system, such as glioblastoma.
November 20, 2025 — Source

Cancer cells have backup metabolic pathway to keep building DNA when blocked, study finds
The discovery could open the door to new treatments that starve tumors of their essential building blocks, said Issam Ben-Sahra, Ph.D., the Thomas D. Spies Professor of Genetic Metabolism and associate professor of Biochemistry and Molecular Genetics, who was senior author of the study.
November 20, 2025 — Source

Chronic hepatitis C linked to increased risk of pancreatic cancer
A Yale University study published in JAMA Network Open found chronic hepatitis C infection is linked to an 1.8-fold increased risk of pancreatic cancer.
November 20, 2025 — Source

Clinical tool helps predict which brain tumors will require treatment
A new study has shown that a clinical tool developed by the University of Liverpool and The Walton Center can accurately predict whether the most common type of brain tumor will grow or cause symptoms, helping doctors and patients make better-informed decisions about care.
November 20, 2025 — Source

Engineered immune cells target and destroy glioblastoma in animal models
With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer. Until now, all available treatments, including immunotherapy—which involves strengthening the immune system to fight cancer—have proved disappointing. CAR-T cells are genetically modified immune cells manufactured in the laboratory and designed to identify and destroy cancer cells.
November 20, 2025 — Source

French scientists probe mRNA's potential to fight cancer
Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger RNA—best known for being used in COVID-19 vaccines—in the hopes of finding a breakthrough treatment for a particularly deadly cancer.
November 20, 2025 — Source

Gene scissors in camouflage mode help in the search for cancer therapies
The immune system plays a crucial role in fighting tumors and metastases. Consequently, it is decisive to conduct cancer research in mouse models with an immune system that is as natural as possible—which is easier said than done.
November 20, 2025 — Source

Heat shock protein masks BRCA1 mutations, suggesting a new treatment path
Researchers from The University of Texas MD Anderson Cancer Center identified a new role for heat shock protein 90 (HSP90) in cancer predisposition and treatment resistance.
November 20, 2025 — Source

New therapeutic strategies show promise against a hard-to-treat prostate cancer
A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.
November 20, 2025 — Source

Study suggests type 1 diabetes may significantly raise bladder cancer risk
People with type 1 diabetes (previously called juvenile diabetes) are 4.29 times more likely to develop bladder cancer, according to a systematic review and meta-analysis by researchers at the Keck School of Medicine of USC. The new analysis is the first to control for the effects of tobacco smoking, a factor that likely obscured the heightened risk in earlier studies.
November 20, 2025 — Source

Health — Cancer — November 14th, 2025

Cancer care crowdfunding increasingly common, but rarely successful
A growing number of desperate cancer survivors are turning to crowdfunding to help pay for their treatment and living expenses, a new study says.
November 14, 2025 — Source

Combination immunotherapy for rare cancers shows improved efficacy and survival rates
Combining nivolumab and ipilimumab in patients with advanced mismatch repair-deficient or microsatellite instability-high cancers resulted in a 63% objective response rate and 71% progression-free survival at six months, substantially exceeding outcomes seen with monotherapy. These findings support combination immunotherapy as a more effective option for rare, difficult-to-treat cancers.
November 14, 2025 — Source

Computational deep dive reveals hidden cancer drug targets and repurposing opportunities
"The kinds of small molecules representing many of our medicines are rarely found in nature, so they haven't evolved to carry out a specific task," said Sanju Sinha, Ph.D., an assistant professor in the Cancer Metabolism and Microenvironment Program at Sanford Burnham Prebys Medical Discovery Institute. "Sometimes the field looks at these drugs with tunnel vision in terms of them having a single target along with some side effects labeled as 'off-target effects."
November 14, 2025 — Source

How brain fluid flow predicts survival in glioblastoma
Glioblastoma—the most aggressive form of brain cancer—remains one of medicine's biggest challenges. Despite surgery, radiotherapy, and chemotherapy, most patients survive only about a year after diagnosis.
November 14, 2025 — Source

Deep learning system could transform skin cancer detection with near-perfect accuracy
Melanoma remains one of the hardest skin cancers to diagnose because it often mimics harmless moles or lesions. While most artificial intelligence (AI) tools rely on dermoscopic images alone, they often overlook crucial patient information (like age, gender, or where on the body the lesion appears) that can improve diagnostic accuracy. This highlights the importance of multimodal fusion models that can enable high precision diagnosis.
November 14, 2025 — Source

MD Anderson launches historic $2.5 billion campaign to end cancer
The University of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer Center today launches its historic $2.5 billion comprehensive philanthropic campaign, Only Possible Here, The Campaign to End Cancer. The campaign represents the largest fundraising effort in MD Anderson's 84-year history, bringing together philanthropic support from around the world to advance the institution's mission to end cancer. Initial donor support already has raised $1.9 billion toward the campaign goal.
November 14, 2025 — Source

Skin cancer cluster found in 15 Pennsylvania counties with or near farmland
Counties in Pennsylvania that contained or were near cultivated cropland had significantly higher melanoma rates compared to other regions, according to a new study led by scientists at Penn State.
November 14, 2025 — Source

Surgery after immunotherapy boosts survival for liver cancer patients
A new Cedars-Sinai Cancer study shows that patients with advanced liver cancer who receive immunotherapy to shrink their tumors have improved outcomes after liver transplant or tumor removal.
November 14, 2025 — Source

Traces of bacteria inside brain tumors may affect tumor behavior
Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets the stage for future studies seeking to improve treatment outcomes.
November 14, 2025 — Source

Transforming colorectal cancer research with patient-derived xenograft models
Patient-derived xenograft (PDX) models are emerging as a transformative tool in colorectal cancer (CRC) research, offering unparalleled insights into tumor biology, drug resistance, and personalized treatment approaches. These models, created by transplanting fresh human tumor tissue into immunodeficient mice, faithfully replicate the genetic, histological, and molecular features of the original tumors. As such, they serve as invaluable resources in the study of tumor heterogeneity and in the development of precision oncology.
November 14, 2025 — Source

UK study exposes cancer care deficit for patients with learning disabilities
Individuals in England with learning disabilities face higher cancer risk, particularly before age 50, and experience lower rates of urgent investigation, later-stage diagnoses, and reduced access to treatment. Life expectancy after cancer diagnosis is significantly shorter, especially for those with severe disabilities or Down syndrome. Certain cancers, such as sarcoma and central nervous system cancers, are notably more common in this group.
November 14, 2025 — Source

Health — Cancer — November 13th, 2025

Extreme age protects against cancer in mouse study
Old laboratory mice develop substantially fewer and less-aggressive lung tumors than younger animals in a new study led by Stanford University researchers. The discovery flies in the face of established dogma that holds that cancer risk increases with age, but it dovetails with what's seen in very elderly people, in whom cancer risk appears to either level off or even decline with age.
November 13, 2025 — Source

Gut bacterium may sabotage liver cancer immunotherapy, study suggests
A research team led by the Department of Clinical Oncology, Center of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has identified a critical factor contributing to the failure of liver cancer immunotherapy. The study discovered that the gut bacterium Phocaeicola vulgatus can disrupt the immune system, leading to resistance to immunotherapy in some liver cancer patients.
November 13, 2025 — Source

Machine learning predicts drug response for personalized colorectal cancer treatment
A Singaporean research team has developed CAN-Scan (short for Cancer Scan), a next-generation precision oncology platform designed to "scan" the molecular features of each patient's cancer. Published in Cell Reports Medicine, CAN-Scan integrates patient-derived tumor models, multi-omics profiling, and machine learning to predict disease progression and therapeutic response, with the potential to personalize treatment for colorectal cancer (CRC) patients in the future.
November 13, 2025 — Source

New 'ultra-mild' sequencing method fixes long-standing flaws in cancer DNA methylation tests
UMBS-seq achieves both accuracy and gentleness, unlocking more reliable cancer biomarker detection. The method, which was initially developed by researchers at the University of Chicago, will be made commercially available to cancer diagnostic test developers by Ellis Bio early next year.
November 13, 2025 — Source

Single-cell study reveals how HPV shapes immune landscape in penile cancer
Although penile cancer represents less than 1% of male malignancies, it carries substantial physical and psychological burden, with a five-year survival rate near 50%. Around half of Penile squamous cell carcinoma (PSCC) cases are associated with persistent HPV infection, which triggers oncogenic transformation via viral oncoproteins E6 and E7. Interestingly, HPV-positive PSCC patients tend to have better survival and treatment responses compared to HPV-negative cases. However, the mechanisms behind this clinical advantage remain poorly understood.
November 13, 2025 — Source

What are the signs of a brain tumor?
Have you been having headaches that won't go away, confusion or changes in your senses? You may wonder if these are signs of a brain tumor.
November 13, 2025 — Source

Health — Cancer — November 9th, 2025

Protein linked to cancer found to play key role in wound healing
When doctors detect elevated levels of SerpinB3 in a blood test, it can signal that something is seriously wrong, from hard-to-treat cancers to severe inflammatory conditions.
November 9, 2025 — Source

Health — Cancer — November 8th, 2025

Nanovaccine shows great promise for treating HPV-related cancers
Therapeutic vaccine eliminated tumors, extended survival in lab setting.
November 8, 2025 — Source

Health — Cancer — November 7th, 2025

Bioengineered bone marrow model successfully used in leukemia research
Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model to carry out vital cancer research, offering new insights into potential therapies for the disease.
November 7, 2025 — Source

How colorectal cancer evades immunotherapy using a dual barrier
Colorectal cancer is one of the leading causes of cancer death worldwide. In recent years, immunotherapies—treatments that reactivate the immune system to attack tumor cells—have transformed the treatment of many types of cancer. However, most patients with metastatic colorectal cancer do not respond to these treatments.
November 7, 2025 — Source

Promising drug can inhibit aggressive breast cancer
Promising drug can inhibit aggressive breast cancer
November 7, 2025 — Source

Single-cell analysis reveals HPV-induced keratinocyte heterogeneity in cervical cancer
Cervical squamous cell carcinoma (CESC), the most prevalent subtype of cervical cancer, remains a major global health burden driven primarily by persistent high-risk HPV infection and genetic susceptibility.
November 7, 2025 — Source

Study reveals trends and future projections of cancer mortality in China
Cancer remains the second leading cause of death in China, accounting for nearly one-quarter of all deaths nationwide. Rapid socioeconomic change, environmental exposure, and an aging population have intensified the burden of cancer across the country. Although national programs in cancer prevention and early detection have improved survival rates, regional inequalities persist. Rural residents face limited access to medical care and lower screening coverage compared to urban populations.
November 7, 2025 — Source

Study reveals tumor defense mechanisms in colorectal cancer
Colorectal cancer is one of the leading causes of cancer death worldwide. In recent years, immunotherapies-treatments that reactivate the immune system to attack tumor cells-have transformed the treatment of many types of cancer. However, most patients with metastatic colorectal cancer do not respond to these treatments.
November 7, 2025 — Source

The hidden "Big Bang" that decides how bowel cancer grows
Bowel cancer's fate is sealed in a single "Big Bang" moment of immune escape, offering new hope for early, targeted treatments.
November 7, 2025 — Source

Health — Cancer — November 6th, 2025

American Cancer Society releases first-ever U.S. Tobacco Atlas
The American Cancer Society (ACS) announced the inaugural release of The U.S. Tobacco Atlas, a fact-based, digital scientific resource offering comprehensive data and insights on tobacco use, control policies, and their impact nationwide. The report notes that cigarette smoking among U.S. adults dropped from 42% in 1965 to 11% in 2023.
November 6, 2025 — Source

Q&A: Managing menopause after cancer
Menopause can bring a wave of physical and emotional changes—and for people with cancer, those changes can start earlier or feel more intense. Treatments like chemotherapy, radiation, surgery, and/or endocrine therapy can trigger menopause or menopause-like symptoms, leaving patients wondering what's normal, what's manageable, and what's safe when it comes to treatment options.
November 6, 2025 — Source

Scanning nanoprobe microscope reveals the hidden flexibility of cancer cells
A new Nanoendoscopy-AFM technique enables direct, minimally invasive measurement of nuclear elasticity in living cancer cells, revealing that changes in nuclear stiffness are primarily determined by chromatin compaction rather than nuclear lamins. These mechanical properties correlate with disease progression and may serve as biomarkers for cancer diagnosis and prognosis.
November 6, 2025 — Source

Health — Cancer — November 5th, 2025

Certain p53 mutations may make tumors more vulnerable to immunotherapy
The gene p53 acts as a tumor suppressor and is often called the guardian of the genome. This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading to cancer. But when p53 mutates, it can flip from protector to promoter of cancer.
November 5, 2025 — Source

Existing drug could reduce breast cancer risk in pre-menopausal women
Ulipristal acetate, a drug that blocks progesterone, reduced breast tissue density and the number of luminal progenitor cells in pre-menopausal women at high risk for breast cancer. Treatment also decreased collagen proteins, especially collagen 6, making breast tissue less favorable for cancer development. These findings suggest potential for ulipristal acetate in breast cancer prevention.
November 5, 2025 — Source

Experimental drug blocks key protein to trigger cancer cell self-destruction in lung tumors
NYU Langone Health researchers found that a type of cell death caused by a buildup of highly reactive molecules suppresses lung tumor growth.
November 5, 2025 — Source

How gray hair and cancer may be linked
Gray hair is an inevitable hallmark of aging. It's a visual reminder of the passing years and all the bodily changes that accompany it.
November 5, 2025 — Source

Macrophage 'bodyguard' disruptors may help overcome hormone-resistant breast cancer
In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have tested a new combination therapy for hormone-resistant, estrogen receptor-positive (ER+) breast cancer and were able to shrink tumors, reduce the number of cancer stem cells and reprogram the immune environment to be less supportive of cancer growth.
November 5, 2025 — Source

Most Americans don't know alcohol can cause cancer
Most U.S. adults don't realize alcohol raises cancer risk, and drinkers themselves are the least aware. Scientists say targeting these misbeliefs could significantly reduce alcohol-related cancer deaths.
November 5, 2025 — Source

Physical activity levels linked to risk for digestive system cancers
Yiwen Zhang, Ph.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues examined the association between physical activity and DSC risk and mortality with a focus on the optimal amount and long-term consistency. The study included data from the Health Professionals Follow-Up Study, the Nurses' Health Study, and the Nurses' Health Study II.
November 5, 2025 — Source

Radiotherapy after mastectomy can be avoided, study finds
Radiotherapy can be safely omitted as a treatment for many breast cancer patients who have had a mastectomy and are taking anti-cancer drugs, a study shows.
November 5, 2025 — Source

Study identifies key genes linked to aggressive prostate cancer in people of African descent
Variants in five genes—ATM, BRCA2, CHEK2, HOXB13, and PALB2—are strongly associated with aggressive and metastatic prostate cancer in men of African descent. Combining these genetic markers with polygenic risk scores and family history enables more precise risk assessment, potentially improving personalized screening and reducing disparities in prostate cancer outcomes.
November 5, 2025 — Source

The case for a cancer warning on processed meat
A group of scientists in the UK recently demanded that bacon and ham products carry health warnings similar to those on cigarettes.
November 5, 2025 — Source

Triggering cell death in metastatic melanoma may pave the way for new cancer treatments
Metastatic melanoma cells that have spread to lymph nodes survive by relying on a protein called ferroptosis suppressor protein 1 (FSP1)—a surprising metabolic dependency that could open the door to a new class of cancer treatments, according to a new study led by Harvard T.H. Chan School of Public Health.
November 5, 2025 — Source

Ultrasound-activated Nanoparticles Kill Liver Cancer and Activate Immune System
A new ultrasound-guided nanotherapy wipes out liver tumors while training the immune system to keep them from coming back.
November 5, 2025 — Source

USC-led study advances understanding of prostate cancer genetics in Black men
New prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of Medicine of USC has yielded discoveries that could improve screening and treatment for patients of African ancestry. The scientists identified variants of five genes linked in this population to aggressive disease or to cancer that spreads, or metastasizes, to other organs. The study also found a wide range of risk among participants. By combining data on the five specific genes with other methods of determining risk, the researchers introduced a method that could help identify those most likely to face deadlier forms of the disease.
November 5, 2025 — Source

Why cancer immunotherapy isn't effective for everyone
A study led by Andre Veillette, a researcher at the Montreal Clinical Research Institute (IRCM) and a professor in the Faculty of Medicine at University of Montreal, sheds new light on the complexity of the immune system and its role in cancer treatment.
November 5, 2025 — Source

Health — Cancer — October 31st, 2025

AI tool makes detection of skin cancer more accurate
Researchers at Fox Chase Cancer Center, Temple University's College of Engineering, and the Lewis Katz School of Medicine at Temple University have developed a new method that enhances the ability of artificial intelligence models to detect and diagnose skin cancer in individuals with darker skin.
October 31, 2025 — Source

Better Treatments Buoy Multiple-Myeloma Patients, Bound by Research Cuts and Racial Disparities
For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms — pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination. Her primary care physician had ruled out diabetes before finally chalking up her ailments to getting older.
October 31, 2025 — Source

Could a cancer vaccine developed long ago hold the key to long-term survival in breast cancer?
A small group of women with advanced breast cancer received a vaccine via a clinical trial more than 20 years ago. Today, they're all still alive. Scientists say that kind of long-term survival is almost unheard of for patients with metastatic breast cancer, and it's what caught the attention of researchers now.
October 31, 2025 — Source

DNA copy-number changes help melanoma develop resistance to immunotherapy, study finds
The team found that relapsing melanoma tumors often acquire genomic DNA copy-number variants, which delete or amplify sections of DNA. These variants frequently affect genes that control the cancer cells' ability to self-destruct in response to damage caused by immune attack. The cumulative effect of copy-number changes, often involving multiple cell-death genes, allows cancer cells to survive immune attacks, leading to tumors relapsing or regrowing months or years after the initial therapy-induced tumor shrinkage.
October 31, 2025 — Source

FDA says drug makers have recalled a blood pressure medicine tainted with a cancer-causing chemical
The U.S. Food and Drug Administration says drug makers have recalled more than a half-million bottles of the blood pressure medication prazosin hydrochloride over concerns it may include a cancer-causing chemical.
October 31, 2025 — Source

Researchers develop nanoparticles that stimulate the immune system to attack ovarian tumors
Targeted particles carrying the cytokine IL-12 can jump-start T cells, allowing them to clear tumors while avoiding side effects.
October 31, 2025 — Source

SNA-Based Drug Slow Cancer Progression 59-Fold in Animal Models
By reengineering a decades-old chemotherapy drug into a DNA-wrapped nanostructure, Northwestern University researchers have turned a poorly soluble medicine into a precision cancer killer. Their findings could redefine how chemotherapy treatments occur in the future.
October 31, 2025 — Source

Studies identify complementary approaches to overcome drug resistance in KRAS G12C--mutant lung cancer
Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C--mutant non-small cell lung cancer.
October 31, 2025 — Source

Targeted nanoparticles can jumpstart T cells, allowing them to attack ovarian tumors while avoiding side effects
Cancer immunotherapy, which uses drugs that stimulate the body's immune cells to attack tumors, is a promising approach to treating many types of cancer. However, it doesn't work well for some tumors, including ovarian cancer.
October 31, 2025 — Source

Health — Cancer — October 30th, 2025

A promising molecule against chemotherapy-induced neuropathies
Currently incurable, peripheral neuropathies are common neurological complications of chemotherapy, causing persistent pain, tingling and burning sensations in the feet and hands, sometimes even after treatment has ended. In the hope of offering a therapeutic option to affected patients, a research team led by a CNRS researcher has identified a molecule capable of preventing the onset of such side effects.
October 30, 2025 — Source

Americans have widespread misbeliefs about the cancer risks of alcohol, study finds
Despite clear evidence linking alcohol use to increased cancer risks, public awareness of this connection remains low in the U.S., according to new research from The University of Texas MD Anderson Cancer Center. Researchers found that more than half of American adults (52.9%) did not know alcohol affects cancer risk.
October 30, 2025 — Source

Breast cancer risk varies between different hormonal contraceptives, research reveals
Some common hormonal contraceptives are linked to a slightly higher risk of breast cancer than others. This is shown by a Swedish study from Uppsala University, in which researchers followed more than two million women and teenage girls in Sweden to identify how different hormonal contraceptives affect the risk of breast cancer.
October 30, 2025 — Source

Dual studies uncover complementary strategies to overcome resistance to KRAS G12C inhibitors in lung cancer
KRAS G12C-mutant non-small cell lung cancers often develop resistance to KRAS G12C inhibitors by reactivating RAS signaling or adapting through alternative mechanisms. Next-generation RAS(ON) inhibitors can block both mutant and wild-type RAS, while CDK12/13 inhibitors exploit resistance-associated vulnerabilities in DNA repair and mitosis. Combined, these strategies delay or prevent resistance and extend treatment response.
October 30, 2025 — Source

Early clinical trial tests immune-boosting therapy before prostate cancer surgery
A small, early clinical trial led by the Icahn School of Medicine at Mount Sinai and collaborators has shown that directly injecting an immune-activating compound into prostate tumors before surgery appears safe and may help the immune system recognize and attack cancer cells.
October 30, 2025 — Source

Experimental cancer drug shows exceptional tumor-fighting potential
A research team has developed a new chemotherapeutic agent, LiPyDau, which shows remarkable efficacy against multiple tumor types in preclinical studies. Published in the journal Molecular Cancer, the study introduces a highly promising strategy for tackling drug-resistant cancers. The team was led by the Medical University of Vienna, the HUN-REN Research Center for Natural Sciences and the Eötvös Loránd University in Budapest.
October 30, 2025 — Source

From antibiotics to antimalarials: How repurposed drugs might keep cancer from returning
Many cancer survivors live with the worry that their cancer might come back. This "recurrence" occurs when cancer cells hide somewhere in the body—like in the bone marrow—and start growing again, sometimes years later. Scientists have been trying to understand how to stop these cells from reactivating and causing cancer to spread.
October 30, 2025 — Source

New method yields up to twice as many therapeutic myogenic cells as previous protocols
If cancer is a disease of overabundance, where cells divide without restraint and tumors grow despite the body's best interests, then degenerative diseases are disorders of deprivation.
October 30, 2025 — Source

Public awareness about the effect of alcohol on cancer risk remains low in the U.S.
Despite clear evidence linking alcohol use to increased cancer risks, public awareness of this connection remains low in the U.S., according to new research from The University of Texas MD Anderson Cancer Center. Researchers found that more than half of American adults (52.9%) did not know alcohol affects cancer risk.
October 30, 2025 — Source

Researchers uncover mechanism by which BRCA2-deficient tumors develop chemoresistance
One of the biggest challenges in cancer treatment is chemoresistance: tumors that initially respond well to chemotherapy become resistant over time. When that happens, treatment options are often limited.
October 30, 2025 — Source

Some hormonal contraceptives linked to higher risk of breast cancer
Some common hormonal contraceptives are linked to a slightly higher risk of breast cancer than others. This is shown by a new Swedish study from Uppsala University, in which researchers followed more than two million women and teenage girls in Sweden to identify how different hormonal contraceptives affect the risk of breast cancer.
October 30, 2025 — Source

Therapeutic potential of Scleromitrion diffusum in gastric cancer treatment
Gastric cancer remains a major global health challenge, characterized by high mortality and limited therapeutic efficacy, especially in advanced stages. With conventional treatments like surgery and chemotherapy often yielding suboptimal outcomes and significant side effects, there is an urgent need for safer and more effective alternatives. Scleromitrion diffusum (Willd.), a traditional Chinese medicine (TCM) herb with a long history of use in oncology, has shown promising clinical potential against gastric cancer.
October 30, 2025 — Source

Thiostrepton suppresses rhabdomyosarcoma progression by targeting the PI3K--AKT pathway
Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas. While multimodal therapies have improved outcomes for low- and intermediate-risk patients, high-risk or metastatic cases still suffer poor survival rates below 30%. Existing treatments are often toxic and limited by drug resistance. Thiostrepton (TST), first isolated in the 1950s from Streptomyces azureus, has recently emerged as a promising anticancer agent due to its unique ability to inhibit tumor-related transcription factors and signaling pathways.
October 30, 2025 — Source

Transcription factor drives chemotherapy resistance in ovarian cancer
Northwestern Medicine scientists have discovered how a specific transcription factor promotes genetic reprogramming and chemotherapy resistance in ovarian cancer cells, findings that may inform new targeted treatment approaches that inhibit this process and improve patient outcomes, according to a recent study published in the Journal of Clinical Investigation.
October 30, 2025 — Source

Health — Cancer — October 25th, 2025

Scientists just found a surprising link between gray hair and cancer
Hair graying and melanoma emerge as two divergent fates of stressed stem cells—protection or peril.
October 25, 2025 — Source

Health — Cancer — October 24th, 2025

Common jobs held by immigrant women may put them at increased risk of breast cancer
Many immigrant women in the U.S. work in jobs that may expose them to chemicals linked to breast cancer, according to a new study led by Silent Spring Institute. The study is among the first to examine how job-related chemical exposures may contribute to breast cancer risk among foreign-born workers, especially in jobs with fewer health and safety protections.
October 24, 2025 — Source

Living tumor-on-a-chip exposes how cancers block immune attacks
For a little over two decades, chimeric antigen receptor (CAR) T cell therapy has emerged as a powerful new way to treat cancer. By extracting patients' T cells, re-engineering them to recognize tumor antigens, and infusing them back into the body, physicians have achieved effective treatments for leukemia and lymphoma cancers.
October 24, 2025 — Source

Medicaid expansion tied to smaller declines in early-stage cancer detection
Xuesong Han, Ph.D., from the American Cancer Society in Atlanta, and colleagues examined the association of Medicaid expansion and changes in cancer stage at diagnosis during the COVID-19 pandemic using data for 1,844,515 individuals aged 18 to 64 years newly diagnosed with cancer in 2018 to 2022 from the National Cancer Database. The changes in proportions of early-stage cancer diagnoses were compared in Medicaid expansion versus nonexpansion states using a difference-in-differences (DD) approach.
October 24, 2025 — Source

Study shows protective effect of Medicaid expansion on early-stage cancer diagnosis
The COVID-19 pandemic disrupted health care, including cancer screening and diagnosis, especially for medically underserved populations, leading to substantial underdiagnosis of early-stage cancers in 2020. In a new study led by the American Cancer Society (ACS), scientists found that Medicaid expansion was associated with smaller declines in early-stage cancer detection among adults during the pandemic.
October 24, 2025 — Source

Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
What if a single test could simultaneously contribute to the diagnosis, characterization, and treatment guidance of childhood cancer—while helping avoid toxic or potentially unnecessary treatments?
October 24, 2025 — Source

Health — Cancer — October 20th, 2025

AI system delivers comprehensive cancer diagnosis
The Hong Kong University of Science and Technology (HKUST) today launched SmartPath, a comprehensive artificial intelligence (AI) system designed to transform the entire pathology workflow for cancer care.
October 20, 2025 — Source

Are cancer surgeries removing the body's secret weapon against cancer?
New research reveals that lymph nodes, often removed during cancer surgery to prevent tumor spread, may actually be crucial for successful treatment.
October 20, 2025 — Source

Colon cancer DNA may guide tailored post-surgery care
Circulating tumor DNA (ctDNA) testing after surgery in Stage 3 colon cancer enables risk-based adjustment of chemotherapy. ctDNA-negative patients received less chemotherapy, resulting in fewer side effects and similar recurrence-free survival compared to standard care. ctDNA-positive patients had higher recurrence rates despite intensified therapy, indicating a need for new strategies in this group.
October 20, 2025 — Source

Combination of immunotherapy and targeted therapy boosts colorectal cancer survival, clinical trial finds
A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer, the second most common cause of cancer death in the U.S., live longer and control their disease better than with the standard treatment drug regorafenib.
October 20, 2025 — Source

Guidance on the safe use of large language models in oncology practice
The ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP) provides structured recommendations for integrating AI language models into oncology. ELCAP outlines three categories: patient-facing, clinician-facing, and institutional systems, each with specific safety, validation, and oversight requirements. Emphasis is placed on human supervision, data quality, transparency, and robust governance.
October 20, 2025 — Source

Immune-altering drug suppresses tumor-protecting cells and enhances stomach cancer treatment
A modified, long-lasting TFF2-albumin protein suppresses immunosuppressive neutrophils in gastric tumors by modulating CXCR4 activity, enhancing immune recognition and response against cancer. Combined with standard therapies, this approach improves tumor reduction and survival in animal models, suggesting potential for broader application in cancer and immune-related diseases.
October 20, 2025 — Source

New generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancer
Trastuzumab deruxtecan (T-DXd), a new-generation antibody-drug conjugate, significantly improves invasive disease-free survival and pathological complete response rates compared to current standard therapies in early-stage HER2-positive breast cancer, with a favorable safety profile and reduced cardiac toxicity. These findings support T-DXd as a new standard of care in both pre- and post-surgical settings.
October 20, 2025 — Source

Obesity-related cancer rising among both younger and older adults worldwide, study finds
A surveillance study compared international cancer incidence trends of 13 cancer types in younger and older adults.
October 20, 2025 — Source

Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer
Sevabertinib, an oral tyrosine kinase inhibitor targeting HER2 mutations, induced tumor reduction in over 70% of patients with advanced HER2-mutant non-small cell lung cancer, including those previously treated with HER2-targeted therapies. The drug showed a manageable safety profile, with diarrhea as the most common side effect and no cases of interstitial lung disease.
October 20, 2025 — Source

Precision reprogramming: How AI tricks cancer's toughest cells
Scientists at University of California San Diego have developed a new approach to destroying cancer stem cells—hard-to-find cells that help cancers spread, come back after treatment and resist therapy. The new approach, which the researchers tested in colon cancer, leveraged artificial intelligence (AI) to identify treatments that can reprogram cancer stem cells, ultimately triggering them to self-destruct.
October 20, 2025 — Source

Researchers find new way to cut cancer's lipid lifeline
Cancer thrives by hijacking the body's own basic survival systems, making it hard to attack tumors without collateral damage and side effects. Now, researchers at Cornell's Weill Institute for Cell and Molecular Biology have discovered what may be a less invasive strategy that shows promise as a potential therapeutic pathway.
October 20, 2025 — Source

Scientists create LED light that kills cancer cells without harming healthy ones
A new light-driven cancer therapy uses LEDs and tin nanoflakes to kill tumors safely and affordably. Developed by teams in Texas and Portugal, it eliminates up to 92% of skin cancer cells without harming healthy ones.
October 20, 2025 — Source

Scientists find immune drug that could halt skin cancer's deadly spread
Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients with Merkel cell carcinoma after surgery. Though recurrence rates overall weren't significantly changed, the results hint at a meaningful benefit in preventing cancer spread. The nationwide trial, one of the largest of its kind, underscores the promise of immunotherapy for rare, aggressive cancers.
October 20, 2025 — Source

SGLT2 inhibitors may slow nodule growth in pulmonary malignancies
In patients with diabetes and early-stage pulmonary malignancies, SGLT2 inhibitors are associated with reduced lung nodule growth (13.8% versus 25.7%) and fewer surgical interventions (5.5% vs 11.9%; hazard ratio 0.15) compared to alternative antidiabetic medications. Treating 15.6 patients with SGLT2 inhibitors prevents one surgical intervention over 10 years.
October 20, 2025 — Source

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies
Within the last two decades, multiple stem cell transplants and immunotherapy have been added to intensive chemotherapy as the standard of care for high-risk neuroblastoma, drastically improving survival of this childhood cancer.
October 20, 2025 — Source

Targeted immunotherapy combination offers hope to older adults with leukemia
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat form of leukemia.
October 20, 2025 — Source

This common vitamin could cut your skin cancer risk in half
Vitamin B3 may be the simple, over-the-counter secret to cutting future skin cancer risk.
October 20, 2025 — Source

Health — Cancer — October 17th, 2025

Automated algorithm can detect cancer in blood samples in as little as 10 minutes
An AI algorithm named RED can rapidly detect rare cancer cells in blood samples within 10 minutes, automating a process that previously required hours of manual review. RED identifies unusual cell patterns without prior knowledge of cancer cell features, achieving detection rates of 99% for epithelial and 97% for endothelial cells, and reducing data volume by 10³-fold.
October 17, 2025 — Source

Collaboration leads to drug candidate for a hard-to-treat type of lung cancer
Sevabertinib, a reversible HER2 inhibitor, shows potential for treating non-small cell lung cancers with ERBB2 (HER2) exon 20 insertion mutations, which affect 2--4% of patients. Preclinical models and early clinical data indicate tumor shrinkage and selective targeting of mutated HER2, with minimal impact on normal EGFR. The drug is under FDA Priority Review.
October 17, 2025 — Source

'Craters' on surface of melanoma cells mark tumor-killing hotspots, study reveals
Distinct crater-like structures on melanoma cell surfaces act as immune hubs where CD8+ T cells aggregate and mediate tumor killing. These CRATERs expand following immune stimulation and are present in both melanoma and other solid tumors, suggesting their potential as markers for immunotherapy efficacy and treatment monitoring
October 17, 2025 — Source

Dense breasts: What it means and what women can do about screening
About half of women over 40 have dense breasts, which increases breast cancer risk and reduces mammogram sensitivity to as low as 25--30%. Since 2024, U.S. mammography centers must inform women of their breast density. Supplemental screening methods such as ultrasound, contrast-enhanced mammography, or MRI may be considered, depending on individual risk factors and insurance coverage.
October 17, 2025 — Source

Leukemia cells evade treatment by reshaping their mitochondria, researchers discover
Leukemia cells develop resistance to venetoclax by increasing OPA1 protein, which alters mitochondrial cristae to prevent apoptosis. Inhibiting OPA1 in mouse models restores drug sensitivity, prolongs survival, and does not harm normal blood cells. This approach may offer a new strategy for overcoming resistance in acute myeloid leukemia and other cancers.
October 17, 2025 — Source

Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer
Treatment with osimertinib plus a platinum--pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone. The finding is based on an analysis of the complete data from the phase 3 global FLAURA2 study, co-led by researchers from Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France). Median overall survival was 47.5 months in the osimertinib plus platinum--pemetrexed group versus 37.6 months in the osimertinib monotherapy group.
October 17, 2025 — Source

Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia
Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (Nasdaq: GRAL), today announced they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL's GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. SCT and SEC have also agreed to invest $110 million into GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, at a price of $70.05 per share of common stock.
October 17, 2025 — Source

Supercharging immune cells to fight drug resistant bowel cancer
Engineered γδT cells expressing stIL-15 and a B7-H3 antibody exhibit prolonged survival and dual cytotoxic mechanisms (AIC and ADCC), enabling effective killing of drug-resistant, slow-growing bowel cancer cells in organoid models. These cells outperform regular γδT cells and may offer a promising immunotherapy approach for solid tumors.
October 17, 2025 — Source

Health — Cancer — October 15th, 2025

Checkpoint inhibitor promotes tissue repair, offering hope for chronic wound treatment
The immune checkpoint inhibitor TIGIT promotes tissue repair by inducing a growth factor in immune cells, which activates repair mechanisms following viral infection. Mice lacking TIGIT experience increased tissue damage, highlighting its protective role. These findings suggest potential therapeutic applications for chronic wounds and fibrosis by targeting TIGIT-mediated pathways.
October 15, 2025 — Source

Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma
Bottom line: Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL), a rare and aggressive cancer with limited treatment options.
October 15, 2025 — Source

Developing a green thumb while young can prevent cancer, study finds
Helping children develop a green thumb could have lifelong health benefits, including preventing cancer, according to new work from a University of Alberta public health researcher.
October 15, 2025 — Source

Fruit fly study reveals genetic targets for rare childhood brain cancer treatment
Using fruit flies, University of Wisconsin--Madison researchers have developed a new model for investigating the genetic drivers of a rare but aggressive brain tumor in children. The work has already identified potential treatment targets for the deadly cancer that has previously had few therapeutic options.
October 15, 2025 — Source

How to double lung cancer screening rates: Multidisciplinary program reaches over 70% screening rate
Lung cancer screening might be the best-kept secret in health care today. Only about 16% of those who are eligible in the U.S. get screened for lung cancer, but a study appearing in NEJM Catalyst provides a roadmap for how health systems can improve those numbers. The study details how the UR Medicine primary care network reached a nearly 72% lung cancer screening rate.
October 15, 2025 — Source

New research aims to develop targeted therapy for hard-to-treat osteosarcoma
For children and young adults diagnosed with osteosarcoma, a common type of bone cancer for that age group, the odds of survival can be devastatingly low (20-30%) when the disease spreads to the lungs.
October 15, 2025 — Source

New research identifies more accurate way of predicting which blood cancer patients will relapse early
A study carried out by a team of researchers from The Institute of Cancer Research, London, found that combining two types of genetic tests gives doctors a much better chance of identifying multiple myeloma patients who are at risk of early relapse.
October 15, 2025 — Source

Scientists identify markers of key stem cell populations driving colorectal cancer formation
Distinct stem cell populations marked by NOX1 and NPY1R proteins drive colorectal cancer formation in specific colon regions. These markers enable the development of region-specific cancer models, improving understanding of tumor origins and regional differences in disease behavior. The findings support the advancement of targeted diagnostics and therapies for colorectal cancer.
October 15, 2025 — Source

Study identifies new approach to protect the brain during radiation therapy
Targeted inhibition of the complement protein C5a and its receptor C5aR1 in the brain protects against cognitive decline caused by cranial radiation therapy, without reducing the therapy's effectiveness against cancer. The orally available inhibitor PMX205, which crosses the blood-brain barrier and is safe in humans, shows promise for preserving cognitive function in brain cancer survivors.
October 15, 2025 — Source

Study links obesity-driven fatty acids to breast cancer, warns against high-fat diets like keto
A team from Huntsman Cancer Institute at the University of Utah (the U) has found that triple-negative breast cancer is fueled by lipids and that these fatty acids are a key feature of obesity that promote tumor growth. Their research, conducted in preclinical mouse models, suggests that breast cancer patients and survivors with obesity could benefit from lipid-lowering therapies—and that they should avoid high-fat weight loss regimens like ketogenic diets.
October 15, 2025 — Source

Health — Cancer — October 13th, 2025

Bioengineering breathes new life into failed cancer treatment
Many advanced cancers develop resistance to treatment and become highly aggressive, often leaving patients with limited treatment options. In some cancers, including lung, pancreatic and prostate tumors, a key driver of treatment resistance and metastasis is a protein called integrin αv&beta3, which is absent in normal tissues but enriched in aggressive tumors.
October 13, 2025 — Source

Bridging innovation and equity to end cervical cancer worldwide
Each year, more than 340,000 women die from cervical cancer, with the majority of deaths occurring in low- and middle-income countries. Despite being highly preventable through vaccination and early detection, the disease remains the fourth most common cancer among women. In 2020, the World Health Organization (WHO) launched the Global Strategy to Accelerate the Elimination of Cervical Cancer, setting ambitious "90-70-90" targets for vaccination, screening, and treatment by 2030. Yet vast inequities in health resources, infrastructure, and implementation capacity threaten progress. Addressing these challenges requires not only scientific advances but also strong policy alignment and international cooperation.
October 13, 2025 — Source

'Google Maps' approach provides cell-by-cell tumor mapping for more personalized lung cancer treatment
Researchers have developed a way to predict how lung cancer cells will respond to different therapies, allowing people with the most common form of lung cancer to receive more effective individualized treatment.
October 13, 2025 — Source

Owlstone Medical wins up to $49.1 million award from ARPA-H to develop at-home multi-cancer-early detection tests
Owlstone Medical ("Owlstone"), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it has won an award of up to $49.1 million from the Advanced Research Projects Agency for Health (ARPA-H) for the Platform Optimizing SynBio for Early Intervention and Detection in Oncology (POSEIDON) program. POSEIDON aims to develop first-in-class synthetic-sensor based Multi-Cancer-Early Detection (MCED) tests for Stage I detection of 30+ solid tumors using only breath and urine samples that can be performed in the home and are available over the counter.
October 13, 2025 — Source

Study Delivers Cancer Drugs Directly to the Tumor Nucleus
A new peptide-based nanotube treatment sneaks chemo into drug-resistant cancer cells, providing a unique workaround to one of oncology's toughest hurdles.
October 13, 2025 — Source

Study offers new models for understanding the causes of chemo brain
Also called "brain fog," this mix of cognitive issues - memory problems, struggling to find words, an inability to concentrate - affects up to three-in-four cancer patients, according to multiple studies. For many, the effects last years beyond cancer treatment.
October 13, 2025 — Source

Targeting aggressive childhood leukemia with nanobody PROTACs
Scientists at the University of Duisburg-Essen are researching new therapies for aggressive forms of childhood leukemia. For the first time, their approach tries to distinguish between two subtypes using so-called nanobody PROTACs. These attack diseased tissue while sparing healthy cells. The Jose Carreras Leukaemia Foundation is supporting the project, led by Prof. Dr. Shirley Knauer and Dr. Mike Blueggel from the Faculty of Biology, with 143,740 euros for two years.
October 13, 2025 — Source

Targeting enzymes to weaken cancer cells could supercharge prostate cancer treatment
An international study has uncovered a new vulnerability in prostate cancer cells that could help improve treatment for one of the most common cancers affecting men.
October 13, 2025 — Source

This experimental "super vaccine" stopped cancer cold in the lab
A next-gen nanoparticle vaccine shows stunning cancer prevention and immunity in mice.
October 13, 2025 — Source

Vitamin B3 supplement may reduce your risk of skin cancer
Nicotinamide, a form of vitamin B3, taken at 500 mg twice daily, is associated with a 14% reduction in new skin cancer risk, with up to a 54% decrease when started soon after a first diagnosis. The effect is strongest for squamous cell carcinoma and diminishes if begun after multiple recurrences. Nicotinamide is safe, inexpensive, and may complement existing prevention strategies.
October 13, 2025 — Source

Health — Cancer — October 10th, 2025

AI-supported cervical cancer screening tested in Kenya and Tanzania
AI can be used to detect cervical cancer in women in resource-limited parts of the world. However, for this method to work, investments are needed in health care staff, reliable supply chains and trust in these communities. This has been shown in a new study from Uppsala University, Karolinska Institutet and the University of Helsinki, where researchers tested an AI-supported diagnostic method at rural hospitals in Kenya and Tanzania.
October 10, 2025 — Source

Blood cancer: Scientists reprogram cancer cell death to trigger immune system
The aim of immunotherapy strategies is to leverage cells in the patient's own immune system to destroy tumor cells. Using a preclinical model, scientists from the Institut Pasteur and Inserm successfully stimulated an effective anti-tumor immune response by reprogramming the death of malignant B cells. They demonstrated an effective triple-therapy approach for treating forms of blood cancer such as certain lymphomas and leukemias which affect B cells.
October 10, 2025 — Source

Engineered stem cells yield millions of tumor-fighting natural killer cells at reduced cost
Chinese researchers have developed a novel method to efficiently engineer natural killer (NK) cells for cancer immunotherapy. NK cells are central to early antiviral and anticancer defense—among other immune system roles—making them well-suited for cancer immunotherapy. For example, chimeric antigen receptor (CAR)-NK therapy involves adding a lab-built receptor (a CAR) to an NK cell, enabling it to recognize a specific antigen on a cancer cell and attack it.
October 10, 2025 — Source

Enhanced multi-omics tool illuminates cancer progression
GoT-Multi, an advanced single-cell multi-omics tool, enables simultaneous detection of multiple gene mutations and gene activity in individual cancer cells, including those from formalin-fixed, paraffin-embedded samples. This technology allows high-throughput analysis, revealing detailed mechanisms of cancer progression and therapy resistance, and may inform new therapeutic approaches.
October 10, 2025 — Source

LED light blasts cancer cells and spares healthy ones
A new cancer treatment combines LED light and tiny tin flakes to neutralize cancer cells while shielding healthy cells and avoiding the painful side effects associated with chemotherapy and other treatments.
October 10, 2025 — Source

New GoT-Multi technology reveals how cancers evolve and resist treatment
A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track multiple gene mutations while simultaneously recording gene activity in individual cancer cells. The technology, which can now use diverse types of pathology samples and quickly process large numbers of cells, has enabled the investigators to glean new insights into how cancers evolve toward greater aggressiveness and therapy resistance.
October 10, 2025 — Source

Peptide nanotubes show promise for overcoming chemotherapy resistance
Cyclic peptide nanotubes can selectively deliver doxorubicin into the nuclei of resistant tumor cells by exploiting their affinity for anionic cancer cell membranes. This approach bypasses common drug resistance mechanisms, maintains antitumor efficacy, and offers a promising strategy for enhancing chemotherapy effectiveness against hard-to-treat cancers.
October 10, 2025 — Source

Top 10 questions about breast cancer answered
Breast cancer receives much attention during October's awareness month. Although sightings of pink ribbons and breast cancer-related information increase during the month, it's crucial to keep screenings and clinical breast exams at the forefront of preventive care year-round.
October 10, 2025 — Source

Health — Cancer — October 8th, 2025

Cancer outcomes in Australia are improving overall
Cancer survival rates have improved over three decades as cancer mortality rates decline, according to new data published today by the Australian Institute of Health and Welfare (AIHW).
October 8, 2025 — Source

Engineered CAR-NK cells could evade immune rejection and target cancer more effectively
One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be programmed to attack cancer cells.
October 8, 2025 — Source or Source

Engineered Salmonella therapy delivers immune payloads to combat cancer
A new research paper was published in Volume 16 of Oncotarget on October 6, 2025, titled "ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response."
October 8, 2025 — Source

Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines
A research team led by Cancer Center at Illinois (CCIL) member Hua Wang has published new research detailing a new mRNA cancer vaccine platform. The study introduces an immune cell homing hydrogel-based platform designed to overcome one of the biggest hurdles in conventional mRNA cancer vaccines: the extremely low efficiency of antigen-encoded mRNAs being processed by the right type of immune cells in the body.
October 8, 2025 — Source

Improved five-year cancer survival observed after Medicaid expansion
Bottom Line: Adoption of Medicaid expansion in U.S. states appeared to improve both five-year cause-specific and overall survival in cancer patients.
October 8, 2025 — Source

Improved genetic tool reveals hidden mutations that can drive cancer
Researchers have refined a powerful DNA sequencing tool that can uncover hidden mutations that occur naturally in our bodies as we age. In the largest study to date, they have used the tool to provide insights into the earliest steps of cancer development and the role of mutations in healthy tissue.
October 8, 2025 — Source

Ireland launches next phase of national precision oncology program
Today (8th October), Ireland's Minister for Further and Higher Education, Research, Innovation and Science, James Lawless TD, launched Phase 2 of the country's leading and largest ever cancer research program, Precision Oncology Ireland (POI).
October 8, 2025 — Source

Kennesaw State researcher explores how hormones influence cancer development
Joanna Wardwell-Ozgo figures to work backward when determining the causes of cancer.
October 8, 2025 — Source

Medicaid cuts could be dangerous for cancer survivors
Earlier in 2025, the Trump administration approved $900 billion in sweeping cuts to Medicaid, the publicly funded health program for low-income families and people with disabilities. Democrats are now demanding that Republicans address some of their concerns about patients who rely on safety-net health care programs, which has led to a deadlock in Washington over a federal spending plan and the ongoing government shutdown.
October 8, 2025 — Source

Nanomedicine emerges as a key tool to boost cancer immunotherapy
Scientists at the Fralin Biomedical Research Institute at VTC and their collaborators are exploring emerging trends in cancer immunotherapy, with back-to-back review articles published in Nature Cancer and Trends in Cancer that look at how nanotechnology could reprogram the immune system and help overcome tumors' defenses.
October 8, 2025 — Source

Novel immunotherapy combination destroys colorectal liver metastases
Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to the liver. Despite progress in surgical therapies aimed at eradicating the cancer, many of these patients will have tumor recurrence in the liver.
October 8, 2025 — Source

Refined DNA sequencing tool reveals hidden mutations behind aging and cancer
Researchers have refined a powerful DNA sequencing tool that can uncover hidden mutations that occur naturally in our bodies as we age. In the largest study to date, they have used the tool to provide insights into the earliest steps of cancer development and the role of mutations in healthy tissue.
October 8, 2025 — Source

Repeated sampling offers insight into glioblastoma therapy response
A multi-institutional study from the Accelerating GBM Therapies Through Serial Biopsies TeamLab, led by investigators from the Mass General Brigham Cancer Institute, found that serially testing tumor samples can help detect when a cancer treatment is activating the immune system in recurrent glioblastoma (GBM), even when traditional imaging measures cannot. Their results are published in Science Translational Medicine.
October 8, 2025 — Source or Source

Scientists are collecting toenail clippings to reveal radon exposure and lung cancer risk
At 47 years of age, Emi Bossio was feeling good about where she was. She had a successful law practice, two growing children and good health. Then she developed a nagging cough. The diagnosis to come would take her breath away.
October 8, 2025 — Source

Should I worry about testicular cancer?
Testicular cancer affects about 1 in 250 men, most commonly young adults, but has a five-year survival rate over 95% if detected early. Key risk factors include family history and undescended testicles. Monthly self-exams are recommended, and any unusual changes should prompt medical evaluation. Treatment is highly effective, and most retain normal fertility and sexual function.
October 8, 2025 — Source

Smoking and biological sex shape healthy bladder tissue evolution, offering clues to cancer risk
Bladder cancer is one of the most common cancers worldwide. Men are around four times more likely to develop it than women, and smoking is the main known environmental risk factor. However, the biological mechanisms behind these risk factors remain unclear. Since cancer can take decades to develop, it is important to look at healthy tissues to understand the very first steps of the disease, with the goal of improving risk prediction, prevention, and early diagnosis.
October 8, 2025 — Source

'Traffic controller' protein that protects DNA discovered, and it may help kill cancer cells
Mayo Clinic researchers discovered a protein, KCTD10, that acts as a "traffic controller" for DNA, protecting it during cell division and potentially aiding in new cancer therapies.
October 8, 2025 — Source

UCSF team uncovers breakthrough immunotherapy for colon cancer liver metastases
Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to the liver. Despite progress in surgical therapies aimed at eradicating the cancer, many of these patients will have tumor recurrence in the liver.
October 8, 2025 — Source

Health — Cancer — October 3rd, 2025

Drop in credit score after cancer diagnosis linked to increased mortality
Patients with cancer whose credit scores decline after their diagnosis face a significantly higher risk of mortality, providing the first objective data linking financial health to physical survival.
October 3, 2025 — Source

Innovative topical cream relieves chemotherapy-induced peripheral neuropathy
Researchers at Miguel Hernández University have developed an innovative topical cream that relieves chemotherapy-induced peripheral neuropathy, improving cancer patients' quality of life.
October 3, 2025 — Source

Mastectomy linked to worsened sexual health and body image after surgery
While mastectomy is often a necessary and life-saving treatment option for many women with breast cancer, the surgery may contribute to worse sexual health, body image, and several other physical and emotional challenges after surgery, according to a new systematic review on the effects of mastectomy in women with breast cancer. Surgeons said the research underscores the importance of screening women before they undergo a mastectomy.
October 3, 2025 — Source

Newly discovered mechanism helps leukemia cells to evade the immune system
A research team at Lund University in Sweden has discovered a mechanism that helps acute myeloid leukemia cells to evade the body's immune system. By developing an antibody that blocks the mechanism, the researchers could restore the immune system's ability to kill the cancer cells in laboratory trials and in mice.
October 3, 2025 — Source

Nuclear Missile Workers Are Contracting Cancer. They Blame the Bases
Former nuclear missile operators are reporting cancer diagnoses, suspecting a link to their workplaces. The Air Force is conducting a study, expected to conclude by the end of 2025, to investigate potential health risks.
October 3, 2025 — Source

Patients value communication skills from cancer surgeons across six key areas, according to research
Patients with cancer value surgeons' communication skills in six main areas: emotional support and optimism, clear expectation setting, use of communication aids, shared decision-making tailored to patient preference, transparent discussion of prognosis, and effective team coordination. These domains contribute to patient satisfaction and treatment adherence, though more research is needed on demographic influences.
October 3, 2025 — Source

Rectal bleeding in young adults linked to 8.5 times higher risk of colorectal cancer
A recent study presented at the American College of Surgeons (ACS) Clinical Congress 2025 highlights a significant link between rectal bleeding and an increased risk of colorectal cancer in young adults. Researchers analyzed data from 443 patients under 50 who underwent colonoscopies at the University of Louisville Health System between 2021 and 2023, finding that rectal bleeding increased the odds of a colorectal cancer diagnosis by 8.5 times. Notably, 44% of these patients were diagnosed with early-onset colorectal cancer.
October 3, 2025 — Source

Scientists just cracked the mystery of why cancer immunotherapy fails
Scientists found a protein stress "Achilles' heel" in T cells that could supercharge cancer immunotherapy.
October 3, 2025 — Source

Untreated depression can make surgical outcomes worse in cancer patients
Cancer patients with untreated depression experience poorer surgical recovery, higher complication rates, and increased costs. Antidepressant treatment in depressed patients is associated with improved outcomes, including shorter hospital stays, lower readmission and mortality rates, and reduced costs compared to untreated depression, though outcomes remain best in patients without depression.
October 3, 2025 — Source

Health — Cancer — September 29th, 2025

AI tool accurately distinguishes between glioblastoma and primary central nervous system lymphoma
A Harvard Medical School AI tool, PICTURE, accurately distinguishes between glioblastoma and PCNSL, two brain cancers often misdiagnosed, aiding treatment decisions during surgery.
September 29, 2025 — Source

Cancer cell nuclear hypertrophy can suppress metastasis
In tissue biopsies, cancer cells are frequently observed to have nuclei (the cell's genetic information storage) larger than normal. Until now, this was considered a sign that the cancer was worsening, but the exact cause and effect had not been elucidated. In this study, the KAIST research team found that cancer cell nuclear hypertrophy is not a cause of malignancy but a temporary response to replication stress, and that it can, in fact, suppress metastasis. This discovery is expected to lead to the development of new diagnostic and therapeutic strategies for cancer and metastasis inhibition.
September 29, 2025 — Source

Cancer-fighting gene plays unexpected role in pancreatic cancer tumor growth
New research from Indiana University School of Medicine scientists has revealed that a well-known cancer-fighting gene also plays an unexpected role in regulating how certain immune cells can support tumor growth. This insight into pancreatic cancer progression could lead to more effective treatments against one of the deadliest forms of cancer.
September 29, 2025 — Source

Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation, compared with radiation alone.
September 29, 2025 — Source

Don't cut them out: Lymph nodes may be key to cancer treatment
Lymph nodes play an active role in supporting immune responses against cancer, particularly by maintaining CD8+ T cells crucial for tumor destruction. Removing lymph nodes can weaken these defenses, especially during immunotherapy, and may increase complications. Modern approaches favor targeted removal to preserve immune function, suggesting that retaining some lymph nodes benefits long-term cancer control.
September 29, 2025 — Source

Gene expression test identifies prostate cancer patients who benefit from hormone therapy
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the first predictive biomarker in this setting.
September 29, 2025 — Source

Enlarged cancer cell nuclei may limit spread rather than signal severity
Enlarged nuclei in cancer cells result from DNA replication stress and actin polymerization, representing a temporary stress response rather than increased malignancy. This nuclear hypertrophy constrains metastatic potential, indicating that larger nuclei may suppress, not promote, cancer spread. These findings suggest nuclear size changes could inform new diagnostic and therapeutic approaches.
September 29, 2025 — Source

Melanoma risk calculator now factors in 16 personal traits and regional UV exposure
QIMR Berghofer has unveiled the next-generation of its world-leading melanoma risk prediction calculator to better help Australians take action against one of the country's most deadly, costly, and common cancers that claims more lives each year than the national road toll.
September 29, 2025 — Source or Watch Video

Novel immunotherapy targets common cancer mutation, offering hope for lung and prostate cancer patients
A novel immunotherapy targeting the CTNNB1_S37F mutation, common in lung and prostate cancers, has shown effective tumor elimination in preclinical models. Engineered T cells with specific T-cell receptors selectively destroyed cancer cells carrying this mutation while sparing normal cells, indicating potential for broad application in patients with solid tumors harboring shared mutations.
September 29, 2025 — Source

One-hour, low-cost HPV test could transform cervical cancer screening in Africa and beyond
A team of researchers led by Rice University, in collaboration with colleagues in Mozambique and The University of Texas MD Anderson Cancer Center, has developed a simple, affordable human papillomavirus (HPV) test that delivers results in less than an hour with no specialized laboratory required. The breakthrough could provide an option for women in low-resource settings to be screened and treated for cervical cancer in a single clinic visit, a step that global health experts say could save countless lives.
September 29, 2025 — Source

Randomized study comparing proton and photon radiation for breast cancer finds both preserve quality of life
The first randomized trial to compare photon- and proton-based radiation therapy for breast cancer finds that patients report equally strong health-related quality of life with either treatment. Patients who received proton therapy were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.
September 29, 2025 — Source

Shorter radiation improves patient experience but not disease control for intermediate-risk prostate cancer, trial finds
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation therapy (SBRT) reported fewer declines in bowel, urinary and sexual functioning but were more likely to experience a rise in prostate-specific antigen (PSA).
September 29, 2025 — Source

Health — Cancer — September 26th, 2025

At 10 years, stereotactic body radiation therapy comparable to surgery for early-stage lung cancer
Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body radiation therapy (SBRT) and surgery achieved similar survival outcomes at 10-year follow-up for patients with early-stage non-small cell lung cancer, with radiation offering quality-of-life benefits. These findings will be presented Sept. 29 by Joe Chang, M.D., Ph.D., professor of Radiation Oncology, and Troy Kleber, M.D., resident.
September 26, 2025 — Source

How a single protein rewires leukemia cells to fuel their growth
Cancer cells are relentless in their quest to grow and divide, often rewiring their metabolism and modifying RNA to stay one step ahead. Now, researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a single protein, IGF2BP3, that links these two processes together in leukemia cells. The protein shifts how cells break down sugar, favoring a fast but inefficient energy pathway, while also altering RNA modifications that help produce the proteins leukemia cells need to survive and multiply.
September 26, 2025 — Source

Kidney cancer cases are projected to double by 2050, says study
Global kidney cancer cases are expected to double by 2050, primarily due to modifiable risk factors such as obesity, smoking, diabetes, hypertension, and lack of exercise. Five-year survival rates range from 40% to 75% depending on region and access to care. Approximately 5--8% of cases are hereditary. Prevention through lifestyle changes can significantly reduce risk.
September 26, 2025 — Source

New T cell therapy targets CTNNB1 cancer mutation with promising results in animal studies
Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers like lung and prostate cancer. This approach has effectively eliminated tumors in animal studies and could benefit thousands of patients with this mutation.
September 26, 2025 — Source

Tumor cells can exploit damaged tissue in the pancreas to create new environments for growth
Pancreatic cancer is an aggressive disease, and unlike many other cancers, survival rates have barely improved. Researchers at Karolinska Institutet, in collaboration with the Department of Pathology at Karolinska University Hospital, have now shown that pancreatic tumor cells not only spread in the connective tissue--rich environment that is a well-known characteristic of pancreatic cancer but also grow into damaged parts of normal pancreatic tissue. There, the cancer can create its own environment.
September 26, 2025 — Source or Source

Health — Cancer — September 25th, 2025

App may improve palliative care for adults with incurable cancer
Ying Yu, Ph.D., from Fudan University in Shanghai, and colleagues explored whether adding a palliative care educational app to clinical palliative care could enhance HRQoL in homebound patients with incurable cancer. The analysis included 147 adults (Karnofsky Performance Status ≤70) receiving palliative care who had consistent family caregivers.
September 25, 2025 — Source

Bacteria coated liquid metal nanoparticles wipe out tumors in mice
New nanoparticles made from bacteria and liquid metal locate tumors, trigger immune attacks, and destroy cancer in mice under near infrared light with no major side effects.
September 25, 2025 — Source

Diet and medication combo interrupts growth of aggressive childhood neuroblastoma tumors, study finds
Researchers at Children's Hospital of Philadelphia (CHOP) found that combining a specialized diet with an approved medication interrupts the growth of high-risk neuroblastoma, a deadly pediatric cancer, by reprogramming tumor behavior.
September 25, 2025 — Source

Sniffing out cancer: Volatile organic compounds show promise for early multi-cancer detectio
A research team led by Prof. Chu Yannan at the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has uncovered a new way to detect cancer early—by analyzing the invisible chemical "scents" that the body gives off.
September 25, 2025 — Source

UPR modulators show promise in treating cancer-related bone disease
Before a chain of amino acids can become an active and useful protein, it must be processed and folded into the appropriate conformation. Much of this processing occurs in the endoplasmic reticulum (ER) of every cell. However, any disruptions in protein homeostasis can be very stressful to the ER, and when the ER gets overwhelmed, a safety system called the Unfolded Protein Response (UPR) engages to slow down protein synthesis and allow the ER to catch up.
September 25, 2025 — Source

Health — Cancer — September 22nd, 2025

A hormone that silences the immune system may unlock new cancer treatments
Study uncovers hormone's role in weakening body's defenses against cancer.
September 22, 2025 — Source

Boosting drug delivery with spiky nanorobots
Researchers engineered magnetic nanorobots that carry anticancer drugs and penetrate tumor cell membranes, improving chemotherapy effectiveness.
September 22, 2025 — Source

Engineered gut bacteria improve survival outcomes in colorectal cancer tumors
In a new study that combines synthetic biology with cancer immunotherapy, researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Central South University in China have developed an engineered strain of gut-homing bacteria that stimulates potent antitumor immune responses against colorectal cancer (CRC).
September 22, 2025 — Source

Metabolic markers may predict breast cancer in high-risk women
Breast cancer remains the most common cancer and the leading cause of cancer-related death among women worldwide, with incidence rates continuing to rise. However, known risk factors, including genetics and lifestyle, do not fully explain the upward trend. Researchers are increasingly turning to metabolomics—the large-scale study of small molecules in biological systems—as a promising avenue for identifying new risk factors and improving prediction methods for breast cancer.
September 22, 2025 — Source

Study reports on recent trends in opioid prescribing for patients with cancer
A recent analysis reveals a modest decline from 2016 to 2020 in new and additional opioid prescriptions for patients with cancer. Among those patients with metastatic cancer, prescribing remained stable for those reporting any pain and declined steeply for those reporting no pain.
September 22, 2025 — Source

When cancer cells feel squeezed, they become more dangerous
New research shows that cancer cells don't just grow; they adapt when stressed. When squeezed inside tissues, they transform into more invasive, drug-resistant versions of themselves. A protein called HMGB2 helps flip this dangerous switch, giving the cells new powers to escape. The findings reveal how the tumor's environment itself can drive cancer's deadly flexibility.
September 22, 2025 — Source

Health — Cancer — September 19th, 2025

Gut bacterial adhesion mechanism revealed as target for novel colorectal cancer therapies
Fusobacterium nucleatum (F. nucleatum) is an anaerobic bacterium notably enriched in the gut microbiota of colorectal cancer (CRC) patients and may play a role in CRC both by colonizing tumor cells and suppressing immune mechanisms. Understanding how this bacterium adheres to cancer cells could provide key targets for developing novel antitumor therapies.
September 19, 2025 — Source

Health researchers discuss Medicaid cancer screening trends, best practices
New Jersey has the 10th-highest rate of cancer incidence in the United States. It is the second leading cause of death in New Jersey, and thousands of residents die from preventable cancers each year.
September 19, 2025 — Source

Scientists Find a Tattoo--Cancer Link—But It's Not What You'd Expect
New research finds a surprising link between a person's risk of melanoma and the amount of tattoos they sport.
September 19, 2025 — Source

Self-collection for HPV testing can improve cervical cancer screening rates among Asian American women
Asian American women given the option to collect their own sample for human papillomavirus (HPV) testing after an educational workshop completed cervical cancer screening at much higher rates compared with workshop attendees who were referred to clinics, according to results presented at the 18th AACR Conference on the Science of Cancer Health Disparities, held September 18--21, 2025.
September 19, 2025 — Source

Sugary drinks may increase risk of metastasis in advanced colorectal cancer
A new study from researchers at The University of Texas MD Anderson Cancer Center shows that the glucose-fructose mix found in sugary drinks directly fuels metastasis in preclinical models of advanced colorectal cancer.
September 19, 2025 — Source

Young adult cancer survivors may face elevated social risks
"There are now more than 18 million cancer survivors in the United States, many living a decade or more after diagnosis. While survivorship is a success story, a cancer diagnosis can heighten vulnerability to social risks such as food, housing, and transportation insecurity," said study presenter Ami E. Sedani, PhD, MPH, assistant professor of epidemiology at UTHealth Houston School of Public Health in Dallas.
September 19, 2025 — Source

Health — Cancer — September 16th, 2025

Biomarkers linked to side effects from cancer immunotherapy
A team led by UT Southwestern Medical Center scientists has identified early signals from the immune system that could help predict which cancer patients are most likely to develop harmful side effects from immunotherapy. The findings, published in the Journal for ImmunoTherapy of Cancer, offer a path toward tests to help doctors tailor care for at-risk patients.
September 16, 2025 — Source

Both weights and high intensity interval training offer health benefits for cancer survivors
Research from Edith Cowan University (ECU) has revealed that both resistance training and high intensity interval training (HIIT) produced sufficient levels of myokines to help in the fight against cancer.
September 16, 2025 — Source

Deep learning tool improves accuracy of lung nodule malignancy detection
An artificial intelligence (AI) deep learning tool that estimates the malignancy risk of lung nodules achieved high cancer detection rates while significantly reducing false-positive results. Results of the study, which used data from large, multi-site lung cancer screening trials, were published today in Radiology, a journal of the Radiological Society of North America (RSNA).
September 16, 2025 — Source or Source

Novel biotechnical vector integrates viral and synthetic features for targeted cancer therapy
Gene therapy offers the possibility of addressing cancer at its molecular roots by targeting disease-causing genes rather than relying solely on surgery, chemotherapy, or radiotherapy. Among RNA-based strategies, microRNA (miRNA) sponges and short-hairpin RNAs (shRNAs) have emerged as promising tools to silence oncogenes and restore tumor-suppressor pathways. However, clinical application remains constrained by delivery inefficiency, instability, and off-target toxicity. Viral and non-viral vectors each present strengths and limitations: while viral vectors provide high transfection efficiency, they often cause immune responses and mutagenesis risks; non-viral carriers are safer but lack sufficient delivery efficiency.
September 16, 2025 — Source

Scientists find a smarter way to activate the immune system against cancer
Scientists have developed a smarter way to activate the immune system against cancer, potentially making treatments safer and more precise.
September 16, 2025 — Source

Too soon to tell if 'liquid biopsies' help more than harm in cancer screening
"Liquid biopsy" tests using blood samples to screen for multiple types of cancer are attracting much attention, for their potential to catch unseen tumors.
September 16, 2025 — Source

Triple negative breast cancer exploits lymph node niches to block immune defense
In almost all solid tumors - i.e. cancers with a solid tissue structure - the detection of tumor cells in the lymph nodes is considered a decisive marker for the progression of the disease. Lymph node involvement has a significant influence on the choice of treatment and the chances of survival for patients. In particular, solid tumors in the breast, on the skin or in the gastrointestinal tract use the lymphatic system as the main route for distant metastasis, for example to the lungs, liver and bones.
September 16, 2025 — Source

Two-part prodrug system activates immune attack only in tumor's unique environment
Scientists have developed a smarter way to activate the immune system against cancer, potentially making treatments safer and more precise.
September 16, 2025 — Source

Health — Cancer — September 9th, 2025

Algorithm uses fluid flow to predict where deadly brain cancer may spread next
Glioblastoma is a devastatingly effective brain cancer. Doctors can cut it out or blast it with radiation, but that only buys time. The cancer has an insidious ability to hide enough tumor cells in tissue around the tumor to allow it to return as deadly as ever.
September 9, 2025 — Source

'Bottlebrush' particles deliver big chemotherapy payloads directly to cancer cells
Using tiny particles shaped like bottlebrushes, MIT chemists have found a way to deliver a large range of chemotherapy drugs directly to tumor cells.
September 9, 2025 — Source

Circulating tumor DNA may guide immunotherapy use in limited-stage SCLC, new study shows
The research, led by scientists at the National Cancer Center of China, assessed ctDNA in 177 patients with LS-SCLC treated with chemoradiotherapy (CCRT), 77 of whom received consolidation immune checkpoint inhibitors (ICIs). Circulating tumor DNA was measured at multiple time points to evaluate its ability to predict survival outcomes and immunotherapy benefits.
September 9, 2025 — Source

City of Hope launches innovative national clinical trials model to expand access to cancer treatments
City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., launched an innovative national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country. This model simplifies the opening of new trial locations and streamlines patient enrollment with the goal of accelerating the development of new cancer treatments and improving clinical care.
September 9, 2025 — Source

FANSS study demonstrates feasibility of U.S.-based lung cancer screening in Asian female nonsmokers
Results from the Female Asian Nonsmoker Screening Study (FANSS) highlight the potential value of low-dose CT (LDCT) screening for lung cancer among a growing but underserved population: Asian women with no history of smoking.
September 9, 2025 — Source

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer
New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.
September 9, 2025 — Source or Source

LuCE study identifies key communication barriers between lung cancer patients and caregivers
A large-scale survey conducted by Lung Cancer Europe (LuCE) has identified critical communication barriers that affect information access, understanding, and shared decision-making among lung cancer patients and caregivers across Europe.
September 9, 2025 — Source

Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC
A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).
September 9, 2025 — Source

New tool can predict where deadly brain cancer might reappear
Glioblastoma is a devastatingly effective brain cancer. Doctors can cut it out or blast it with radiation, but that only buys time. The cancer has an insidious ability to hide enough tumor cells in tissue around the tumor to allow it to return as deadly as ever.
September 9, 2025 — Source

Novel immunotherapy strategy shows promising long-term survival in certain advanced NSCLC patients
A new study presented reports encouraging long-term survival outcomes from an experimental viral immunotherapy, CAN-2409, in patients with advanced non-small cell lung cancer (NSCLC) who previously failed to respond adequately to immune checkpoint inhibitors (ICI).
September 9, 2025 — Source

Radioactive iodine therapy used for canine cancer treatment
Radioactive iodine therapy used for canine cancer treatment
September 9, 2025 — Source

Real-time measurement of boron in individual cancer cells could enhance understanding of tumor-killing drugs
A new technique has measured boron in individual cancer cells for the first time, enabling researchers to better understand how drugs act to kill tumors in some cancers.
September 9, 2025 — Source

Smoking status should influence lung cancer staging, new study shows
The University of Kentucky Markey Cancer Center's Graham Warren, M.D., Ph.D., and international collaborators have led a groundbreaking study that could change the way lung cancer is diagnosed and treated.
September 9, 2025 — Source

Sponge-like gold nanoparticles could upgrade ovarian cancer diagnostics
A project led by University of Queensland Ph.D. student Javeria Bashir has produced specially crafted gold nanoparticles that can highlight cancer markers in samples like urine, saliva, or blood. Bashir said she hoped to use her gold nanoparticles to help improve survival rates for a cancer that is considered particularly deadly.
September 9, 2025 — Source

Study highlights communication gaps and need for shared decision-making in lung cancer diagnosis
A large-scale survey conducted by Lung Cancer Europe (LuCE) has identified critical communication barriers that affect information access, understanding, and shared decision-making among lung cancer patients and caregivers across Europe.
September 9, 2025 — Source

Study highlights potential value of low-dose CT screening for lung cancer among Asian women
Results from the Female Asian Nonsmoker Screening Study (FANSS) highlight the potential value of low-dose CT (LDCT) screening for lung cancer among a growing but underserved population: Asian women with no history of smoking.
September 9, 2025 — Source

Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC
A new analysis from the PALOMA-2 study shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).
September 9, 2025 — Source

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC
A randomized Phase II trial from National Taiwan University Hospital reports early evidence that resecting the primary thoracic tumor following EGFR tyrosine kinase inhibitor (TKI) therapy may prolong disease control in patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
September 9, 2025 — Source

Health — Cancer — September 5th, 2025

Discovery of a new biomarker for early detection of bladder cancer in both dogs and humans
Bladder cancer is a painful and often recurring disease, not just for humans, but for our canine companions as well. Urothelial carcinoma, the most common type of bladder cancer, affects both species in remarkably similar ways—from the genetics to the clinical progression. This shared burden also means a shared challenge: how to detect and treat the aggressive form of the disease that's responsible for most relapses.
September 5, 2025 — Source

Cancer study identifies why patients do not respond to personalized immune therapy, sparking new vaccine
Immune-checkpoint therapy (ICT), which attempts to harness a patient's own immune system to fight cancer, has revolutionized cancer care over the past two decades. However, many patients do not respond to this therapy, and drug resistance due to immune-evasive (or "cold") tumors remains poorly understood.
September 5, 2025 — Source

New radiotheranostic targets identified for diagnosis and treatment of endometrial cancer
Two molecular targets—human epidermal growth factor 2 (HER2) and cluster of differentiation 24 (CD24)—are highly promising candidates for new nuclear diagnostics and therapeutics for endometrial cancer, according to new research published in The Journal of Nuclear Medicine.
September 5, 2025 — Source

Why discussing sex is important for patients after treatment for gynecological cancer
Anita Paulsen is a nurse and sexologist. She recently defended her doctoral thesis on sexual health communication after gynecological cancer. Through her work and research, she has met many cancer survivors who miss the intimacy in their lives.
September 5, 2025 — Source

Health — Cancer — September 4th, 2025

Dietary changes could provide a therapeutic avenue for brain cancer
Glioblastomas are the deadliest form of malignant brain tumor, and most patients diagnosed with the disease live only one or two years. In these tumors, normal cells in the brain become aggressive, growing rapidly and invading the surrounding tissue. The resulting cancer cells are metabolically different from their neighboring healthy cells.
September 4, 2025 — Source or Watch Video

DNA analysis shows colorectal cancer has unique microbial fingerprint
Colorectal cancer is unique in having its own microbial "fingerprint," according to new research from the University of East Anglia.
September 4, 2025 — Source

Novel embolization-on-a-chip model allows testing various embolic agent classes to treat liver cancer
Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents. This novel platform reflects the microenvironment of liver tumors, particularly a functional and perfusable microvasculature that can be embolized. This in vitro tool aligns with the National Institutes of Health (NIH) efforts to reduce animal testing and promote alternative methods, including microfluidic devices that mimic human organs.
September 4, 2025 — Source

Prolonged use of injectable contraceptive tied to brain tumor diagnoses
From Case Western Reserve University School of Medicine and Cleveland Clinic, investigators report that depot medroxyprogesterone acetate use was associated with a higher relative risk of meningioma brain tumor diagnosis in US women, with risk concentrated after more than four years of exposure or initiation at older than 31 years.
September 4, 2025 — Source

Squeezing through tiny blood vessels may trigger melanoma cells to spread
Nine of the 10 most common cancer deaths in Australia are caused by solid tumors, but in most cases it's the cancer's spread to other parts of the body—known as metastasis—that proves fatal.
September 4, 2025 — Source

Startup spun out of Nobel Laureate's lab teams with Eli Lilly to fight cancer with AI
Lila Biologics, a startup that spun out of Nobel Laureate David Baker's lab at the University of Washington, announced a collaboration with pharmaceutical giant Eli Lilly to develop therapies for treating solid tumors.
September 4, 2025 — Source

Study shows how smoking drives pancreatic cancer
A new study explains why smokers have a higher chance of developing pancreatic cancer and why they tend to have worse outcomes than nonsmokers.
September 4, 2025 — Source

Sugar-Coated Nanoparticles Boost Cancer Drug Efficacy
Over a tenth of breast cancer diagnoses are for triple-negative breast cancer. Triple-negative breast cancer (TNBC) gets its name because it lacks three common targets: estrogen, progesterone, and HER2. It disproportionately affects young women, especially African American women, making it an urgent priority for new treatment strategies.
September 4, 2025 — Source

Survival in people with myeloma nearly doubled since 2005
People diagnosed with multiple myeloma—one of the most common forms of blood cancer—are now living nearly twice as long on average as they were in 2005, according to a new study.
September 4, 2025 — Source

Health — Cancer — September 1st, 2025

How B-cell receptor types shape lymphoma cell survival and growth
A Northwestern Medicine study has uncovered new insights that may aid in understanding and potentially treating one of the most common and aggressive forms of non-Hodgkin lymphoma, according to findings published in Science Advances.
September 1, 2025 — Source

How pediatric brain tumors grow: Blocking a chemical messenger could offer new route to treatment
The most common type of brain tumor in children, pilocytic astrocytoma (PA), accounts for about 15% of all pediatric brain tumors. Although this type of tumor is usually not life-threatening, the unchecked growth of tumor cells can disrupt normal brain development and function.
September 1, 2025 — Source

Urine test can assess risk of kidney cancer recurrence
A simple urine test that can assess the risk of kidney cancer recurrence at an early stage could spare patients from frequent X-ray examinations and thus reduce the associated radiation, anxiety and costs.
September 1, 2025 — Source